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Abstract
SerpinB2 [plasminogen activator inhibitor type-2 (PAI-2)] was first described as a
placental protein, which regulated plasminogen activation via the inhibition of the
urokinase (uPA) or tissue-type (tPA) plasminogen activators during pregnancy.
Further work has confirmed that SerpinB2 is an efficient inhibitor of cell surface,
receptor bound uPA and clearance of the serpin:protease complex occurs via
members of the low density lipoprotein receptor (LDLR) family, specifically very
low density lipoprotein receptor (VLDLR) and low density lipoprotein-related
protein receptor (LRP). This property has allowed for the development of SerpinB2
drug conjugates for the selective targeting of uPA positive carcinoma cells.
However, potential utility of SerpinB2 in haematological disorders, such as acute
myeloid leukaemia (AML), as well as its role as a physiological inhibitor of tPA is
not well characterised. To date biochemical analysis has shown that SerpinB2 is
able to inhibit the two-chain (active) form of tPA. However, whether this inhibitory
function occurs within the cellular context was unknown.

This thesis investigates the potential use of exogenous SerpinB2 as a delivery
vehicle for the specific targeting of lymphoma or leukaemia, via cell surface uPA
using the relatively low versus high uPA expressing, monocytic cell lines U-937
and THP-1, respectively, as disease models. We show here that uPA:SerpinB2 is
internalised via the Low Density Lipoprotein Receptor (LDLR) family members,
specifically Low Density Lipoprotein-Related Protein (LRP) and Very Low Density
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Lipoprotein Receptor (VLDLR) in a uPA dependent manner and these findings are
consistent with those previously reported for epithelial cancer cell lines.

In order to clarify the role of SerpinB2 in the inhibition and clearance of tPA from
the cell surface of monocytes and macrophages, we next assessed the formation
and endocytosis of tPA:SerpinB2 complexes at the cell surface of freshly isolated
peripheral

blood

monocytes

(PBM),

as

a

non-transformed

tPA-

dependent/negligible uPA-expressing cellular model representing normal myeloid
lineages. We demonstrated that while both SerpinE1 (PAI type-1) and SerpinB2
inhibit surface-bound tPA and are internalised predominately via LDLR family
members, SerpinE1 enhanced the endocytosis of tPA, whereas SerpinB2 did not.
Surface plasmon resonance biochemical analyses revealed differential binding
affinities between VLDLR and tPA or tPA:SerpinE1 complexes in addition to those
previously described for LRP. Moreover, tPA:SerpinB2 bound to both endocytosis
receptors with similar kinetics to tPA. These differential biochemical interactions
between tPA and the tPA:serpin complexes may underlie the observed differences
in endocytosis mechanisms on the PBMs. This suggests that while SerpinE1 and
SerpinB2 function similarly in the control of cellular plasmin generation by tPA, they
may have disparate effects on the alternative functions of tPA via modulation of its
engagement with endocytosis receptors in a physiological setting. Importantly, this
work suggests that in the treatment of haematological disorders non-specific
delivery of therapeutics via tPA using SerpinB2 would be negligible, thus
contributing to the proof of concept for the use of SerpinB2 as a cancer targeting
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molecule. However, assessment within an animal model of haematological
disease is required to confirm this.

SerpinB2 has been reported to have a multitude of other activities including
regulation of monocyte and keratinocyte proliferation and differentiation, inhibition
of apoptosis and necrosis, modulation of immune responses and to display
cytoprotective properties in neurons. Some of these activities for SerpinB2 are
strongly associated with its classical serpin inhibitory function within the pericellular
space as, apart from pregnancy, it can be detected at very high concentrations in
body fluids associated with inflammation, infection and other pathophysiological
conditions. In many of these circumstances however, SerpinB2 protein is retained
primarily in intracellular pools. SerpinB2 has been reported to interact with a
number of intracellular proteins including components of the autophagy-lysosomal
and ubiquitin-proteasome systems. These appear to be independent of SerpinB2
protease inhibitory interactions, suggesting a novel non-serpin function for
SerpinB2. It was thus postulated that SerpinB2 is one of the many intracellular
proteins that maintain homeostasis during cellular damage or stress.

The latter chapters of this thesis investigated this putative function for intracellular
SerpinB2 as a chaperone-like protein using a series of cellular and biochemical
assays. Biochemical experiments revealed that SerpinB2 binds preferentially to
misfolded proteins and is an efficient inhibitor of amorphous protein aggregation in
some but not all models tested. SerpinB2 was also able to completely inhibit fibril
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formation of amyloid-β 1-40 peptide (Aβ1-40) and significantly delay fibril formation
by Aβ1-42. Incubation of SerpinB2 with Aβ was found to obstruct protease:SerpinB2
complex formation, suggesting that Aβ may bind within β-sheet-A, breach region,
of the serpin. We further explored the potential for SerpinB2 as a modulator of
cellular proteotoxic stress using a well-established huntingtin protein (Htt)
aggregation model, comprising an exon 1 fragment fused to either 25
polyglutamine (Httex125Q-mCherry) or 46 (Httex146Q-mCherry) polyglutamine
sequences. Wild-type or SerpinB2-/- mouse embryonic fibroblasts (MEF) were
transiently transfected with expression vectors containing either Htt ex125QmCherry or Httex146Q-mCherry, and cellular processing of aberrant Htt-fusion
protein was examined. These experiments revealed a clear difference in
phenotype, whereby inclusion body formation was evident in the wild-type MEF
controls and minimal in the absence of SerpinB2, where small foci predominated.
The impaired inclusion body formation was found to correspond with a significant
loss in cell viability for the SerpinB2-/- MEFs. Importantly, recovery of the wild-type
MEF phenotype and cell viability was achieved in a human SerpinB2 knock-in MEF
line. Given previous literature that suggests a possible role for SerpinB2 within both
the autophagy-lysosomal and proteasome degradation pathways, we compared
activity of each in the wild-type and SerpinB2-/- cell lines. Interestingly, both
systems were found to be impaired in the absence of SerpinB2. It was thus
concluded that intracellular SerpinB2 plays an important role in proteostasis as its
loss leads to a proteotoxic phenotype associated with an inability to
compartmentalize aggregating proteins. This represents a major contribution
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towards understanding the otherwise elusive cytoprotective role of intracellular
SerpinB2 and it is likely that further research will uncover therapeutic targets for
neurodegenerative disorders, as well as in cancer.
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1. Introduction

1

1.1.

Overview

SerpinB2 is a member of the Serine Protease Inhibitor super family and was
originally isolated from placental tissue and described as an inhibitor of the serine
proteinase urokinase-type plasminogen activator (uPA) (Kawano et al. 1968;
Kawano et al. 1970). Subsequent investigations revealed that SerpinB2 was also
able to inhibit the tissue-type plasminogen activator (tPA) (Astedt et al. 1985;
Astedt et al. 1985; Thorsen et al. 1988). On this basis SerpinB2 was named
plasminogen activator inhibitor type-2 (PAI-2) distinguishing it from PAI-type-1
(PAI-1) (referred to herein as SerpinE1), also a newly discovered inhibitor of
plasminogen

activators

(PAs)

(Loskutoff

and

Edgington

1977).

Initial

characterisation of SerpinB2 focussed on its role as an extracellular mediator of
plasmin generation with frequent comparison to SerpinE1. With the finding that
SerpinE1 was the faster acting inhibitor (Kruithof et al. 1995) and was present in
normal and pregnancy plasma, whereas SerpinB2 was only detectable during late
pregnancy (Kruithof et al. 1984), SerpinE1 was originally considered the primary
physiological mediator of thrombosis and fibrinolysis. Increasing evidence
supports a role for SerpinB2 as a physiological inhibitor of PAs however,
consistently placing the serpin within the extracellular milieu of diseased tissue
exhibiting localised inflammation and homeostatic imbalance (Kruithof et al. 1995;
Croucher et al. 2008; Schroder et al. 2010; Siefert et al. 2014).

The highest concentration of SerpinB2 protein is found intracellularly, in vitro,
within cells of the monocytic lineage (Kruithof et al. 1986; Genton et al. 1987).
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However, an intracellular serine protease target for this serpin is yet to be defined.
Furthermore, intracellular SerpinB2 seems to be promiscuous with many nonprotease binding partners described over the years, since its discovery (Schroder
et al. 2010). This combined with the finding that intracellular SerpinB2 upregulation in response to inflammation, infection and other pathophysiological
conditions, suggest a non-classical role for this serpin, independent of its protease
inhibitory capabilities.

This review will focus on 1) the known roles of SerpinB2 as an extracellular
protease inhibitor, specifically literature relating to inhibition of uPA and tPA; and
2) the putative roles of intracellular SerpinB2 which suggest it’s possible placement
as a pivotal protein functioning within proteostasis pathways.

1.2.

Serine Protease Inhibitor Super Family

The Serine Protease Inhibitor (serpin) Super Family consists of a large group of
multi-functional proteins with highly conserved structure and variable amino acid
sequence homology, with exception of highly conserved residues within the breach
and shutter regions (Fig.1.1.A) (Gettins 2002). Typically, serpins range between
330-500 amino acids, consist of three β sheets (A,B and C), 8-9 α helices (hA-hI)
and a reactive centre loop (RCL) which contains the protease recognition site (Fig.
1.1.A). Formation of a serpin-protease complex involves a suicide substrate-like
inhibitory mechanism, whereby the initial interaction results in an intermediate
conformational change of the inhibitor from a stressed to relaxed state (Fig.1.1.B),
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which allows the irreversible insertion of the RCL into β-sheet A of the serpin –
initiating in the breach region - in a 1:1 covalently linked, stable conformation (Fig.
1.1.C) (Huntington et al. 2000). The rate and efficiency of complex formation
between a serpin and its target protease is dependent on the complete insertion of
the RCL into β-sheet A and partial inhibition or blocking of this step results in the
substrate-like cleavage of the RCL, followed by serpin release (Fig.1.1.D)
(Silverman et al. 2001). Whilst the suicide inhibitory mechanism of serpins is most
typical, some serpins inhibit their target protease via the substrate mechanism,
never forming an SDS-stable serpin:protease complex.
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(C)

(A)

(B)

(D)

Figure 1.1: Highly conserved tertiary structure of Serpin Super Family. (A)
Native serpin structure, represented by serpinA1 (Protein Data Bank (PDB) #
1QLP (Elliott et al. 1996)) showing A-β-sheet (red), B-β-sheet (green), C-β-sheet
(yellow) and helices A-I (blue). Positioning of the reactive center loop (RCL)
(magenta) in stressed (solid line) and relaxed (dashed line) confirmation. The
breach and shutter regions are labelled. (B) Initial serpin:protease interaction via
the RCL results in the intermediate Michaelis complex formation as represented
by SerpinA1 and inactive trypsin (multicolours) (PDB # 1OPH (Ye et al. 2001)),
which leads to either (C) the 1:1 covalently linked, stable serpin:protease
complex (PDB # 1EZX (Huntington et al. 2000)) or (D) cleaved serpin in the
relaxed and inactive confirmation (RCL insertion) (PDB code 7API (Loebermann
et al. 1984)) and active protease. In this case the serpin has acted as a substrate
for the protease. Adapted from Law et al. (2006)).

Serpin distribution is diverse with over 1000 members found across higher order
plants, mammals, invertebrates, prokaryotes, archea, fungi and some viruses.
Originally thought to only target serine proteases, some serpins have now been
5

shown to inhibit cysteine protease targets (Hook et al. 1993; Komiyama et al. 1994;
Schick et al. 1998; Schick et al. 1998; Higgins et al. 2010; Kantyka et al. 2011),
furthermore, non-inhibitory serpins have also been described, which function in
hormone transport (Hammond et al. 1987; Pemberton et al. 1988) or stabilisation
of structural support molecules (Tasab et al. 2000; Sauk et al. 2005). Given the
diversity of serpins, they have been arranged into sub-families (Clades) based on
their evolutionary relationships (Irving et al. 2000).

As the focus of this thesis is specifically SerpinB2, a member of the serpin clade B
(see below), a full discussion of all other clades is beyond the scope of this chapter,
however for comprehensive reviews see Gettins (2002), Irving et al. (2000),
Silverman et al. (2010) and Whisstock et al. (2010).

1.3.

Serpin Clade B

The ovalbumin-serpin sub family (serpin clade B) consists of 14 members, 13 of
which are found within the human genome (Tab. 1.1) and classified as such, due
to their similarity to ovalbumin (SerpinB14). All members of this clade feature: (i) a
high degree of amino acid homology (~ 50%), (ii) a lack of N- and C- terminal
extensions found in many other serpins, (iii) a similar gene organization, three of
the 13 human serpins within this clade map to position 6p25 (B1, B6 and B9), whilst
all others map to position 18q21.3, and (iv) the presence in several members of an
inter-helical domain connecting helices C and D, encoded by an exon 3 (RemoldO'Donnell 1993; Scott et al. 1999).
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Table 1.1: Members of the Serine Protease Inhibitor (serpin) Clade B; known function and expression profiles.
Clade-B
Member
SerpinB1

SerpinB2

Alternative Names
Monocyte Neutrophil
Elastase Inhibitor
(MNEI)
Plasminogen Activator
Inhibitor Type-2

Target Protease
Neutrophil Elastase
Human granzyme H
Proteinase3
Cathepsin G
Extracellular;
Urokinase and Tissue
Type Plasminogen
Activators
Intracellular; unknown

Location/Cell
specificity/functions (if known)
Intracellular, immune
Neutrophils, monocytes,
macrophages, NK
Extracellular; inhibition of
plasminogen activators; immune
modulator
Intracellular inflammation
response protein, immune
modulator.

Reference
(Remold-O'Donnell
et al. 1992; Wang et
al. 2013)
(Kruithof et al. 1984;
Kruithof et al. 1995;
Schroder et al. 2010)
Reviewed in;
(Croucher et al.
2008; Schroder et al.
2010; Medcalf 2011)

(Refer Table 1.2 for list of cells
which have been shown to
express SerpinB2)
SerpinB3

Squamous cell
carcinoma antigen-1
(SCCA-1)

Cathepsin K, L, & S
papain and JNK1.

Intracellular; Squamous epithelial
cells

SerpinB4

Squamous cell
carcinoma antigen-2
(SCCA-2)
Maspin

Cathepsin G, Mast
Cell Chymase

Intracellular; Squamous epithelial
cells

Non-inhibitory

Intracellular; tumour suppressor
Hypothesized functions;
Extracellular matrix remodeling via
Rac and Cdc42 signaling. Proapoptotic mediator. Potential

SerpinB5
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(Takeda et al. 1995;
Schick et al. 1998;
Schick et al. 1998;
Zheng et al. 2009)
(Schick et al. 1997)

(Odero-Marah et al.
2003; Liu et al. 2004;
Bailey et al. 2005;
Latha et al. 2005;
Romani et al. 2006;

Clade-B
Member

Alternative Names

Target Protease

SerpinB6

Proteinase Inhibitor-6

Cathepsin G, kallikrein
2 and 8, neuropsin,
Granzyme B,
thrombin, trypsin,
plasmin, urokinase,
chymotrypsin.

SerpinB7

Megsin

Plasmin,
metalloproteinase 2
and 9

SerpinB8

Proteinase Inhibitor-8

Furin. Trypsin-like
serine proteinases.

SerpinB9

Proteinase Inhibitor-9

SerpinB10

Proteinase Inhibitor-10,
Bomapin, MENT
(Chicken ortholog)

Cytotoxic lymphocyte
protease granzyme B,
subtilisin A, caspase1, 4, 8 & 10
Unknown. Trypsin-like
serine proteinases.

Location/Cell
specificity/functions (if known)
involvement in cellular stress
responses.
Intracellular; nucleocytoplasm of
neutrophils, cytotoxic T cells,
keratinocytes, skeletal muscle,
placenta, heart, lung, liver, kidney
pancreas, inner ear hair cells,
normal mast cells and by mast
cells in mastocytoma lesions.
Intracellular;
Mesangial cells within the
glomerulus (kidney). Involved in
mesangial - cell proliferation and
extracellular matrix expansion.
Secretion of collagen type- IV
Extracellular; released from
platelets
Intracellular; monocytes, platelets,
squamous epithelial and
neurocrine cells.
Intracellular; nucleocytoplasm of
cytotoxic lymphocytes. Protects
against granzyme B-mediated
apoptosis.
Intracellular; monocytic cells.
Chromatin remodeling protein
(MENT).

Reference
Shi et al. 2007; Teoh
et al. 2010)
(Scott et al. 1999;
Scarff et al. 2004;
Zhang et al. 2006;
Sirmaci et al. 2010)

(Miyata et al. 1998;
Miyata et al. 2002;
Ohtomo et al. 2008;
Xia et al. 2011)

(Dahlen et al. 1998;
Strik et al. 2002;
Leblond et al. 2006)

(Sun et al. 1996;
Bird et al. 1998; Bird
et al. 2001; Hirst et
al. 2003)
(Riewald et al. 1998;
Chuang and Schleef
1999; Springhetti et
al. 2003)
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Clade-B
Member
SerpinB11

Alternative Names
Epipin

Target Protease
Non-inhibitory
(humans)

SerpinB12

Yukopin

Unknown. Trypsin-like
serine proteinases

SerpinB13

Proteinase Inhibitor-13,
Hurpin, Headpin

Lysosomal cathepsin
L

SerpinB14

Ovalbumin

Non-inhibitory

Location/Cell
specificity/functions (if known)
Unknown.
Avian SerpinB11 expression is
restricted to oviduct epithelial cells.
Hoof wall structure in Connemara
Ponies.
Unknown. Wide tissue distribution;
brain, bone marrow, lymph node,
heart, lung, liver, pancreas, testis,
ovary and intestines
Intracellular; Keratinocytes

Storage/structural protein found in
chicken eggs.

Reference
(Askew et al. 2007;
Lim et al. 2011;
Finno et al. 2015)

(Askew et al. 2001)

(Jayakumar et al.
2003; Welss et al.
2003)
(Hunt and Dayhoff
1980)
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Despite their sequence and structural similarities the independent Serpin clade B
members appear to be quite diverse in cell distribution and specific protease
targets and/or function (Table 1.1) whilst sharing common placement as either
enhancers or suppressors of inflammation and tumorigenesis. Serpins within this
clade can be either non-inhibitory, ie SerpinB5, B11 and B14 or have clearly
defined protease targets (Table 1.1). Furthermore, some members are restricted
to the cytoplasm, others localise within the nucleus, ie SerpinB2 and B10, whilst
SerpinB8 (Leblond et al. 2006) and SerpinB2 are found within both the intracellular
and extracellular environment.

1.4.

SerpinB2

The SERPINB2 gene is located between 18q21.3 – 18q22.1 (Webb et al. 1994),
within the known serpin B-clade cluster on chromosome 18q (van Gent et al.
2003). SerpinB2 protein consists of 415 amino acids, and has a predicted
molecular weight of 47 kDa. The conventional hydrophobic amino-terminal signal
sequence, necessary for protein direction into the secretory pathway, is internally
positioned within SerpinB2, resulting in inefficient processing down this classical
pathway (von Heijne et al. 1991), whilst allowing for intra and extracellular
distribution. SerpinB2 contains three potential N-linked glycosylation sites, at asn75, asn-115 and asn-339 positions, and occupation of all three gives rise to the 60
kDa extracellular species of SerpinB2 (Ye et al. 1988). The RCL is positioned at
P1 arg-380 and P1’ thr-381 (Kiso et al. 1988) and the loop is disordered in structure
(Harrop et al. 1999). In SerpinB2, the inter-helical domain between helices C and
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D is called the CD-loop. The CD-loop is highly mobile structure and can translocate
by approximately 40 Ǻ between the side and the bottom of the molecule (Lobov et
al. 2004). Due to this flexibility, the structure of the CD-loop has yet to be resolved,
however the rest of SerpinB2 conforms to the general tertiary structure conserved
across all known serpins (Harrop et al. 1999; Jankova et al. 2001) (Figure 1.1).

1.5.

Expression of the SERPINB2 gene

Isolation and characterisation of the SerpinB2 promoter region has identified
mechanisms by which transcription of SerpinB2 mRNA can be up-regulated by a
wide range of activating molecules, within a variety of cell types (Table 1.2). The
SerpinB2 promoter region contains a putative MAZ site (Almeida-Vega et al. 2009),
an ASC-1 site (Almeida-Vega et al. 2009), two AP1-like binding sites (Cousin et al.
1991), an AP2-like binding site (Kruithof and Cousin 1988), CRE-like element
(Cousin et al. 1991; Park et al. 2005) and a NF-κB binding site (Mahony et al. 1999;
Park et al. 2005). Response elements to glucocorticoids (Schuster et al. 1993;
Schuster et al. 1994), retinoic acid (Schuster et al. 1993; Schuster et al. 1994) and
xenobiotics (Sutter et al. 1991) have also been localised to the 5’ promoter region
of SerpinB2. Recently, the transcription factor C/EBP-β has been shown to
mediate constitutive and LPS-inducible transcription of murine SerpinB2 (Udofa et
al. 2013) and an AP-1 element binds FosB which is necessary for PMA induced
up-regulation of SerpinB2 expression in U937 cells (Stringer et al. 2012).
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Table 1.2: The expression of SerpinB2 mRNA and/or protein can be regulated by a range of biological agents in a
diverse set of cell types.
Expression
Agent
mRNA Protein
Cell Type
Cell Line
Ref.
Pro-inflammatory Cytokines
TNF-α

Interferon-γ

↑

↑

Fibroblast

HT-1080

(Medcalf et al. 1988)

↑

ND

Fibroblast

HT1080

(Ong et al. 2000)

↑

↑

Fibroblast

PC

(Pytel et al. 1990)

Melanocyte

SK-MEL-109

↑

ND

Myeloid

U-937, PC

(Gyetko et al. 1992)

↑

↑

Vascular SM

PC

(Jang et al. 2004)

↑

↑

Keratinocyte

PC

(Wang and Jensen

↑

↑

ND

↑

1998)
Monocyte

U-937, PC

(Gyetko et al. 1992)

Fibroblast

RT4, RT112,

(Champelovier et al.

(Bladder)

DAG-1, T24,

2003)

J82S, TCCsup
IL-1β

ND

↑

↑

ND

Fibroblast (BM)

PC

(Hannocks et al. 1992)

Monocyte

PC

(Gyetko et al. 1993)
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Fibroblast

PC

↑

↑

IL-2

↑

ND

IL-13

↑

ND

G-CSF

↑

↑

Monocyte

PC

(Hamilton et al. 1993)

M-CSF

↑

↑

Monocyte

PC

(Hamilton et al. 1993)

Epithelial (Gastric)

AGS

(Varro et al. 2002)

Epithelial

A-431

Steroids/Growth Factors
Gastrin
↑
ND
Epidermal
Growth Factor
(EGF)

Glucocorticoids

↑

↑

↑

ND

(Synovial)
Monocyte

PC

Epithelial

PC

(Bronchial)

(Epidermal)
Cumulus

PC

Granulosa-luteal

PC

↓

↓

Fibroblast

HT-1080

↓

ND

Epithelial
(Bronchial)

PC

(Hamilton et al. 1993)
(Gyetko et al. 1993)
(Woodruff et al. 2007)

(George et al. 1990)
(Piquette et al. 1993)

(Medcalf et al. 1988)
(Woodruff et al. 2007)

Pathogenic Stimuli
LPS

Monocyte

PC (Schwartz and Bradshaw

↑

↑

↑

ND

Macrophage

RAW-267, PC

(Costelloe et al. 1999)

↑

ND

Monocyte

PC

(Suzuki et al. 2000)

1992)
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↑
Signalling mediators
cAMP
↑

↑

ND

Fibroblast

PC

(Gingival)

(Xiao and Bartold 2004)

Myeloid

PL-21

(Niiya et al. 1994)

Keratinocytes

PC, HaCaT

(Wang and Jensen

↑

↑

↑

ND

Neurons

PC

(Zhang et al. 2009)

↑

ND

Keratinocyte

SCC-12F

(Sutter et al. 1991)

↑

ND

Epithelial (Breast)

M13SV1

(Ahn et al. 2005)

Kainate

↑

ND

Neuronal

Whole tissue

(Sharon et al. 2002)

Okadaic acids

↑

ND

Fibroblast

HT-1080

(Medcalf 1992)

Myeloid

U-937

Myeloid

U-937 (Dear and Medcalf 2000)

Calcium

Toxins
Dioxin

Oxamflatin

↑

↑

Tumour promoting agents
PMA
↑
ND
↑

↑

1998; Seo et al. 2002)

Macrophage

RAW-267, PC

(Costelloe et al. 1999)

Myeloid

U-937, THP-1,

(Genton et al. 1987;

HL-60, K-562

Schleuning et al. 1987;
Schuster et al. 1993)
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Vasculature effectors and regulators
Angiotensin II
↑
ND
D-Dimer
Factor VIIa

ND

↑

↑

ND

Thrombin

Aortic SM
Myeloid

PC

(Feener et al. 1995)

NOMO-1 (Hamaguchi et al. 1991)

Keratinocytes

HaCaT

(Camerer et al. 2000)

Monocyte/Macrop

U-937, PC

(Lundgren et al. 1994;

hage

Ritchie et al. 1995)

Other
Lipoprotein-a

↑

↑

Retinoic acid

↑

↑

↑

ND

↑

↑

Monocyte

PC (Montemurro et al. 1999)

ND

↑

Monocyte

PC

VLDL and LDL

Monocyte

PC

Myeloid

U-937, THP-1,
HL-60, K562

Keratinocytes

PC

(Buechler et al. 2001)
(Schuster et al. 1993)
(Braungart et al. 2001)

(Wada et al. 1994)

ND: Not Determined
PC: Primary Culture
VLDL: Very low density lipoprotein
LDL: Low density lipoprotein
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In addition to the promoters described above, the SerpinB2 gene contains at least
two repressor regions in the 5’ region of the SerpinB2 gene (positions,1859-1100
and 259-219) (Antalis et al. 1996). The latter site also contains a binding site for
an as yet unidentified nuclear protein (Dear et al. 1996). A repressor motif termed
PAUSE-1

(SerpinB2

upstream

silencer

element-1,

sequence:

5’-

CTCTCTAGAGAG-3’) (Antalis et al. 1996) is located at position -1832 and binds a
specific, ~ 67 kDa binding factor (Ogbourne and Antalis 2001). This region
overlaps with the repressor described by Dear et al. (1996), suggesting that these
studies may have described the same repressor region.

Full length SerpinB2 mRNA is unstable, with a half-life of approximately one h
(Maurer et al. 1999). The best characterised mRNA degradation components are
AU-rich regions in the 3’ region of mRNAs. The 3’-untranslated region of SerpinB2
mRNA contains an AU-rich region which plays an important role in the degradation
of SerpinB2 mRNA (Maurer and Medcalf 1996). Disruption of the nonameric motif
UUAUUUAUU via mutagenesis led to an increase in SerpinB2 mRNA and protein
expression levels (Maurer et al. 1999). Additionally, this motif is a binding site for
HuR, which has been associated with mRNA decay (Maurer et al. 1999).
Tristetraprolin, a CCCH tandem zinc finger protein that binds to ARE-containing
transcripts, also interacts with the AU-rich region of the 3’-UTR and mediates
SerpinB2 mRNA degradation (Yu et al. 2003). Exon 4 of SerpinB2 also contains
an mRNA instability region, sharing homology with instability determinants of other
mRNAs (Tierney and Medcalf 2001).
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1.6.

Polymorphisms

SerpinB2 has not, as yet, been linked to any ‘serpinopathies’, that is, diseases
directly related to or caused by aberrant SerpinB2 function. However, there are
numerous studies showing correlation between disease states and polymorphisms
of the SerpinB2 gene. Two forms of SerpinB2 have been described, with variations
in three amino acids (Antalis et al. 1988; van den Berg et al. 1990). These
variations occur at positions 120, 404 and 413 with Asn, Asn and Ser in form A
and Asp, Lys and Cys in form B. Each of these changes is the result of a single
base change in each codon (120, Aat/Gat; 404, aaC/aaG; 413, tCc/tGc), however
it appears that all three mutations are linked and do not exist in isolation. Whilst
the functional consequences of these residue changes are unknown, a number of
studies have linked SerpinB2 genotype and disease. Form A has been associated
with lupus erythematosus and thrombotic pneumonia in patients with this condition
(Palafox-Sanchez et al. 2009), anti-phospholipid syndrome (Vazquez-Del Mercado
et al. 2007) and mycocardial infarction (Buyru et al. 2003; McCarthy et al. 2004;
Corsetti et al. 2013), although Foy and Grant (1997) found no evidence of the link
between SerpinB2 variants and mycocardial infarction. These disease states all
relate to disorders in haemostasis, highlighting the role of SerpinB2 in this system.
In addition, Shioji et al.(2005) showed an association between the A form and
prostate cancer. SerpinB2 form B is linked to preterm birth in subjects later
diagnosed with cerebral palsy (Gibson et al. 2007) and poor overall survival in
patients with non-small cell lung cancer (Di Bernardo et al. 2009). Many
serpinopathies described for other serpins, result from serpin polymerisation that
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gives rise to protein aggregation diseases (Belorgey et al. 2007). In this context,
SerpinB2 is unique.

1.7.

Polymerisation of SerpinB2

SerpinB2 can spontaneously form polymers in vitro (concentration and
temperature dependent) and also in vivo when directed to the cell secretory
pathway (Mikus et al. 1993; Mikus and Ny 1996; Wilczynska et al. 2003). Most
serpins require amino acid substitution(s) in key structural positions to provide the
ability to polymerise as is the case for natural mutants of α1-antitrypsin, C1inhibitor, α1-antichymotrypsin and neuroserpin (Stein and Carrell 1995; Davis et
al. 1999). In these instances, serpin polymerisation underlines a variety of genetic
disorders

including

emphysema

(α1-antithrypsin

deficiency),

hereditary

angioneurotic edema (C1-inhibitor deficiency), and dementia (neuroserpin
mutations). In contrast, SerpinB2 does not require additional mutagenesis and wild
type protein can exist in a highly polymerogenic conformation (Wilczynska et al.
2003). Polymerisation of SerpinB2 has not been linked with any pathological
outcomes. Furthermore, the role of SerpinB2 polymers and their relative
abundance compared to non-polymerised SerpinB2 in the organism remains
unknown.

SerpinB2 can exist in two different monomeric and inhibitory active forms: the
polymerogenic and the stable monomeric form (Wilczynska et al. 2003). The
polymerogenic (prone to polymerisation) form is characterised by open β-sheet A

18

and is stabilised by a disulfide bond connecting C79 in SerpinB2 CD-loop to C161
at the bottom of the molecule (Mikus et al. 1993; Wilczynska et al. 2003; Lobov et
al. 2004). Under reducing conditions, the di-sulfide bond is not formed and the CDloop folds on the side of the molecule; in this form the β-sheet A is closed and the
molecule remains as a monomer under physiological conditions providing the
stable monomeric form of SerpinB2 (Mikus et al. 1993; Wilczynska et al. 2003;
Lobov et al. 2004). The two forms are fully inter-changeable, depending on the
redox status of the environment and thus reduction/oxidation of the di-sulfide bond
determines whether SerpinB2 is present in the stable monomeric or the
polymerogenic form (Lobov et al. 2004) or potentially, polymers. Interestingly,
SerpinB2 seems to be able to form different types of polymers under different
conditions. For example, polymers of recombinant SerpinB2 obtained upon
incubation at 37 oC or induced by bis-ANS have no inhibitory activity (Wilczynska
et al. 2003; Wilczynska et al. 2003), while polymers of SerpinB2 formed in the cell
secretory pathway retain their inhibitory activity (Wilczynska et al. 2003). Different
mechanisms for serpin polymers have been proposed, including the so called
“loop-sheet” and “domain-swapping” polymers (Whisstock and Bottomley 2008).
Interestingly however, SerpinB10 has also been shown to undergo redox sensitive
conformational changes giving rise to polymers, similar to those described for
SerpinB2 (Przygodzka et al. 2010). Whilst the functional significance of SerpinB10
is also unknown, it’s close homology to SerpinB2 and shared polymerisation
characteristics give strength to the physiological relevance of redox sensitive
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conformational changes. Thus, the mechanisms of SerpinB2 polymerisation and
the activity of its different polymer types require further investigation.

1.8.

Extracellular SerpinB2

The main physiological producers of SerpinB2 are activated monocytes and
macrophages (Wohlwend et al. 1987; Hamilton et al. 1993; Ritchie et al. 1997).
However, many other cell types including eosinophils (Swartz et al. 2004),
adipocytes (Lijnen et al. 2007), microglia (Akiyama et al. 1993), neurons
(Yamanaka et al. 2005; Zhang et al. 2009), astrocytes (Dietzmann et al. 2000),
trophoblasts (Astedt et al. 1998) and mesothelial (Ivarsson et al. 1998) (in addition
to those listed within Table 1.2), produce this serpin. It has been suggested that a
non-classical secretory pathway for SerpinB2 exists due to the presence of both
the 47 kDa and 60 kDa forms of SerpinB2 within the extracellular matrix in localised
tissues and the detection of similar concentrations of both forms in the blood of
pregnant women (Kruithof et al. 1987; Ritchie and Booth 1998). Indeed, recent
studies show the secretion of 47 kDa SerpinB2, in response to inflammatory
stimulus (LPS), via transport-like vesicles (Boncela et al. 2013). Furthermore,
Schroder et al. (2014) have now shown SerpinB2 associated with micro-particles,
which facilitate its secretion from metastatic murine B16 melanoma cells.
Importantly, SerpinB2 was secreted as an active serpin, able to inhibit urokinasetype plasminogen activator (uPA) and therefore inhibit plasmin formation within the
extracellular environment.
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Plasmin is a broad-spectrum protease, which is derived from the circulating
zymogen plasminogen, by activation via either tPA or uPA systems (Dano et al.
2005). The role of tPA is predominantly associated with fibrinolysis (clot
dissolution) (Hoylaerts et al. 1982) and has more recently been identified in
important neurobiological processes, discussed below in section 1.11 and
reviewed in (Melchor and Strickland 2005). Conversely, uPA is generally
implicated in pericellular proteolysis resulting in ECM degradation (Andreasen et
al. 1997).

1.9.

Urokinase Plasminogen Activator System

Controlled expression of the uPA system is associated with cell surface proteolysis
and tissue remodelling during normal physiological conditions such as wound
healing and embryogenesis (Andreasen et al. 2000; Dano et al. 2005). However,
de-regulation of the uPA system is known to allow tumour invasion and metastasis
through the proteolytic degradation of the ECM, effectively presenting a gateway
for proximal and distal spread of malignant cells. It is now accepted that the role
of uPA in cancer is broader than ECM degradation and incorporates nonproteolytic functions, including cell proliferation, cell migration and cell adhesion
(Andreasen et al. 1997; Ranson and Andronicos 2003; Duffy 2004; Dano et al.
2005).

The uPA cascade is initiated by the high affinity binding of pro-uPA, the zymogen
form of uPA, to the uPA receptor (uPAR) (discussed below) at the cell surface (Fig.

21

1.2) (Ellis et al. 1989; Andreasen et al. 1997). Pro-uPA is subsequently activated
to form the serine protease uPA through cleavage of the peptide bond Lys 158 Ile159, via a number of proteases, with plasmin being most common (Andreasen et
al. 1997). It has been suggested that pro-uPA contains intrinsic activity and that
this may, in part, contribute to the activation of the uPA cascade (Behrendt et al.
2003).

The binding of pro/uPA to its cell surface receptor uPAR via the N-terminal growth
factor domain (GFD), results in the placement of the serine protease domain (SPD)
within the extracellular matrix (Andreasen et al. 1997) (Fig. 1.2). As its substrate,
plasminogen binds to co-localised receptors, e.g. Annexin II hetratetramer (AIIt)
resulting in the accelerated activation of plasmin at the cell surface (Plesner et al.
1997) (Fig. 1.2).
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Figure 1.2: Components of the uPA system at the cell
surface. 1. uPAR bound uPA is co-localised with
plasminogen allowing proteolytic activation of
plasminogen, at its C-terminal serine protease domain
(SPD), to form plasmin. 2. Plasmin directly breaks down
the ECM through its SPD, or indirectly through activation
of MMPs. 3. The uPA system is inhibited by SerpinE1
(PAI-1) and SerpinB2 (PAI-2), which deactivates the
SPD of uPA by direct binding. 4. Binding of serpins to
uPA allows interaction with LDLRs due to conformational
changes and facilitates the accelerated clearance of
uPAR:uPA:serpin complex from the cell surface. 5. The
complex and receptors are delivered to lysosomes via
transport vesicles, where uPA:serpin complexes are
enzymatically degraded. 6. uPAR and the LDLRs are
recycled to the cell surface. 7. Non-proteolytic activity of
uPA system; uPAR interactions with integrins result in
cell signalling, uPAR interactions with vitronectin allows
cell adhesion and migration.
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1.10.

Urokinase Plasminogen Activator Receptor

The uPA receptor (uPAR) is a glycoprotein containing 283 amino acid residues
and

is

bound

to

the

cell

surface

through

a

carboxyl

terminal

glycosylphosphatidylinositol (GPI) anchor (Andreasen et al. 1997; Huai et al. 2006)
(Fig. 1.2). The uPAR protein is comprised of three extracellular domains (D1 –
D3) (Fig. 1.2) and whilst bound through the GPI anchor, does not contain an
intracellular domain or membrane spanning peptide segment (Behrendt and
Stephens 1998). Until recently it was widely accepted that D1 contained the
binding domain for the growth factor region of (pro)-uPA, however using x-ray
crystallography, Huai et al. (2006) have shown that all three domains are involved
in binding interactions. The GFD within uPA contains an omega loop with residues
critical for binding to D1, D2 and D3 of uPAR (Behrendt and Stephens 1998).
Soluble forms of uPAR (suPAR) have also been identified within plasma and are
thought to originate through the cleavage of the GPI anchor at the cell surface by
plasmin (Hoyer-Hansen et al. 2001; Rasch et al. 2008). Whilst SerpinE1 binding
to uPA interrupts the vitronectin interactions (Andreasen et al. 1997), it also
facilitates the internalisation of uPAR and associated integrins (Czekay et al.
2001). As SerpinE1 can also bind to vitronectin it is able to inhibit uPAR/vitronectin
interactions from re-occurring and these two processes lead to cell detachment
(Degryse et al. 2004).
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1.11.

Tissue Type Plasminogen Activator

The tissue type plasminogen activation system was predominantly associated with
fibrinolysis and under normal physiological conditions plasma tPA concentration is
~ 0.1 nM (Dano et al. 1985). However, it is now known that tPA is not restricted to
maintaining homeostasis of coagulation and fibrinolysis. For example, tPA has
been shown to play a role in angiogenesis via cell surface interactions with annexin
II (p36) (Ling et al. 2004) and has emerged as a key component of neurobiology
with a vast number of roles described such as; effector of learning and memory
(Seeds et al. 2003; Obiang et al. 2012; Li et al. 2013); stress, as a modulator, via
stabilisation of the NMDA (N-methyl-D-aspartate) receptor during stress and
participating in behavioral changes and synaptic plasticity via NMDA signaling
within the hippocampus (Norris and Strickland 2007). Furthermore, links to
protection against neuronal degeneration have been found, whereby tPA has been
shown to degrade amyloid-β (Aβ) in vivo, within two different mouse models of
Alzheimer's disease (Melchor et al. 2003) and has recently been shown to
neutralise Alzheimer's disease progression (Oh et al. 2014). Of interest however
is the role plasminogen activators play in monocyte biology, given that cells of
myeloid lineage interchangeably express tPA, uPA and SerpinB2/SerpinE1,
specifically during activation or differentiation processes (McWilliam et al. 1998;
Missen et al. 2006), although the physiological implications of this flexibility
requires further investigation.
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Many cells secrete tPA such as; melanocytes (Rijken and Collen 1981), endothelial
cells (Ljungner et al. 1983; Larsson and Astedt 1985) and peripheral blood
monocytes (Hart et al. 1989; Hart et al. 1989; Soo et al. 1996). As a single chain
polypeptide, tPA is a glycosylated protein with molecular weight ~ 72 kDa (Rijken
and Collen 1981; Dano et al. 1985; Vassalli et al. 1992). Cleavage of sc-tPA, via
hydrolysis of the Arg275-Ile276 peptide bond, produces the 62.9 KDa two chain (tc)
tPA conformation (Rijken and Collen 1981; Collen and Lijnen 2004). Linked by
one disulfide bridge, chain A and chain B have Mr ~ 33 kDa and 39 kDa,
respectively (Rijken and Collen 1981; Pennica et al. 1983). The basic structure
of the tPA molecule contains 4 domains; i) the N-terminal region of 47 residues
comprising the finger domain (F Domain), which is homologous with the finger
domain of fibronectin, ii) an epidermal growth factor domain (E-domain) residues
50-87, iii) two kringle domains, residues 87-176 (K1), and 176-256 (K2), which
share similar amino sequences to the five kringle domains within plasminogen and
iv) the serine protease domain within the C-terminus, containing the active sites
His322, Asp371 and Ser478 (Pennica et al. 1983). Domains 1-3 are found in the A
chain of activated tPA, whilst the protease domain is located within the B chain
(Pennica et al. 1983). The high affinity binding of tPA to fibrin is mediated by the
finger domain and lysine sites within the kringle domains of tPA (Hoylaerts et al.
1982; van Zonneveld et al. 1986; Kaczmarek et al. 1993). Furthermore, the
regions of homology identified within the kringle domains of plasminogen and tPA
enable the co-localisation of these proteins via fibrin on the clot surface, which in
turn facilitates the accelerated production of plasmin (Hoylaerts et al. 1982).
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Soluble tPA is cleared from circulation via parenchymal and endothelial cells in the
liver (Kuiper et al. 1988; Nguyen et al. 1992; Simon et al. 1995), whilst cell bound
inactivated tPA is internalised via endocytosis and degraded in lysosomes
(Camani et al. 1994; Hardy et al. 1997). The characterisation of a tPA receptor on
the cell surface of human umbilical vein endothelial cells (HUVEC) by Hajjar and
Hamel (1990) identified the annexin II heterotetramer (AIIt) (Cesarman et al. 1994;
Hajjar et al. 1994) as an important binding site for both tPA and plasminogen. In
addition, high density - low affinity binding sites for tPA have also been described
for HUVECs, the U-937 and THP-1 monocytic cell lines and peripheral blood
monocytes (Felez et al. 1991). Investigation of the role of glycosaminoglycans in
cell surface tPA interactions by Camani et al. (2000) concluded that these receptor
types are not involved.

Little is understood about the role of SerpinB2 as a physiological inhibitor of tPA
due to limited reports of tPA:SerpinB2 complexes identified in vivo (Kruithof et al.
1995). Yet, co-expression of tPA and SerpinB2 has been shown in normal bone
marrow (McWilliam et al. 1998), skin (Chen et al. 1993), saliva and salivary gland
tissue (Virtanen et al. 2006), gingival fluid (Brown et al. 1995; Kinnby 2002), as
well as during pregnancy (Astedt et al. 1998), and SerpinB2 is able to inhibit cell
surface bound tc-tPA in vitro (Lobov et al. 2008). Furthermore, enhanced
expression of both tPA and SerpinB2 by epithelial cells is indicative of some
disease states, e.g. periodontal disease (Kinnby 2002), psoriasis and
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pre/eclampsia (Kruithof et al. 1995), strongly suggesting a role for SerpinB2 in the
control of tPA activity at sites of localised inflammation and warrants further
investigation.

1.12.

Inhibition of uPA or tPA

SerpinB2 is an efficient inhibitor of soluble and receptor bound, activated (twochain) tc-uPA and soluble activated (two-chain) tc-tPA (Thorsen et al. 1988;
Kruithof et al. 1995) (Table 1.3). While SerpinB2 can inhibit the soluble proenzyme (single-chain) sc-uPA, albeit less efficiently than tc-uPA, it cannot form
stable covalent complexes with the former (Schwartz 1994). Since sc-uPA has
some intrinsic plasminogen activation capacity, but is inefficiently inhibited by
SerpinB2 (Table 1.3) (or SerpinE1), it has been suggested that this may allow
initiation of cell surface proteolysis in PAI rich environments (Schwartz 1994).
Once sufficient tc-uPA activity is formed, SerpinB2 can then efficiently inhibit
further plasmin formation. It is important to note here that since most of the uPA in
plasma/fluids appears to be in the sc-uPA form (Wojta et al. 1989), only cell surface
associated activity is thus of relevance when considering the inhibitory effects of
PAIs on uPA. This is supported by the findings of Siefert et al. (2014) that the
absence of SerpinB2, not SerpinE1 coincided with an increase in uPA activity and
faster venous thrombus resolution using a deep vein thrombosis model within wildtype C57BL/6, SerpinB2(-/-) , and SerpinE1(-/-) mice.
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Table 1.3: Inhibition kinetics of SerpinB2 for uPA and tPA (adapted from
(Lee et al. 2011)).
Plasminogen
Solution phase
Receptor bound
Activator
sc-tPA
(4.6±0.6) x 103 M-1s-1 ⃰
(Thorsen et al. 1988)
tc-tPA
(2.0± 0.02) x 105 M-1s-1
(Thorsen et al. 1988)
2.5 pM †‡ (Leung et al. 1987)
sc-uPA
ND
ND
tc-uPA
(2.1± 0.2) x 106 M-1s-1
(Thorsen et al. 1988)
5.3 x 105 M-1s-1 (Ellis et al. 3.3 x 105 M-1s-1 ¥ (Ellis et al.
1990)
1990)
~ 20 pM ‡ (Leung et al.
60 - 80 pM ‡∞ (Al-Ejeh et al.
1987)
2004)
⃰ 2nd order rate constant
† Bound to poly-D-lysine
‡ Inactivation constant K
i
¥ Bound to human monocytoid cell lines
∞ Bound to human carcinoma cell lines
ND – not determined

SerpinB2 is also a poor inhibitor of free circulating (single chain) sc-tPA (in contrast
to SerpinE1) (Thorsen et al. 1988; Kruithof et al. 1995) (Table 1.3). The ability of
SerpinB2 to inhibit bound tc-tPA appears to depend on the type of tPA binding
interaction. For example, fibrin-bound tPA is protected from inhibition by SerpinB2
(Leung et al. 1987) (although SerpinB2 crosslinked to fibrin can inhibit tPA (Ritchie
et al. 2001)), while poly-D-lysine-bound-tPA is not protected (Leung et al. 1987)
(Table 1.3). SerpinB2 has also been shown to inhibit tc-tPA bound to various cell
types in vitro and to purified AIIt (Lobov et al. 2008). Where studied, SerpinB2 has
poor inhibitory activity against other serine proteases (reviewed in (Kruithof et al.
1995)).
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1.13.

Intracellular SerpinB2

A new focus into SerpinB2 research was invoked when it became apparent that
unlike SerpinE1, the highest expression levels of SerpinB2 are found intracellularly
within monocytes and macrophages in vitro (Kruithof et al. 1986; Genton et al.
1987). The potential roles described for intracellular SerpinB2 have typically not
been associated with a classical inhibitory serpin function but rather with a variety
of potential functions ranging from signal transduction (Antalis et al. 1998) to
inhibition of apoptosis in some cell models (Dickinson et al. 1995) but not others
(Fish and Kruithof 2006). Whilst a definitive function for intracellular SerpinB2 has
not been forthcoming, it has become clear that SerpinB2 is an immune modulator
(Schroder et al. 2010; Zhao et al. 2013; Shea-Donohue et al. 2014). This role is
supported by the subsequent reports showing up-regulation of SerpinB2 in
response to a barrage of inflammatory stimuli within these and other cell types
(Table. 1.2).

1.14.

Inflammation and Pathogenesis

The role of SerpinB2 in response to inflammatory mediators is well studied and a
strong association between IL-1β suppression and SerpinB2 has been formed
using in vivo mouse and in vitro cell models (Bystrom et al. 2004; Park et al. 2005;
Greten et al. 2007; Sekine et al. 2009). The initial hypothesis for how SerpinB2
controlled IL-1β activation, rotated around the inhibition of caspase-1 (interleukin1β-converting enzyme [ICE]) by SerpinB2 (Jensen et al. 1999). Whilst this has
never been proven, it is now known that SerpinB2 gene expression is regulated by
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transcription factor NF-κβ under inflammatory conditions and the up-stream
mediators of NF-κβ (i.e. IKKβ) are thought to be responsible for the control of IL1β secretion (Greten et al. 2007). This is supported by a study in which Schroder
et al. (2010) were unable to detect any difference in IL-1β secretion when
comparing resting peritoneal macrophages isolated from the SerpinB2-/- mouse
model (Dougherty et al. 1999), to littermates (SerpinB2+/+). Importantly, this study
reinforced the link between SerpinB2 expression and adaptive immunity, with the
finding that SerpinB2 appears to function in the suppression of TH1-promoting
cytokine production (Schroder et al. 2010). The mechanisms associated with this
are currently unclear. Of interest however, is the recent finding that SerpinB2
depletion in macrophages induces caspase-1 activation and IL-1β production in
response to TLR agonists and Escherichia coli (Chuang et al. 2013). Furthermore,
interactions between SerpinB2 and Beclin 1 lead to an increase in autophagy,
which coincided with decreased IL-1β maturation. Thus providing possible insight
into the functional mechanisms of SerpinB2 as an immune modulator and
inflammatory mediator.

The link between SerpinB2 with immune function is not new and up-regulation of
SerpinB2 by monocytes and macrophages in response to a variety of pathogens
such as Dengue Virus (Krishnamurti and Alving 1989; Krishnamurti et al. 1989),
Legionella pneumophilia (Losick and Isberg 2006), Borrelia burgdorferi (Haile et
al. 2006) and Mycobacterium avium infection (Gan et al. 1995) has been reported.
Also, elevated SerpinB2 mRNA in eosinophilic leukocytes has been linked to
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protection from parasitic organisms, inflammation and asthma (Swartz et al. 2004).
In asthma patients, SerpinB2 levels are suppressed by anti-inflammatory steroids
such as glucocorticoids (Table. 1.3). More recently, elevated SerpinB2 expression
has been observed in monocytes co-cultured with Aspergillus fumigatus, a fungi
infecting immuno-compromised patients (Loeffler et al. 2009). Whilst the
expression profiles for SerpinB2 in response to inflammation and pathogenesis are
consistent, the function of SerpinB2 has not been defined, although the hypothesis
that SerpinB2 protects against apoptosis within these environments appears to be
supported in some cell models, but not others.

1.14.1.

Apoptosis

The hypothesis that intracellular SerpinB2 may play a role in protection against
apoptosis arose due to the chromosomal co-localisation of a potent inhibitor of
apoptosis bcl-2 (B-cell lymphoma) and SerpinB2 genes, along with their coexpression during cellular stress (Silverman et al. 1991). Early work conducted
using the HT1080 fibro sarcoma cell line transfected with SerpinB2 reported
delayed apoptotic responses within these cells following TNF-α challenge, when
compared to controls (Kumar and Baglioni 1991; Dickinson et al. 1995).
Furthermore, SerpinB2 was found to protect primary cultures of human
macrophages from apoptosis following in vitro infection with Mycobacterium avium
and treatment with indomethacin (Gan et al. 1995). Therefore the hypothesis that
SerpinB2 may inhibit an undefined intracellular protease was formed. This was
supported by the identification a cleaved 33 kDa intracellular SerpinB2 species in
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NB4 leukaemia cells following induction of apoptosis with okadaic acid, calyculin A
and the protein synthesis inhibitor cycloheximide (Jensen et al. 1994). It was
suggested SerpinB2 may undergo intracellular processing during apoptosis
resulting in a cleaved yet active inhibitor, given the detection of cleaved SerpinB2
in complex with uPA. Indeed, Jensen et al. (1999) found that SerpinB2 cleavage
occurred within the first two hs of okadaic acid or camptothecin induced apoptosis
in the HL-60 pro-myeloid cell line and that this occurrence was negated by the
inhibition of caspase-1 using the peptide inhibitor YVAD-cmk. However, an in vitro
assay revealed that SerpinB2 was not a substrate for caspase-1 or caspase-3. The
functional mechanisms, significance and protease/s involved in the production of
the 33 kDa species of SerpinB2 during early apoptosis are still unknown.

Interestingly, transfection of HeLa cells with the SerpinB2-∆C-D interhelical loop
mutant did not replicate the protective effect of wild-type SerpinB2 against TNFα/cycloheximide induced apoptosis, indicating a functional role for the unique C-D
loop (Dickinson et al. 1998). The identification of Gln residues at positions 83,84
and 86 as substrate sites for transglutaminase within the C-D interhelical loop
(Jensen et al. 1994) and subsequent characterisation of SerpinB2 in complex with
members of the transmembrane annexin family (annexins I, II, IV and V) (Jensen
et al. 1996) suggests a role for stabilisation of the apoptotic envelope during early
apoptosis. This is supported by the observation of SerpinB2 incorporation into the
cornified envelope of differentiated keratinocytes (Jensen et al. 1995), possibly
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through transglutaminase cross-linking. It is thought that SerpinB2 may help to
maintain membrane structure and integrity within keratinocytes.

The epidermis is a high SerpinB2 expressing environment, under normal
physiological conditions (Hibino et al. 1988). Therefore the role of SerpinB2 in
keratinocyte biology presents another area of interest to researchers. A link
between reduced proliferation and SerpinB2 expression in keratinocytes was
reported by Hibino et al. (1999). Shortly after, Zhou et al. (2001) found that basal
keratinocytes over expressing SerpinB2 in a transgenic mouse model, were highly
susceptible to chemically induced cutaneous papilloma formation. Repeated
application of 12-O-tetradecanoylphorbol-13-acetate (TPA) to the skin of the mice
resulted in lesion formation on 97% of the transgenic mice versus 65% in the
control group. Furthermore, the papilloma lesions observed on the skin of control
mice were found to regress as a result of apoptosis once treatment was withdrawn,
whilst those of the transgenic mice persisted. The authors reported very low
detection of apoptotic cells within the papillomas of the transgenic mice compared
to controls. It is important to note that the control mice were SerpinB2 positive and
therefore representative of a normal expression profile, which was below
detectable levels. However, taken together the persistence of the papilloma lesions
on the skin of the transgenic mice contributes to the idea that in this context at
least, SerpinB2 protects against commitment to cell death. Indeed, this is in line
with the recent characterisation of Annexin I and SerpinB2 high molecular weight
complexes extracted from cell lysates of human macrophages undergoing
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apoptosis following in vitro infection with Mycobacterium avium (Gan et al. 2008)
and corroborates the earlier works of Jensen et al. (1994) and Jensen et al. (1996).

However, despite the accumulated support for SerpinB2 as an anti-apoptotic agent
the specific function and mechanisms associated with this proposed role have not
been identified or fully characterised. Recently Fish and Kruithof et al. (2006)
conducted a thorough investigation of SerpinB2 in the prevention of TNF-α induced
apoptosis using HeLa, Isreco-1 and HT1080 cell lines. The study compared the
effect of wild-type SerpinB2, SerpinB2-∆-C-D interhelical loop and reactive centre
(R380A) mutants; SerpinB2 null, SerpinB2 expressing and SerpinB2 overexpressing cell models in addition to the application of exogenous SerpinB2 to
cultures. Despite this, however, they were unable to replicate any of the earlier
work showing a protective role for SerpinB2 in apoptosis. Unlike earlier works,
these investigators used a lenti-viral transfection system which may explain the
contrast in results between their findings and others works. Furthermore,
overexpression of SerpinB2 in pulmonary arterial smooth muscle cells was
recently shown to enhance apoptosis whilst suppressing proliferation and
migration (Zhang et al. 2015). Knockdown of SerpinB2 was then shown to
suppress apoptosis and enhance proliferation and cell migration, suggesting
possible cell context differences.
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1.14.2.

Other intracellular binding partners of SerpinB2

Irrespective of the conflicting results supporting a role for SerpinB2 in apoptosis, a
protease binding partner for intracellular SerpinB2 remains to be identified. The
distribution of SerpinB2 within the nucleus, cytoplasm and the extracellular
environment suggests alternate functions, independent of its role as a serpin,
which may be dependent on the previously described binding sites within the C-D
interhelical loop.

The C-D interhelical loop contains three transglutaminase sites previously
mentioned, a cysteine at position 79 (C79) which is functional in the polymerisation
of SerpinB2 (Mikus and Ny 1996; Wilczynska et al. 2003; Lobov et al. 2004)
(discussed in section 1.7), and a PENF motif: in addition, asparagine at position
75 (N75) is glycosylated in extracellular SerpinB2. It is not surprising therefore that
non-serpin related interactions, most of which are dependent on the C-D
interhelical loop of SerpinB2 have been reported and include; Interferon regulatory
factor-3 (Zhang et al. 2003), PSMB1 (Fan et al. 2004; Schroder et al. 2010; O'Hara
et al. 2013), Annexin I, II, IV and V (Jensen et al. 1996; Gan et al. 2008) and
retinoblastoma protein (Rb) (Darnell et al. 2003).

The tumour suppressor, Rb protein, was identified as a binding partner for
SerpinB2, by Darnell et al. (2003). Stable transfection of the HeLa cervical
carcinoma cell line with SerpinB2 resulted in an increase in Rb protein levels
compared to control cells. This was supported by the detection of increased Rb
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expression and stability in the Jurkat cell line when transfected with SerpinB2.
Furthermore, co-localisation of SerpinB2 with Rb in the nucleus of HeLa and other
cell lines, was observed.

HeLa cells are positive for human papilloma virus (HPV) – 18 oncoproteins, of
which, E6 and E7 fusion proteins are responsible for the degradation of Rb
(Scheffner et al. 1992; Boyer et al. 1996). Interestingly the authors reported a
decrease in mRNA for E6/E7 within the SerpinB2 positive HeLa cells. Taken
together it was hypothesised that SerpinB2 was acting to inhibit degradation of Rb
protein by an undefined cellular protease, recently hypothesised to be calpain
(Tonnetti et al. 2008), and in the case of HPV-18 positive cells, through the
suppression of E6/E7 mRNA expression. Further investigation by Darnell et al.
suggested that SerpinB2 suppresses HPV oncogenes by stabilisation of Rb, which
subsequently silences the HPV-18 up-stream regulatory region (URR) responsible
for E6 and E7 transcription (Darnell et al. 2005).

Whilst this represented the first solid indication of a role for intracellular SerpinB2,
Fish et al. (2006) were unable to detect any difference in Rb expression when
comparing IS-1 and HT1080 cell lines transfected with wild-type SerpinB2 or
inactive SerpinB2 (R380A), relative to controls and between transfected cells.
They did however; report a slight elevation of Rb protein within transduced HeLa
cells compared to control cells, although there was no difference in Rb detection
between wild-type SerpinB2 or inactive SerpinB2. In a recent study, no correlation
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between SerpinB2 expression and prognostic outcomes could be found following
assessment of 225 cervical biopsy specimens. SerpinB2 expression did however
increase with lesion grade (Syrjanen et al. 2009).

1.14.3.

Neurology

Very little is known about the role of SerpinB2 within neurobiology, however
astrocytes (Dietzmann et al. 2000) and neurons (Yamanaka et al. 2005) have been
reported to synthesise this protein. Furthermore, an early study conducted by
Akiyama et al. (1993) reported high SerpinB2 deposition within microglia, which
surrounded the senile plaques associated with Alzheimer’s Disease (AD) and
much lower antigen detection in control tissue. The authors surmised that
SerpinB2 was inhibiting proteolysis within the localised extracellular environment
and therefore contributing to the prevalence of the disease. Importantly, AD lesions
represent high inflammatory environments (McGeer and McGeer 2002) and
microglial cells are the macrophage equivalent within the central nervous system.
Therefore, up-regulation of SerpinB2 by microglia in AD is most likely due to the
inflammatory environment of AD lesions, which is in-line with the many cell models
showing increases of SerpinB2 mRNA and/or antigen in response to proinflammatory cytokines (Table. 1.2). Recently, SerpinB2 was identified as a binding
partner for the cell adhesion molecule CHL1 which promotes CHL1-induced
neurite outgrowth and neuronal migration in mice (Katic et al. 2014). Whilst, Zhang
et al. (2009) have identified SerpinB2 as one of nine key neuronal protective
proteins expressed in response to brain trauma, that are required for survival of
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cultured hippocampal neurons suggesting that SerpinB2 may be important in
controlling haemostasis within the central nervous system also. SerpinB2 is highly
expressed within micro-environments undergoing acute and chronic homeostatic
imbalances which suggest a broader function as an inflammation modulator, not
limited to immune response pathways. Most of the early in vivo studies utilised
immunohistochemisty to assess expression of SerpinB2 in-conjunction with other
aspects of the PA system and while this confirmed the presence of SerpinB2 within
the tissue examined, it has not contributed to the development of functional role/s.
Furthermore, it is difficult to accurately discern the location of SerpinB2 antigen as
either intracellular or extracellular within the earlier immunohistochemistry works.
Therefore, this line of investigation is warranted given the earlier reports of
SerpinB2 deposition within amyloid plaques of Alzheimer’s patients and more
recent associations with Amyloid Lateral Sclerosis (ALS) animal model and
oxidative stress induced expression of SerpinB2 (Boutahar et al. 2011).

1.15.

Rationale and Specific Aims of the Thesis

This thesis aims to examine; 1) the role of SerpinB2 within the extracellular
environment as a plasminogen activator inhibitor in monocytes and 2) the role of
SerpinB2 within the intracellular environment as a stress response protein.

There have been many studies conducted which have defined and supported the
role of SerpinB2 as a classical inhibitory serpin, at a biochemical level. More recent
studies have clearly shown that SerpinB2 facilitates the rapid endocytosis of
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uPA:uPAR complexes from the cell surface of PC-3 (Croucher et al. 2006) and
MCF-7 (Croucher et al. 2007; Cochran et al. 2011) cell lines, via members of the
Low Density Lipoprotein Receptor (LDLR) family. However, these findings
contradict those described using the THP-1 monocytic cell line by Ragno et al.
(1995). This inconsistency within the published literature led us to examine, using
similar techniques to those described for the above mentioned breast and prostate
cells, the role SerpinB2 may or may not play in uPA clearance from the surface of
monocytic cell lines. Furthermore, the role of either SerpinE1 or SerpinB2 in the
inhibition and endocytosis of tPA at the cell surface is unclear. Given that the main
producers of SerpinB2 are monocytes and macrophages the control of plasmin
generation via uPA or tPA, by SerpinB2 at the cell surface warrants further
investigation.

Therefore, the aims of chapter 2 were to investigate the inhibition of cell surface
uPA by SerpinB2 and characterise the endocytosis pathways facilitating clearance
of uPA:SerpinB2 complexes, once formed at the surface of monocytic cell lines.
Confirmation of similar endocytosis pathways to those described by Croucher et
al. (2006) and Croucher et al. (2007), will aid in establishing a robust model for
SerpinB2 and contribute towards establishing its role as a physiological inhibitor of
uPA. An additional aim addressed in chapter 2 was to assess the potential for use
of SerpinB2 based therapeutics in the treatment of acute myeloid leukaemia
(AML).
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The specific aims of chapter 3 were to examine inhibition of tPA by SerpinB2 and
characterise the role of LRP and VLDLR as potential endocytosis receptors for tPA
and tPA:PAI complexes on these cells. Cell profiling of the U-937 and THP-1 cell
line in addition to PBMs was undertaken to ascertain the basal PA levels present
on the surface of malignant versus healthy myeloid cells with the aim of assessing
the potential impact SerpinB2 directed therapeutics may have through non-uPA
facilitated endocytosis pathways.

Up-regulation of intracellular SerpinB2 in response to acute and chronic
homeostatic imbalances suggests a potential function within cellular stress
response pathways. This hypothesis is supported by the lack of an intracellular
protease target for SerpinB2, suggesting a non-inhibitory role. Of interest is the
finding that some non-inhibitory serpins appear to function as transport
chaperones/molecules, cytoskeleton support molecules or heat shock proteins, all
with very specific targets or niches (Hammond et al. 1987; Pemberton et al. 1988;
Tasab et al. 2000; Sauk et al. 2005; Finno et al. 2015). In this context, SerpinB2
presents as a co/chaperone or shuttle protein given the promiscuity of described
binding interactions with many partners and no known associated function, despite
40 years of research. Importantly, promiscuity is a common characteristic
associated with molecular chaperones (Hartl et al. 2011). Therefore the specific
aims of chapter 4 were to assess the possible chaperone-like activity of SerpinB2,
using an array of amorphous and fibril forming substrate models.
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The specific aims of chapter 5 were to gauge a better understanding of the cellular
pathways in which SerpinB2 may function as a stress response protein. The
intracellular processing of aberrant protein trafficking was assessed using wildtype and SERPINB2-/- murine embryonic fibroblasts and a transient huntingtin
expression model.
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2. Investigation of SerpinB2 as a potential therapy
delivery mechanism for the treatment of acute
myeloid leukaemia.
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2.1.

Abstract

The high prevalence of drug resistance in Acute Myeloid Leukaemia (AML) has
led to the development of toxin-fusion-proteins for the treatment of this disease.
Here we report the preliminary investigation of SerpinB2 as a potential toxin
delivery and internalisation mechanism in the treatment of AML. The U-937 and
THP-1 cell lines were found to endocytose SerpinB2 via the urokinase
plasminogen activation system (uPA) and low density lipoprotein receptor (LDLR)
family pathways. This work indicates the potential for use of SerpinB2 based
therapeutics in the treatment of AML.

2.2.

Introduction

Acute myeloid leukaemia (AML) originates from the myeloid stem cells within the
bone marrow and has traditionally been sub-typed based on morphology with
respect to their stage of myeloid differentiation (Meshinchi and Arceci 2007).
Despite the advances in therapy development for the treatment of AML, this
disease accounts for more than half of the leukaemia related deaths in paediatric
patients (Meshinchi and Arceci 2007). This appears to be linked to the high
occurrence of multiple drug resistance (MDR) within this patient cohort (Meshinchi
and Arceci 2007). Due to the problematic treatment of AML patients with MDR,
research focus is growing in the development of targeted toxin-fusion protein
therapies.
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Of particular interest as a potential cell surface targeted antigen in AML patients is
the urokinase plasminogen activation (uPA) system, which is associated with
pericellular proteolysis via the conversion of plasminogen to plasmin (Ellis et al.
1990). Elevated expression of the uPA system by leukaemic cells has been widely
documented and is thought to contribute to excessive bleeding and poor prognosis
of patients (Wada et al. 1993; Hildenbrand et al. 1999; Scherrer et al. 1999; Graf
et al. 2005; Ohba et al. 2005). Control of cell surface plasmin generation may be
mediated through the inhibitory functions of the serpins plasminogen activator
inhibitors (PAI) type 1 (SerpinE1) and 2 (SerpinB2) (Ellis et al. 1990). Inhibition of
receptor bound uPA at the cell surface facilitates the rapid endocytosis of the
inhibited complex via the family of low density lipoprotein receptors (LDLR)
(Croucher et al. 2006). Pre-clinical evaluations conducted using human breast and
prostate carcinoma xenograft murine models, have shown that systemic (i.p.)
administration of
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causes tumour growth inhibition in a dose-

dependent manner (Allen et al. 2003; Stutchbury et al. 2007).

Furthermore, the

delivery pathway was found to be uPA dependant (Al-Ejeh et al. 2004; Croucher et
al. 2006; Croucher et al. 2007). Whilst SerpinB2 shows promise as a delivery
mechanism for anti-cancer therapy directed at solid tumours, it’s suitability for use
in the treatment of haematological malignancies has not been investigated.

2.2.1.

Specific Aims

The aims of this study were to investigate the inhibition of cell surface uPA by
SerpinB2 and characterise the endocytosis pathways facilitating clearance of
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uPA:SerpinB2 complexes once formed at the surface of monocytic cell lines. Using
a fluorescence quenching internalisation assay and inhibitory antibodies (Al-Ejeh
et al. 2004), we show that SerpinB2 is endocytosed by the histocytic lymphoma U937 cell line and the AML cell line THP-1, in a uPA and LDLR family dependent
manner indicating that further development of SerpinB2 based therapies is
warranted for the treatment of AML.

2.3.

Experimental Procedures

2.3.1.

Proteins, Antibodies and Reagents

Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd
(Sydney, Australia). Purified human receptor associated protein (RAP) was from
Molecular Innovations (MD, USA). Monoclonal murine anti-human uPA B-chain
IgG1 (#394), monoclonal murine anti-human uPAR IgG2a (#3936) and monoclonal
murine anti-human LRP -chain IgG1 (#3402) were from American Diagnostica
Inc. (USA).

Polyclonal rabbit anti-human VLDLR IgG was from Santa Cruz

Biotechnology, Inc.

Polyclonal goat anti-rabbit FITC conjugate IgG (whole

molecule), goat anti-mouse IgG (Fab specific) FITC conjugate, propidium iodide
(PI), Hanks balanced salt modified and non-modified and bovine serum albumin
(BSA) were from Sigma-Aldrich. Anti-DNP rabbit polyclonal isotype control was
from DakoCytomation (Glostrup, Denmark). Alexa-488 labeling kit and Alexa-488
quenching polyclonal antibody were from Molecular Probes (OR, USA). RPMI1640 powder and foetal calf serum were from Trace Bioscientific (NSW, Australia).
The rabbit anti-human LRP polyclonal and murine anti-human VLDLR monoclonal
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antibodies 1H5, 5H3 and 1H10 were a kind gift from Professor Dudley Strickland,
USA (Ruiz et al. 2005; Croucher et al. 2006).

2.3.2.

Cell Lines and Tissue Culture Conditions

The monocyte like U-937 histocytic lymphoma and THP-1 human monocytic
leukaemic cell lines were used for all experiments. Cells were maintained in
medium consisting of RPMI-1640, 5% (U-937) or 10% (THP-1) heat inactivated
fetal calf serum and 2 mM glutamine at 37 C and 5% CO2 enriched humidified air.

2.3.3.

Immunofluorescence Assays

Cell surface antigens were measured by dual colour immunofluorescence and flow
cytometry as previously described (Al-Ejeh et al. 2004). Internalisation assays
were conducted using the fluorescence quenching internalisation assay as
described previously (Al-Ejeh et al. 2004; Croucher et al. 2006). Briefly, cells were
incubated at 37 C for 1 h in the absence (control) of presence of 10 nM
SerpinB2Alexa488 in Hanks buffer. The cells were next washed twice and incubated
on ice for 30 min with 4 g.mL-1 Alexa488 quenching antibody (quenches any
remaining cell surface fluorescence and is thus a measure of internalised ligand)
in ice cold Hanks buffer. Finally, the cells were washed twice with ice cold PBS
and analysed using flow cytometry as described above.

All assays were

conducted in triplicate and appropriate background controls subtracted.
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2.3.4.

Plasmin Generation Assays

Briefly, cells were harvested, washed twice and resuspended at 1x10 6 cells.mL-1
in Tris-buffered saline (TBS) (50 mM Tris HCl, 150 mM NaCl, pH 7.4). Cells were
pre-incubated in the absence or presence of 10 nM uPA on ice for 30 min, washed
twice in TBS and then resuspended in 100 μL TBS in the presence of 10 μg
plasminogen. Following 15 min pre-incubation at room temperature, 100 uL of
Spectrozyme PL substrate was added to a final concentration of 0.25 mM.
Substrate conversion by plasmin was measured kinetically at 405 nm over a 2 h
period at 37 C in a Molecular Devices SpectraMax 250 plate reader, and analysed
using SoftMax® Pro software (Molecular Devices, USA).

Negative controls

contained TBS buffer and either 0.25 mM Spectrozyme PL or whole cell
suspension made to a final volume of 200 μL with TBS buffer. Positive control
consisted of 1 μg uPA, 10 μg plasminogen in 100 μL TBS and 100 μL 0.5 mM
Spectrozyme Pl.

All assays were conducted in triplicate and appropriate

background controls subtracted.

2.3.5.

Statistical analysis

Students paired t-tests were performed using Graphpad Prism (USA) to determine
statistical significance p<0.05.
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2.4.

Results

To confirm basal cell surface expression levels of the uPA and uPAR by the U-937
and THP-1 cell lines, immunofluorescence assays were undertaken using flow
cytometry. Both components were detected at the cell surface of both cell lines,
but compared to the U-937 cell line, the THP-1 cell line showed 7 and 16.5 fold
higher levels of uPAR and uPA antigens, respectively (Fig. 2.1).

Previous studies have shown that the rapid endocytosis of uPA:SerpinB2
complexes on human carcinoma cell lines are facilitated by interactions with LRP
(Croucher et al. 2006) and VLDLR (Croucher et al. 2007). Therefore LRP and
VLDLR were considered the most probable LDLR candidates for the endocytosis
of uPA:SerpinB2 complexes on the U-937 and THP-1 cell lines. Indeed VLDLR
and LRP were detectable on both cell lines (Fig. 2.1). While low on both cell lines
the expression level of LRP was 2-fold higher on the THP-1 cell line compared to
the U-937 cell line (Fig. 2.1). Both cell lines displayed distinctly measurable
VLDLR, with the THP-1 cell line displaying a 6-fold increase in VLDLR expression
compared to the U-937 cell line (Fig. 2.1).
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u-PAR

u-PA

LRP

VLDLR

A

GM: 13.4 ± 0.79

GM: 4.27 ± 1.27

GM: 4.13 ± 0.79

B

GM: 92.93 ± 16.98

GM: 71.19 ± 0.96

GM: 9.14 ± 1.17

GM: 19.28 ± 3.30

GM: 145 ± 18

Figure 2.1: Histogram plots showing cell surface expression levels of u-PAR, u-PA, LRP and
VLDLR, on the (A) U-937 and (B) THP-1 monocytic cell lines. Cells were assayed using indirect
immunofluorescence and flow cytometry. Geometric means (GM) indicate fluorescence intensity
values for specific antibodies (unfilled) with isotype-matched control antibody (filled) values
subtracted, ± SD, (n=3).
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To obtain a quantitative indication of the cell surface plasminogen activation
potential of U-937 and THP-1 cell lines and to compare the SerpinB2 inhibitory
capacity, whole cell plasmin generation assays were conducted. Low levels of
intrinsic plasmin generation by the U-937 (Fig. 2.2) cell line was detected which is
indicative of low endogenous uPA, or indeed tPA levels (refer Fig.2.1). While still
low, the THP-1 cell line had higher levels of endogenous plasmin generation than
the U-937 cell line (Fig. 2.2), reflecting higher levels of uPA on these cells.
Importantly this activity was found to be inhibited in the presence of SerpinB2 (Fig.
2.2), confirming previous studies (Ellis et al. 1990). Pre-treatment with 10 nM uPA
significantly increased the plasminogen activating potential of both cell lines (Fig.
2.2), indicating that a portion of the uPAR detected at the cell surface was
unoccupied in both cell lines. In both cases SerpinB2 significantly abrogated this
activity to below levels in the absence of added uPA (Fig. 2.2).
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Figure 2.2: Inhibition of cellular plasminogen activation by SerpinB2. U-937
(unfilled bars) and THP-1 (filled bars) cells were pre-treated in the absence or
presence of 10 nM u-PA and 10 nM SerpinB2 as indicated. Then glu-plasminogen
was added at a final concentration of 0.25 μM and the rate of plasmin formation in
the
absence
or presence
of 10to
nM
SerpinB2
where
indicated
wassurface,
analysed using
Given
the ability
of SerpinB2
efficiently
inhibit
uPA
at the cell
Spectrozyme PL substrate (ADI). Assays were conducted over 2 hs at 37C. Data
represents mean ± SEM, (n=3), background (cells only) subtracted. Statistical
analysis by 2-way ANOVA (solid lines) or t-test (dotted line) * = p<0.05, *** =
p<0.001, ns = not significantly different.

uPA:SerpinB2 complex clearance pathways were investigated. Inhibition in the
presence of RAP, a commonly used antagonist of ligand binding specific to the
LDLR family, significantly inhibited SerpinB2 internalisation seen in both the U-937
and THP-1 cell lines (Fig. 2.3A). The dependence of uPA was demonstrated using
a monoclonal antibody specific for the catalytic domain of uPA that, at the
concentration used, is known to block SerpinB2 complex formation with uPA at the
cell surface of other cell lines (Al-Ejeh et al. 2004). SerpinB2 internalisation was
significantly reduced by the MAb in both the U-937 (20%) and THP-1 (80%) cell
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lines (Fig. 2.3B). Again, this effect was more pronounced in the THP-1 cell line
which expresses significantly greater levels of endogenous uPA and uPAR
compared to the U-937 cell line. Taken together these results confirmed the role
of receptor bound uPA and LDLRs in the endocytosis of uPA:SerpinB2 by
monocytic cell types and that the effect was dependent on endogenous uPA
expression.

The involvement of VLDLR and LRP in the endocytosis of SerpinB2 was
investigated further using inhibitory antibodies.

Anti-VLDLR monoclonal

antibodies 1H5 and 1H10 were reported to be effective inhibitors of binding
interactions with VLDLR and apolipoprotein E (apoE) (Ruiz et al. 2005) and
uPA:SerpinB2 complexes in the MCF-7 cell line (Croucher et al. 2007). Therefore
an antibody cocktail comprising of 1H5, 1H10 and 5F3 was used to inhibit
uPA:SerpinB2 complex interactions with VLDLR.

Although 5F3 alone was not

found to efficiently inhibit apoE:VLDLR interactions this monoclonal epitope is
specific for the ligand binding repeats within VLDLR (Ruiz et al. 2005) suggesting
it may efficiently inhibit the uPA:SerpinB2 complex interactions. As expected, the
application of the antibody cocktail inhibited a proportion of SerpinB2
internalisation showing some VLDLR dependence in the endocytosis of SerpinB2
by the U-937 and THP-1 cell lines (Fig. 2.3C).

Higher concentrations of the

antibody cocktail gave similar results. Consistent with this, the rabbit anti-LRP
polyclonal antibody previously found to inhibit uPA:SerpinB2 complexes (Croucher
et al. 2006) was also able to block SerpinB2 internalisation in the U-937 cell line
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Figure 2.3: Internalisation of SerpinB2:Alexa488 by U-937 (unfilled) and THP-1
(filled) cell lines. (A) Representative data shows SerpinB2 internalisation signal
pattern. Assays were conducted in the absence (control) or presence of 200 nM
RAP and either (B) 20 μg.mL-1 anti-uPA monoclonal antibody or 20 μg.mL-1
matched isotype control (MIC) where indicated, or (C) 15 μg.mL-1 anti-VLDLR
monoclonal antibodies (5H1, 5F3, and 1H10, 5 μg.mL -1 each) or 15 μg.mL-1 MIC
where indicated or (D) 50 μg.mL-1 anti-LRP polyclonal antibody or 50 μg.mL-1 MIC.
Cells were cultured for 1 h at 37 C in the presence of 10 nM SerpinB2:Alexa488,
surface bound SerpinB2:Alexa488 was quenched by incubating cells with 4 μg.mL1 anti-Alexa488 monoclonal antibody for 30 min prior to analysis by flow cytometry.
All values shown are means ± SEM (n=3). For panels B-D values are normalised
to the control (representing no inhibitory antibody and therefore total internalised
SerpinB2) for each cell line. Statistical analysis by 2-way ANOVA (solid lines) or ttest (dotted line) * = p<0.05, *** = p<0.001, ns = not significantly different.
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but not in the THP-1 cell line (Fig. 2.3D). The difference in antibody blocking
efficiency between the cell lines may be a result of substantially more VLDLR and
LRP on the THP-1 cell line (refer Fig. 2.1.B) and therefore less efficient inhibition.

2.5.

Discussion

In this study, we confirmed the presence of uPA, uPAR and LDLR family members
at the surface of U-937 and THP-1 monocytic cell lines. The basal levels of uPAR
and uPA detected at the cell surface were higher on the THP-1 cell line compared
to the U-937 cell line. This is likely due to their differences in maturation along the
myeloid differentiation lineage. However, it is important to note that the THP-1 cell
line is a naturally occurring SerpinB2 null model, in that the SerpinB2 mRNA is
truncated and the translation product inactive (Gross and Sitrin 1990; Katsikis et
al. 2000). Therefore the lack of endogenous SerpinB2 in the THP-1 cell line may
also contribute to the higher uPA levels detected, compared to the U-937 cell line.
Importantly, the differences in detectable uPA and uPAR expression levels
observed between these cell lines was supported by the clear difference in
plasminogen activation potential, therefore presenting two distinctive cell models
for the examination of uPA facilitated SerpinB2 internalisation. The data presented
here is consistent with previous studies on carcinoma cell lines (Croucher et al.
2006; Croucher et al. 2007), using similar techniques and reagents. However, this
contradicts the work of Ragno et al (1995), who reported that the majority of
preformed uPA:SerpinB2 complexes added to THP-1 cells were cleaved and
released into the supernatant as a 70 KDa species rather than being internalised.
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Conditioned supernatants were not examined within our study, therefore the
presence of a 70 KDa species representing cleaved uPA complexed with SerpinB2
cannot be ruled out, however distinct differences in methodology may explain the
conflicting results. Specifically, Ragno et al (1995) used widely accepted acid
stripping techniques to remove uPAR bound uPA from the cell surface, prior to
incubation with pre-formed uPA:SerpinB2 or uPA:SerpinE1 complexes. The
method described here (and as per (Croucher et al. 2006)) did not require harsh
pre-treatment of the cell line, which could compromise the balance of membrane
associated proteases, thus leading to premature degradation of the uPA:SerpinB2
complex.

Furthermore, we pre-loaded uPAR with uPA, prior to addition of

SerpinB2 which is therefore indicative of mechanisms associated with cell surface
inhibition of uPA, which may alter endocytosis dynamics, specific to the THP-1 cell
line, or indeed myeloid cells. Regardless, our results clearly show the involvement
of VLDLR and LRP in the endocytosis of SerpinB2 via a uPA dependant
mechanism by both the U937 and THP-1 cell lines.

Thorough investigation of expression for both antigens by malignant haemopoietic
cell types has revealed a correlation between differentiation and uPAR expression.
AML - M0 subtype displays low levels of uPAR expression compared to M5
subtype, whilst all AML subtypes have been found to express uPA (Lanza et al.
1998; Scherrer et al. 1999).

Importantly, uPA is the predominant plasminogen

activator in leukemic marrow, a characteristic not found in healthy marrow
(McWilliam et al. 1998; Scherrer et al. 1999), therefore SerpinB2 targeted

56

therapeutics may prove successful in eradicating MDR leukaemic blasts and stem
cells within the marrow of patients. As SerpinB2 interaction with uPA at the cell
surface facilitates the rapid endocytosis of the uPA:SerpinB2 complexes (Croucher
et al. 2006) this allows for fast uptake of therapeutics. The use of
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directed at solid tumours in preclinical trials has shown that SerpinB2 can target
uPA and deliver attached cytotoxins (Stutchbury et al. 2007), it is therefore
hypothesised that SerpinB2 directed therapies may be as effective for the
treatment of haematological malignancies expressing uPA if not more so due to
the enhanced cell surface accessibility of single cell malignancies.

Furthermore, as the endocytosis of uPA:SerpinB2 complexes is in part VLDLR and
LRP dependent in the U-937 and THP-1 cell lines, utilisation of this specific
endocytosis process in the design of fusion toxins will allow increased specificity
for SerpinB2 directed therapeutics, giving potential for tailoring to the individual.
This is of particular importance given the potential for alternative endocytosis
pathways for internalisation of SerpinB2, as indicated by this work. Whereby,
complete inhibition of SerpinB2 internalisation using either RAP or LDLR inhibitory
antibodies was not possible. Investigation of the role scavenger receptors may play
is therefore required to further the development of SerpinB2 directed therapeutics.

Current treatment regimes for AML comprise of intensive combination induction
therapies and in some cases stem cell transplantations, despite this at least half
of paediatric patients who reach complete remission will relapse with poor
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prognostic outcomes (Meshinchi and Arceci 2007). For patients exhibiting high
uPA expression, SerpinB2:toxins may prove successful in targeting residual
leukaemic cells post-induction therapy, therefore reducing the cases of disease
relapse.

The preliminary work presented here contributed towards the proof of concept data
for the use of SerpinB2:cytotoxin targeting of the U-937 and THP-1 cell line.
Importantly, further work within our research group has since shown successful
uPA specific targeting of these cell lines (Vine et al. 2012).
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3. Differential Endocytosis of Tissue Plasminogen
Activator by Serpin E1 and SerpinB2 on Human
Peripheral Blood Monocytes
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3.1.

Abstract

Generation of the broad spectrum protease plasmin is facilitated by the tissue (tPA)
and urokinase (uPA) plasminogen activators, within multiple physiological and
disease states. Finely tuned control of this proteolytic cascade is exerted by the
plasminogen activator inhibitors type-1 (PAI-1/SerpinE1) and 2 (PAI-2/SerpinB2).
Expression of this network of activators and inhibitors by cells of myeloid lineage
appears to be highly interchangeable between physiological environments, and
whilst the role of SerpinE1 and SerpinB2 in regulating uPA-dependent functions is
well established, the interaction between tPA and SerpinB2 on myeloid cell types
is poorly characterised. To this end, we used freshly isolated peripheral blood
monocytes (PBM) as a model of a tPA-dependent cellular environment. We
demonstrate that while both SerpinE1 and SerpinB2 could inhibit surface-bound
tPA and are internalised predominately via low density lipoprotein receptor family
members, SerpinE1 enhanced the endocytosis of tPA, whereas SerpinB2 did not.
Surface plasmon resonance analyses revealed differential binding affinities
between the very low density lipoprotein receptor (VLDLR) and tPA and
tPA:SerpinE1 complexes in addition to those previously described with low density
lipoprotein receptor-related protein (LRP). Moreover, tPA:SerpinB2 bound to both
endocytosis receptors with similar kinetics to tPA. These differential biochemical
interactions between tPA and the tPA:PAI complexes may underlie the observed
differences in endocytosis mechanisms on the PBMs. This suggests that while
SerpinE1 and SerpinB2 function similarly in the control of cellular plasmin
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generation by tPA, they may have disparate effects on the alternative functions of
tPA via modulation of its engagement with endocytosis receptors.

3.2.

Introduction

The tissue plasminogen activator (tPA) converts plasminogen to plasmin, which is
involved in fibrinolysis, tissue remodelling and cell migration (Kruithof et al. 1995).
tPA is secreted as a single chain (sc-tPA), 72 kDa glycosylated protein, by
peripheral blood monocytes (Hart et al. 1989) and endothelial cells (Hajjar 1993).
Cleavage of sc-tPA produces the 62.9 kDa two chain (tc-tPA) conformation (Rijken
and Collen 1981). Both sc-tPA and tc-tPA display enzymatic activity towards
plasminogen, which is enhanced when they are bound to fibrin (Hoylaerts et al.
1982). In addition to fibrin interactions, both forms of tPA also bind and efficiently
activate plasminogen at the cell surface of monocyte (Felez et al. 1991; Felez et
al. 1996), macrophage (Noorman et al. 1995), endothelial (Ljungner et al. 1983)
and human tumour (Lobov et al. 2008) cell lines.

Control of plasmin generation by either form in vivo is thought to be mediated
predominantly through the inhibitory functions of the plasminogen activator
inhibitor type 1 (PAI-1/SerpinE1) and potentially to a lesser extent by plasminogen
activator inhibitor type 2 (PAI-2/SerpinB2) (Jorgensen et al. 1987). Both SerpinE1
and SerpinB2 efficiently inhibit tc-tPA in solution phase with second order rate
constants of ~107 and 105 M-1.s-1 , respectively, and both are inefficient inhibitors
of fibrin bound tPA (Thorsen et al. 1988; Ritchie et al. 1999). Therefore tPA:PAI
complexes are typically formed after tPA dissociates from the fibrin clot. However,
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SerpinE1 is considered the primary inhibitor of tPA as it is able to form serpinprotease complexes with both sc-tPA and tc-tPA and is found in normal human
plasma at concentrations ranging from 140 pM to 1.9 nM (Estelles et al. 1989).
SerpinB2 is only detected within plasma during late stage pregnancy but, with
concentrations ranging between 100-250 ng/mL (Kruithof et al. 1987; Hunt et al.
2009). A role in maintaining placental integrity has been described for SerpinB2,
as a regulator of fibrinolysis in normal pregnancy (Astedt et al. 1998), however,
little is understood about the potential of SerpinB2 as a physiological inhibitor of
tPA due to limited reports of tPA:SerpinB2 complexes identified in vivo (Kruithof et
al. 1995). Yet, co-expression of tPA and SerpinB2 has been shown in normal bone
marrow (McWilliam et al. 1998), skin (Chen et al. 1993), saliva and salivary gland
tissue (Virtanen et al. 2006), gingival fluid (Brown et al. 1995; Kinnby 2002), as
well during pregnancy (Astedt et al. 1998), and SerpinB2 is able to inhibit cell
surface bound tc-tPA in vitro (Lobov et al. 2008). Furthermore, enhanced
expression of both tPA and SerpinB2 by epithelial cells is indicative of some
disease states, e.g. periodontal disease (Kinnby 2002), psoriasis and
pre/eclampsia (Kruithof et al. 1995), strongly suggesting that SerpinB2 may control
tPA activity at sites of localised inflammation.

Whilst SerpinB2 expression can be up-regulated by a variety of cell types under
stress conditions, the predominant physiological producers of SerpinB2 are
monocytes and macrophages (Kruithof et al. 1995). Monocytes also express and
secrete tPA (Hart et al. 1989) which has been shown to bind to the surface of these
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cells via numerous and varied receptors (Felez et al. 1991; Otter et al. 1991;
Noorman et al. 1995). Furthermore, Ritchie et al. (1995) reported the up-regulation
of SerpinB2 expression by monocytes cultured in the presence of thrombin. This
suggests a potential role for SerpinB2 in the homeostatic balance between
thrombosis and fibrinolysis at local sites of inflammation or during wound healing
processes, possibly through the inhibition and clearance of tc-tPA from the
pericellular environment.

Clearance of tPA and tPA:SerpinE1 from the circulation via endocytic processes
in the liver is well characterised (Wing et al. 1991; Nguyen et al. 1992). The
mechanisms for endocytosis of these ligands have been shown to be dependent
on members of the low density lipoprotein receptor (LDLR) family, specifically LRP
(Bu et al. 1992; Orth et al. 1992) and scavenger receptors such as the mannose
receptor (CD206) (Otter et al. 1991). The rate of endocytosis of SerpinE1-inhibited
tPA was shown to be accelerated compared to tPA only, on rat hepatoma cells
(Camani et al. 1994). This acceleration in clearance was found to be due to the
increased affinity of tPA:SerpinE1 complexes for LRP (Horn et al. 1998).
Interestingly, Camani et al. (2000) found that Novikoff rat hepatoma cells, MEF-1
mouse embryonic fibroblasts, HT1080 fibroblasts and COS African green monkey
kidney cells were all able to degrade [125I]tPA and [125I]tPA:SerpinE1 via LRPmediated uptake, whilst the THP-1 and U-937 monocytic cell lines were not. The
authors suggested that a co-receptor, absent on the THP-1 and U-937 cell lines,
may be required for these ligands to interact with LDLRs. However, tPA was shown
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to specifically bind to the surface of freshly isolated peripheral blood monocytes
(PBM), THP-1 and U-937 cell lines (Felez et al. 1991). Macrophages derived from
human PBMs were shown to take up and degrade [ 125I]tPA via the mannose
receptor (Noorman et al. 1995). Furthermore, Simon et al. (1995) showed LDLRfamily dependant endocytosis and degradation of [ 125I]tPA:SerpinE1 by the THP1 cell line. Thus, the potential function of SerpinE1 or SerpinB2 in the inhibition
and enhanced endocytosis of tPA bound to myeloid cell types remains unclear.

3.2.1.

Specific Aims

In order to clarify and compare the role of these serpins as regulators of cellular
tPA, freshly isolated PBMs were utilised as a non-transformed tPA-dependent
cellular model representing myeloid lineages (McWilliam et al. 1998). The specific
aims of this chapter were to examine inhibition of tPA by SerpinB2 and
characterise the role of LRP and VLDLR as potential endocytosis receptors for tPA
and tPA:PAI complexes on these cells. Cell profiling of the U-937 and THP-1 cell
line in addition to PBMs were undertaken to ascertain basal PA levels present on
the surface of malignant versus healthy myeloid cells with the aim of assessing the
potential impact, if any SerpinB2 directed therapeutics may have through non-uPA
facilitated endocytosis pathways.
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3.3.

Methods

3.3.1.

Materials

Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd
(Sydney, Australia). Purified human receptor associated protein (RAP),
recombinant human serpinE1 (stable mutant) and human tc-tPA were obtained
from Molecular Innovations (MD, USA). Spectrozyme PL substrate, murine antihuman uPA B-chain IgG1 (#394), murine anti-human tPA IgG1 (#E-4) and murine
anti-human LRP -chain IgG1 (#3402) were supplied by American Diagnostica Inc.
(USA). Rabbit anti-human VLDLR IgG and rabbit anti-annexin II (p36) were from
Santa Cruz Biotechnology, Inc. Goat anti-S100A10 (p11) was from R&D Systems.
Goat anti-rabbit FITC conjugate IgG (whole molecule), goat anti-mouse IgG (Fab
specific) FITC conjugate, rabbit anti-goat IgG (whole molecule) FITC conjugate,
goat IgG, propidium iodide (PI), Hanks balanced salt modified and non-modified,
bovine serum albumin (BSA), human fibrin, D-phenylalanyl-L-prolyl-L-arginine
chloromethyl keytone (PPACK) and OptiPrepTM density gradient medium were
from Sigma-Aldrich. Alexa 488 protein labelling kit and Alexa 488 quenching
polyclonal antibody were from Molecular Probes (OR, USA). Murine α-CD14-texas
red conjugated monoclonal antibody was purchased from Invitrogen (USA).
Murine α-CD206 monoclonal antibody was purchased from Hycult-biotech
(Netherlands). Recombinant human tPA (Actylise, a mixture of sc and tc-tPA) was
a kind gift from Boehringer-Ingelheim, Australia.
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3.3.2.

Isolation of Human Peripheral Blood Monocytes

Peripheral venous blood was collected from donors into EDTA vacuum tubes (BD
Biosciences, Nth Ryde, Australia) under controlled conditions by a trained
phlebotomist at the University of Wollongong (UOW) (protocol approved by UOW,
Human Ethics Committee, approval number HE00/221). Buffy coats were
prepared by centrifuging whole blood samples at 1300 g for 30 min. White blood
cells were removed under sterile conditions and monocytes isolated using
OptiPrepTM as per the manufacturer’s instructions. This methodology yielded cell
preparations containing 60 to 80% CD14 positive (monocyte) cells as determined
by flow cytometry. Freshly isolated PBMs were used immediately for all
experiments.

3.3.3.

Plasminogen Activation Assays

Cells were washed and resuspended at 1x106 cells.mL-1 in Tris Buffered Saline
(TBS) (50 mM Tris, 150 mM NaCl, pH 7.4), incubated on ice in the absence or
presence of 100 nM tPA for 40 min and then washed twice in TBS to remove
excess unbound protein. Triplicate 50 μL cell suspensions were then aliquoted into
96-well microtitre plates and incubated for 15 min at room temperature, in the
absence or presence of increasing concentrations of serpinE1, SerpinB2 and 10
μg.mL-1 plasminogen made up to a final volume of 100 μL with TBS buffer.
Spectrozyme PL substrate (100 μL) was then added to a final concentration of 0.25
mM and substrate conversion by plasmin measured kinetically at 405 nm over 2 h
at 37 C using a SpectraMax 250 plate reader; data was recorded using SoftMax®
Pro software (Molecular Devices, USA). Negative controls contained cells alone
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(no tPA or plasminogen). Other controls consisted of tPA (100 nM) in the absence
or presence of 1.4 M fibrin, plasminogen (10 μg.mL-1) and Spectrozyme PL (0.25
mM), as previously described (Lobov et al. 2008). Background absorbance (buffer
only wells) was subtracted from all data.

3.3.4.

Flow Cytometry Analysis

3.3.4.1.

Cell surface antigen detection

Membrane bound antigens were detected using indirect immunofluorescence
assays, essentially as previously described (Ranson et al. 1998). Briefly, cells were
suspended at a final concentration of 1x10 6 cells.mL-1 in ice cold binding buffer
(phenol red-free Hanks buffered salt solution, pH 7.4, containing 1 mM CaCl 2, 1
mM MgCl2 and 0.1% BSA) containing 10 g.mL-1 of primary antibody and
incubated on ice for 40 min. After washing steps, the cells were resuspended with
ice-cold binding buffer containing 1:100 dilution of FITC conjugated secondary
antibody, followed by incubation with 10 μg.mL -1 α-CD14-texas red conjugated
antibody (for identification of PBMs). Cells were then washed prior to analysis by
flow cytometry, with viable cell populations selected through propidium iodide (PI)
exclusion. Isotype matched control antibodies were used to assess non-specific
binding due to the primary antibody. All data obtained was analysed using FLOJO
software version 7.1 (Treestar, Inc) and was restricted to CD14 positive/PI
negative cells. All geometric mean fluorescence values reported represent mean
fluorescence intensity for specific binding ± SEM. All assays were conducted in
triplicate.
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3.3.4.2.

Ligand binding assay

Cell surface binding analyses were conducted by incubating cells on ice in binding
buffer containing increasing amounts of Alexa488-labelled tPA (tPAAlexa488) or BSA
(BSAAlexa488) (negative control) for 40 min. This was done in order to allow maximal
cell surface binding by also minimising internalisation of tPA. Cells were then
washed twice with ice cold PBS and analysed using flow cytometry as described
above.

3.3.4.3.

Internalisation assays

This assay has previously been utilised to characterise the clearance pathways of
uPA:SerpinB2 complexes on PC-3 cells (Croucher et al. 2006) and was therefore
adapted for characterisation of Actylise-tPA:Alexa488 clearance pathways in this
study. Briefly, cells were incubated for 40 min at 1x106 cells.mL-1 in binding buffer,
containing 0 (control) or 100 nM tPA or tPAAlexa488, on ice to minimise
internalisation. After washing to remove excess unbound tPA, cells were incubated
with either SerpinB2 or SerpinB2Alexa488 (where stated), SerpinE1 or no additions
and incubated at 37 C for the time periods indicated. All subsequent steps were
performed at 4 C. The cells were next washed twice and incubated for 30 min with
4 g.mL-1 Alexa488 quenching antibody (quenches any remaining cell surface
fluorescence and is thus a measure of internalised ligand). Then, after washing,
the cells were incubated for 40 min with 10 μg.mL-1 α-CD14 monoclonal antibody.
Finally, the cells were washed twice with ice cold PBS and analysed using flow
cytometry as described above.
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3.3.5.

Surface Plasmon Resonance Assays

Kinetic analysis was performed using a BIAcore 2000 (BIAcore AB, Uppsala,
Sweden). LRP or VLDLR was immobilised on to a CM5 BIAcore chip according to
the manufacturer’s instructions. Briefly, the chip was activated using a 1:1 mixture
of 0.2 M N-ethyl-N’-(3-dimethylaminopropyl)carbodi-imide and 0.05 M Nhydroxysuccimide. LRP or VLDLR was coated on to the chip at 40 μg.mL -1 in 10
mM sodium acetate buffer (pH 3) for 7 min at 5 μL.min -1, as previously described
(Croucher et al. 2007), to a level of 2000 response units (VLDLR) or 2000 to 10000
response units (LRP). The un-occupied binding sites were blocked using 1 M
ethanolamine, pH 8.5. Analytes (tPA, tPA:PAI) were buffer exchanged into running
buffer (10 mM HEPES (pH 7.4), 140 mM NaCl, 1 mM CaCl2, 0.05% v/v Tween-20)
before applying to the BIAcore chip at 20 μL.min-1. A serial dilution of analytes
ranging from 500 – 15 nM were used to allow kinetic analyses. tPA:PAI complexes
were prepared by incubating tPA with SerpinE1 (1:1 molar ratio) or SerpinB2 (1:3
molar ratio) for 60 min at 37 ˚C. An excess of SerpinB2 could be used and not
removed from the tPA:SerpinB2 solutions as un-reacted SerpinB2 does not bind
LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007; Cochran et al. 2009;
Cochran et al. 2011). SDS-PAGE confirmed the presence of tPA:SerpinE1 or
tPA:SerpinB2 complexes with minimal/negligible residual free tPA or SerpinE1
(Fig. 3.1). In all cases the analyte concentration refers to the concentration of tPA
present. Regeneration of the chip was achieved using 100 mM H3PSO4. All buffers
were filtered and degassed before use. For kinetic analysis, a blank cell was used
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as the reference cell and data was analysed using BIAevaluation software (Version
3).

Complexes

t-PA
SerpinB2 SerpinB2

t-PA

t-PA
SerpinE1 SerpinE1

t-PA
PAI

Figure 3.1: Representative gel showing preformed tPA:PAI complexes.
Stock solutions were prepared by incubating tPA with SerpinE1 (1:1 molar ratio)
or SerpinB2 (1:3 molar ratio) for 60 min at 37 ˚C and used for comparison of
kinetic interactions with LRP and VLDLR using Surface Plasmon Resonance.
Excess PAI-2 could be utilised to make the complexes as residual (free) PAI-2
does not interact with LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007;
Cochran et al. 2011).

3.3.6.

Statistical Analysis

Statistical significance was determined using Students t-test and was performed
using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego
California USA (www.graphpad.com).
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3.4.

Results

3.4.1.

Cell surface expression profiles of tPA, uPA and potential
receptors on U-937, THP-1 and Peripheral Blood Monocytes.

To ascertain basal cell surface expression levels of the plasminogen activation
systems by the U-937, THP-1 cell lines compared to peripheral blood monocytes
(PBMs), immunofluorescence assays were undertaken on all cells using flow
cytometry. As described in chapter 2, the uPA system was detected at the cell
surface of both cell lines, with highest expression observed on the THP-1 cell line
corresponding to a 17 and 39 fold increase in specific fluorescence intensity
compared to the U-937 and PBMs respectively (Tab. 3.1). Conversely, surface
bound tPA was detectable on PBMs whilst absent from both monocytic cell lines
(Tab. 3.1).

Table 3.1: Ligand expression profiles of plasminogen activators and associated
receptors.
U-937
Cell Line
Ligand
uPA
tPA
LRP
VLDLR
Annexin 2A (P36)
S100A10 (P11)
Mannose Receptor
(CD206)

4.27 ± 1.27
ND
5.0 ± 0.8
19.4 ± 3.2
67.0 ± 4.6
ND
ND

THP-1
Peripheral Blood
Cell Line
Monocytes
Relative MFI ± SEM
71.19 ± 0.96
1.82 ± 0.5
ND
5 ± 0.9
9.14 ± 1.17
15.7 ± 1.3
145 ± 18
70.5 ± 0.8
43 ± 4
68.78 ± 5.9
18 ± 9
ND
ND
ND

Data represents mean fluorescence intensity (MFI), with relevant matched isotype control values
subtracted (n=3, ± SEM). ND = not detected.
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Both LRP and VLDLR were detected on all cell types. The PBMs exhibited the
highest LRP expression with 1.7 and 3 fold higher mean fluorescence intensity
compared to the THP-1 and U-937 cell lines, respectively (Tab. 3.1). The THP-1
cell line was found to have the highest VLDLR cell surface level with 2 and 7.5 fold
higher mean fluorescence intensity compared to the PBMs and U-937 cells,
respectively (Tab. 3.1). As tPA is reported to also bind the mannose receptor and
the annexin II heterotetramer (AIIt), cell surface profiles for these antigens were
undertaken. All cell types expressed detectable levels of annexin 2A (p36) with
comparable expression between the U-937 cell line and PBMs, whilst the THP-1
cell line exhibited 1/3 less detectable P36 (Tab. 3.1). Interestingly the THP-1 cell
line was found to also express p11, the second component of the AIIt, whilst it was
not detectable on the surface of either the U-937s or the PBMs. It was not possible
to detect the mannose receptor (CD206) on any cells (Tab. 3.1).

3.4.2.

Tissue Plasminogen Activator; cell surface binding potential
(exogenous protein addition)

Since at least one known tPA receptor, p36, was detected, we tested the binding
of exogenous tPA to PBMs. When incubated on ice to minimise internalisation
and/or proteolytic activity, the binding of tPA to PBMs was saturable within 40 min,
showing maximum binding at about 200 nM (Fig. 3.2A). A negative control BSAAlexa488 did not bind to the cell surface at the highest equivalent tPA
concentration (Fig.3.2B). We next tested the contribution of LDLRs to the direct
binding of tPA to PBMs. Pre-incubation of the cells with RAP significantly reduced
cell surface binding of exogenous tPA to PBMs (Fig. 3.2C) by 30%. This level of
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inhibition was consistent with previous studies using human umbilical vein
endothelial cells (Mulder et al. 1997), indicating that LDLR family members are
functional cell surface receptors for tPA in addition to the potentially numerous
other receptors represented by the non-RAP inhibitable binding interactions.
Furthermore, tPA bound only to the CD14-positive stained (i.e. PBM) cells within
the cell suspension, indicating that the other blood cell types present did not bind
measurable amounts of tPA (Fig. 3.2D).

Figure 3.2: Characterisation of Actylise-tPA binding to PBMs. (A) Plot
showing the concentration dependence of the binding of Alexa488-labelled
Actylise-tPA to the surface of PBM. (B) Binding of 200 nM Alexa488-labelled
Actylise-tPA or Alexa488-BSA (control) to the cell surface of PBM. (C) Plot
showing the effects of RAP on cell surface binding of Alexa488-labelled ActylisetPA using flow cytometry. Data within A, B and C plots, represents the geometric
mean (GM) fluorescence, corrected for auto-fluorescence, n=3 ± SEM. (D) Two
dimensional flow cytometry dot plot showing Alexa488-labelled Actylise-tPA
binding (515 nm) to CD14 positive (660 nm) cell population.
73

Of note, significantly more Actylise-tPA:Alexa488 bound to the PBMs (> 4 fold at 100
nM or 200 nM) compared to the U-937 and THP-1 cell lines which bound
comparable levels (Fig. 3.3A). The specificity of tPA binding to the U-937 cell lines
was confirmed using the negative control, BSA-Alexa488, which did not bind to the
cell surface at the highest equivalent tPA concentration (Fig.3.3B). Non-specific
binding of Actylise-tPA was not tested for the THP-1 cell line and therefore cannot
be ruled out.
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Figure 3.3: Exogenous tPA binding potential of cell models. A) The U-937 and THP1 monocytic cell lines were incubated on ice for 40 min in the absence (auto fluorescence)
or presence of Actylise-tPAAlexa488 at concentrations indicated. Unbound ActylisetPAAlexa488 was then removed via centrifugation and cell surface bound Actylise-tPAAlexa488
measured using flow cytometry. B) Specificity of Actylise-tPA binding to the U-937 cell
line was confirmed using 100 nM BSAAlexa488 under the same conditions. Data represents
the geometric mean (GM) fluorescence (panel A and B) with background (auto
fluorescence) removed (panel A only), n=3 ± SEM.

3.4.3.

tc-tPA mediated cell surface plasmin generation

To obtain a quantitative indication of the cell surface plasminogen activation
potential, whole cell plasmin generation assays were conducted. Saturation of the
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cell surface with exogenous tc-tPA caused a significant increase in cellular plasmin
activity (Fig. 3.4). As expected from previous work showing inhibition of cell surface
tPA by SerpinB2 on the MCF-7 and HeLa cell lines (Lobov et al. 2008), SerpinB2
was also able to inhibit cell surface tc-tPA on PBMs at similar concentrations (Fig.
3.4). SerpinE1 was overall more efficient at inhibiting plasmin formation compared
to SerpinB2, resulting in 95 - 100% inhibition at all concentrations used (Fig. 3.4).
However, at 50 nM SerpinB2 inhibited about 80% of plasmin formation while at
Basal plasmin
0.
50.
100.
200 nM both serpins inhibited
formation
by > 90%.200.

Rate of plasmin formation
( OD405/min)

0.004

PAI-2
PAI-1

0.003

0.002

0.001

0.000

tc-tPA SerpinE1 PAI-2 -

+
-

+
50 nM
50 nM

+
100 nM
100 nM

+
200 nM
200 nM

Figure 3.4: Plot showing inhibition of PBM-mediated plasminogen activation
by exogenous SerpinE1 and SerpinB2. Freshly isolated PBMs were preincubated in the absence or presence of 100 nM tc-tPA where indicated. Then
glu-plasminogen was added at a final concentration of 0.25 μM and the rate of
plasmin formation in the absence (grey) or presence of either SerpinE1 or
SerpinB2 (50, 100, 200 nM), was analysed using Spectrozyme PL substrate (ADI).
Assays were conducted over 2 hs at 37 C. Data represents mean ± SEM, (n=3),
background (cells only) value subtracted.
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Investigation of plasmin formation at the cell surface in the absence or presence
of SerpinB2 was also conducted using the U-937 and THP-1 cell lines. Low levels
of intrinsic plasmin generation were detected (Fig.3.5), which is indicative of low to
negligible endogenous of either tPA or uPA levels on these cell lines (see Table
3.1). The addition of tc-tPA resulted in a significant enhancement of cell surface
plasmin activity on both cell lines (Fig 3.5) reflecting the ability if these cells to
specifically bind exogenous tPA (see Fig 3.3). At tc-tPA to SerpinB2 concentration
ratios of 2:1, 1:1 and 1:2, SerpinB2 was able to inhibit the rate of plasmin formation
on the U-937 cell line by 60%, 70% and 80%, respectively when compared to no
SerpinB2 control (Fig. 3.5). Importantly, these results were consistent with those
obtained using freshly isolated PBMs (Fig. 3.4). Conversely at the same
concentration ratios SerpinB2 was only able to inhibit the rate of plasmin
generation on THP-1 cells by 18%, 30% and 43%, respectively (Fig 3.5). It is
important to note that the THP-1 cell line was shown to have significantly more
surface bound endogenous uPA compared to the U-937 cell line and PBMs (Table
3.1). Furthermore, pro-uPA is activated by plasmin, therefore addition of
exogenous tc-tPA may also increase uPA activity. Therefore the reduced efficiency
of SerpinB2 to inhibit plasmin generation at the cell surface of the THP-1 cell line
may be attributed to the variability in ratios of SerpinB2 to total plasminogen
activator potential, at the cell surface.
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Figure 3.5: Inhibition of cellular plasminogen activation by SerpinB2. U-937
(un-filled) and THP-1 (filled) cells were pre-treated in the absence or presence of
100 nM tc-tPA where indicated. Then glu-plasminogen was added at a final
concentration of 0.25 μM and the rate of plasmin formation in the absence or
presence of SerpinB2 (50, 100, 200 nM), was analysed using Spectrozyme PL
substrate (ADI). Assays were conducted over 2 hs at 37 C. Data represents
mean ± SEM, (n=3), background (cells only) subtracted.

3.4.4.

Endocytosis of Tissue Plasminogen Activator by Monocytic
Cell Lines and Peripheral Blood Monocytes

As tPA bound to the cell surface generated plasmin and this activity was inhibited
by SerpinB2 we next examined the internalisation of Actylise-tPA:SerpinB2
complexes by the U-937 and THP-1 cell lines. A moderate but significant increase
in SerpinB2Alexa488 internalisation was observed for both cell lines upon preincubation with 50 nM Actylise-tPA compared to no exogenous Actylise-tPA
controls (Fig. 3.6). As these cells were incubated on ice in the absence (control)
or presence of Actylise-tPA to facilitate binding of exogenous tPA prior to
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incubation at 37 °C with SerpinB2Alexa488 this data represents internalisation of
tPA:SerpinB2 complexes formed at the cell surface.
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Figure 3.6: Tissue Plasminogen Activator facilitated internalisation of
SerpinB2:Alexa488 by the (A) U-937 and (B) THP-1 monocytic cell lines. Cells
were incubated in the absence (control) or presence of 50 nM exogenous
Actylise-tPA on ice for 40 min. Excess Actylise-tPA was removed by
centrifugation, the cells were then resuspended in 10 nM SerpinB2: Alexa488 and
incubated at 37C for 1 h. Surface bound SerpinB2:Alexa488 was quenched on ice
for 30 min with 4 μg.mL-1 rabbit-α-Alexa488 prior to analysis using flow
cytometry.
Data represents geometric mean (GM) fluorescence with
background (auto-fluorescence) removed, n=3 ± SEM. * p<0.05 significantly
different from cell line control.

We next investigated the internalisation of Actylise-tPA complexes by freshly
isolated PBMs in the absence or presence of either SerpinB2 or SerpinE1. Blood
samples were collected and cells isolated using OptiPrepTM for immediate use in
flow cytometry experiments and PBMs selected for, using anti-CD14 antibodies
(Fig 3.7).
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Figure 3.7: Identification of Peripheral Blood Monocytes. Freshly isolated
blood monocytes where initially gated for based on side and forward scatter (i)
then viable cells within this gate where selected using propidium iodide exclusion
(695/40A) (ii) Cells where pre-stained with α-CD14 MAb, detected using αmouse:Alexa633 and positive cells gated further for analysis (iii). ActylisetPA:Serpin complex internalisation was therefore assessed on PI negative, αCD14 positive cells and quantitated on Alexa488 positive fluorescence intensity
(iv).

PBMs were found to endocytose both Actylise-tPAAlexa488 and ActylisetPAAlexa488:Serpin complexes using a quenching internalisation assay (Fig. 3.8).
Cells were pre-treated with 100 nM Actylise-tPA:Alexa488 and excess unbound
protein removed prior to addition of either SerpinE1 or SerpinB2, therefore
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complexes cleared in this assay were those formed at the cell surface.
Comparison of clearance efficiency between Actylise-tPA only, ActylisetPA:SerpinB2 and Actylise-tPA:SerpinE1 was assessed at 37 C, over a 30 min
period. In the absence of serpins, increasing levels of Actylise-tPA:Alexa488 were
internalised over the time course (Fig. 3.8). Interestingly, SerpinE1 was found to
enhance Actylise-tPA uptake from the cell surface after 20-30 min incubation time
whilst SerpinB2 did not (Fig. 3.8). At the 20 min time point SerpinB2 treated cells
exhibited a slight, but significant (p = 0.023, n=3) increase in tPA clearance
compared to tPA alone, however this was not sustained and at 30 min the amount
of tPA only was comparable to tPA:SerpinB2 (Fig. 3.8).

80

GM Fluorescence
(515/20A)

100

*

t-PA:SerpinE1

80

t-PA:SerpinB2
t-PA

60

*
*

40
20
0
0

10

20
Time (min)

30

40

Figure 3.8: Internalisation of Actylise-tPAAlexa488 by PBMs. Cells were
incubated on ice for 40 min in the absence (auto-fluorescence) or presence of 100
nM Actylise-tPAAlexa488 after which, excess protein was removed by centrifugation.
Cells were then resuspended in binding buffer in the absence (tPA only) or
presence of 100 nM SerpinB2 or SerpinE1, where indicated and incubated at 37
C for 10, 20 or 30 min. Remaining cell surface bound Actylise-tPAAlexa488 was
then quenched by addition of 4 μg.mL-1 rabbit-α-Alexa488 and incubated on ice for
30 min with 10 µg.mL α-CD14 MAb. Indirect detection of CD14 was performed by
a further 30 min incubation on ice in the presence of α-mouse:Alexa633 prior to
analysis using flow cytometry.
Data represents geometric mean (GM)
fluorescence with background (auto-fluorescence) removed, n=3, ± SEM. * p<0.05
significantly different from tPA only control.

This differential effect on tPA endocytosis by SerpinB2 and SerpinE1 was
surprising as SerpinB2 has previously been shown to enhance the uptake of uPA
from the surface of prostate cancer cells, albeit not to the same extent as SerpinE1
(Croucher et al. 2007). As these experiments were conducted using Alexa488
labelled Actylise, which contains a mixture of sc and tc-tPA the significant but
modest increase in tPA:SerpinB2 internalisation at the 20 min time point may be
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indicative of tc-tPA clearance only, as SerpinB2 does not efficiently inhibit sc-tPA.
This is supported by the 2-fold difference in internalisation of ActylisetPA:SerpinE1 after 30 min as SerpinE1 is known to be an efficient inhibitor of both
sc and tc-tPA (Thorsen et al. 1988).

To address this and confirm that SerpinB2 not only inhibited (i.e., bound) to cell
surface tPA but was itself subsequently endocytosed as a tPA:Serpinb2 complex,
internalisation assays using SerpinB2Alexa488 and exogenous active-tPA or PPACKinactivated tPA were performed. Furthermore comparison of SerpinB2Alexa488
internalisation via Actylise-tPA and tc-tPA was undertaken. Cell surface bound
PPACK-inactivated Actylise-tPA significantly reduced the internalisation of
SerpinB2 by 25% compared to the active control (Fig 3.9A) whilst inactivation of
tc-tPA reduced internalisation of SerpinB2 by 90% (Fig. 3.9B), indicating that
SerpinB2 bound at the PBM cell surface was subsequently endocytosed as a tctPA:SerpinB2 complex.
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Figure 3.9: Actylise and tc-tPA dependent internalisation of SerpinB2. (A)
Freshly isolated PBM were incubated on ice for 40 min in the absence (autofluorescence) or presence of 100 nM Actylise-tPA. Excess Actylise-tPA was
then removed by centrifugation and cells were incubated for a further 15 min on
ice in the absence (control) or presence of 100 μM PPACK (itPA).
SerpinB2Alexa488 was then added at a final concentration of 10 μM and the cells
incubated for 1 h at 37 C. Cell bound SerpinB2Alexa488 was quenched using 4
μg.mL-1 rabbbit-α-Alexa488 for 30 min on ice prior to analysis using flow
cytometry. (B) Freshly isolated PBMs were prepared as per (A), substituting
100nM purified tc-tPA for 100 nM Actylise-tPA. Data represents normalised (to
control), geometric mean (GM) fluorescence with background (autofluorescence) removed, n=3, ± SEM. * p<0.05 significantly different from control.

In order to characterise the mechanisms involved in the clearance of tPA and
tPA:serpin complexes from the cell surface of PBM the roles of scavenger proteins
and the LDL receptor family were investigated. Where previous internalisation
assays had been conducted on pre-treated (addition of exogenous Actylise-tPA)
cells, pre-formed complexes were used to characterise internalisation pathways
allowing for pre-treatment with inhibitors, followed by addition of Actylise-tPA.
RAP, a commonly used antagonist of ligand binding specific to the LDLR family,
significantly inhibited Actylise-tPA:Alexa488/complex internalisation by 80 to 90% in
all cases (Fig. 3.10). Furthermore the use of fucoidin, which is known to block
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Figure 3.10: Role of LDLR family and scavenger receptors in the
endocytosis of tPA. (A) Freshly isolated PBMs where initially gated on side
and forward scatter, selecting viable cells based on morphology (i) Cells where
pre-stained with α-CD14:PE-TR MAb and positive cells gated for analysis (ii).
Actylise-tPA:serpin complex internalisation was therefore assessed α-CD14
positive cells and quantitated on Alexa488 positive fluorescence intensity (iii).
(B) Freshly isolated PBMs were incubated for 15 min at 37 C in the absence
(control) or presence of either 300 nM RAP or 300 μg.mL-1 Fucoidin, after which
100 nM tPAAlexa488 or tPAAlexa488:serpin complexes were added and the cells
incubated for a further 20 min at 37 C. Cell bound tPAAlexa488 and complexes
were quenched using 4 μg.mL-1 rabbbit-α-Alexa488 for 30 min on ice prior to
analysis using flow cytometry. Data represents normalised (to control) geometric
mean (GM) fluorescence with background (auto-fluorescence) removed, n=3, ±
SEM. * p<0.05 significantly different from control.
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scavenger receptors was also able to inhibit internalisation, however to a much
lesser extent then RAP with 20 – 10 % inhibition observed. Importantly, the
combined percentage of inhibition for RAP and Fucoidin in the endocytosis of
Actylise-tPAAlexa488, Actylise-tPAAlexa488:SerpinB2 or Actylise-tPAAlexa488:SerpinE1
totalled 94%, 83% and 99% respectively (Fig. 3.10).

This finding indicates that the LDLR family plays a predominant role in the
clearance of tPA and tPA:serpin complexes from the cell surface of PBMs whilst
scavenger receptors contribute a minor role. As tPA clearance is reported to be
facilitated via the mannose receptor by liver cells (Kuiper et al. 1988; Otter et al.
1991; Nguyen et al. 1992) and expression of the mannose receptor has been
reported for primary macrophages (Noorman et al. 1995) immunofluorescence
assays were conducted to assess cell surface expression of the mannose receptor
(CD206) by the peripheral blood monocytes used in these experiments. There
were no detectable levels of the mannose receptor found within three independent
assays indicating that this receptor was not involved in the fucoidin dependent
clearance of tPA or tPA:serpin complexes by the PBMs (see Table. 3.1).

Given the dominance of the LDLR family of endocytosis receptors in cell surface
tPA clearance we next investigated their role in direct binding of tPA to PBM’s.
Cells were pre-incubated in the absence (control) or presence of RAP for 15 min
prior to the addition of tPAAlexa488 followed by further 30 min incubation on ice.
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Under these conditions RAP was able to reduce cell surface binding of tPAAlexa488
by 30 % (Fig. 3.11), confirming previous studies (Mulder et al. 1997).
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Figure 3.11: Role of LDLR family in the cell surface binding of Actylise-tPA.
Freshly isolated PBMs were incubated for 15 min on ice in the absence (control)
or presence of 300 nM RAP after which 100 nM tPAAlexa488 was added and the
cells incubated for a further 40 min on ice. Cell bound tPAAlexa488 was then
analysis using flow cytometry. Data represents normalised (to control) geometric
mean (GM) fluorescence with background (auto-fluorescence) removed, n=3, ±
SEM. * p<0.05 significantly different from control.

3.4.5.

Surface plasmon resonance analysis of tc-tPA and tc-tPA:PAI
complexes with LDLR members.

To obtain a more quantitative analysis of the role of LRP and VLDLR in the cell
surface interactions of tPA and tPA:serpin complexes the kinetics of binding of
these ligands to immobilized LRP and VLDLR were analysed using surface
plasmon resonance (SPR). Initial specificity analyses using overlay plots of
sensorgrams indicated that tPA:SerpinE1 bound more strongly to LRP than tPA
alone or in complex with SerpinB2 (Fig. 3.12A). This effect was less obvious with
VLDLR (Fig. 3.12B). For kinetic analyses a serial dilution of ligands were used,
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which revealed dose dependent binding for all of the analytes (Fig. 3.12) and
complex binding interactions of tc-tPA:SerpinE1 to both LRP and VLDLR.
Nevertheless, in both cases, the data best fit competitive heterogeneous analyte
models, suggesting the presence of a relatively low and a high affinity binding site
within the complex for both LRP (KD1 ~ 21.2 nM, KD2 ~ 0.95 nM, respectively) and
VLDLR (KD1 ~ 139 nM; KD2 ~ 23 nM) (Table 3.2). tc-tPA and tc-tPA:SerpinB2 also
bound to LRP and VLDLR. However, these data were best fit by a one-binding site
model with tc-tPA and tc-tPA:SerpinB2 binding with very similar, moderate
affinities to LRP (KD 67 – 57 nM) and VLDR (KD 124 – 98 nM), respectively. The
higher affinity binding (KD2) of tPA:SerpinE1 to both LRP and VLDLR was due to a
substantial (100 to 16 fold, respectively) decrease in the dissociation rate constant,
indicating much slower dissociation of the complex (Table 3.2). The binding affinity
of tc-tPA and tc-tPA:PAI complexes for LRP was generally higher than that
obtained with VLDLR (Table 3.2). To our knowledge, there is no previously
published data describing the binding of tc-tPA:SerpinB2 to LRP and VLDLR
however the affinities reported here for the binding of tc-tPA and tPA:SerpinE1 to
LRP are comparable to those obtained by others using SPR (Gliemann et al.
2004).
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Figure 3.12: Surface plasmon resonance analysis of the interaction between
tc-tPA, tc-tPA:SerpinB2 and tc-tPA:SerpinE1 and VLDLR or LRP.
Sensorgrams showing the does dependent binding of analytes (15-500 nM) to
either (A) LRP or (B) VLDLR. Data shown are representative of at least 3 separate
experiments.
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Table 3.2: Surface Plasmon Resonance kinetic analysis of the interaction
between LDLRs and tc-tPA or tc-tPA:serpin complexes.

Analyte
tPA
tPA:SerpinB2
tPA:serpinE1

Model
1:1
1:1
Heterogeneous
analyte competing

tPA
tPA:SerpinB2

ka (1/Ms)
5.22 x 105
9.19 x 105
2.21 x 105

LRP
kd (1/s)
KD (nM)
-3
67
3.51 x 10
57
51.9 x 10-3
-3
21.2
4.69 x 10

4.62 x 104

4.38 x 10-5

5

0.95

2
1.52
1.24
5.61

VLDLR
124
51.7 x 10-3
98
54.4 x 10-3
-3
139
74.8 x 10

1:1
4.18 x 10
2.55
1:1
4.16 x 105
2.23
Heterogeneous 5.37 x 105
tPA:serpinE1
analyte 5.07
5
-3
23.0
2.00
x
10
4.60
x
10
competing
Binding data was fitted to normalised sensorgrams using the BIAevaluation 3.0 software.
The binding model chosen represents that with the lowest χ2 value.

3.5.

Discussion

The results presented here show that both SerpinB2 and SerpinE1 inhibit the
enzymatic activity of cell surface bound tPA and that tPA:serpin complexes formed
at the cell surface are subsequently endocytosed, predominantly via an LDLR
dependent pathway. While both tPA:serpin complexes are internalised, only
inhibition by SerpinE1 accelerates tPA endocytosis.

The differences in

endocytosis of these ligands may be explained by the kinetic data obtained for the
binding of tPA and tPA:SerpinE1 to LRP and VLDLR using SPR. The formation of
complexes between SerpinE1 and either tPA or uPA are thought to cause a
conformational change within SerpinE1 resulting in it exposing a high affinity
binding site for LRP (Horn et al. 1998; Stefansson et al. 1998) or potentially
VLDLR, which contributes directly to the enhanced endocytosis of tPA:SerpinE1
or uPA:SerpinE1 complexes from the cell surface. Indeed work by Cochran et al.
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(2011) showed the importance of an LDLR minimal binding motif present in the αhelix D of SerpinE1 but not SerpinB2 that is responsible for the higher affinity
interaction and enhanced endocytosis of uPA:SerpinE1 complexes.

Both LRP (Strickland et al. 2002; Croucher et al. 2006) and VLDLR (Strickland et
al. 2002; Croucher et al. 2007) play a pivotal role in the rapid clearance of surface
bound uPA:SerpinE1 and uPA:SerpinB2 complexes. Like SerpinE1, SerpinB2 has
been shown to accelerate uPA internalisation due to an increased affinity of
uPA:SerpinB2 for LRP and VLDLR compared to uPA alone (Croucher et al. 2006;
Croucher et al. 2007). It is possible that formation of the uPA:SerpinB2 complex
results in a conformational change within uPA as SerpinB2 does not bind to either
LRP or VLDLR (Croucher et al. 2006; Croucher et al. 2007). Importantly, tc-tPA
alone and tc-tPA:SerpinB2 show almost identical one-site binding affinities for LRP
and VLDLR, suggesting that complex formation does not significantly alter the
binding interaction of tc-tPA to LRP or VLDLR. Furthermore, especially in regards
to VLDLR binding, the similar KD values obtained for the lower affinity binding
interactions of tPA:SerpinE1 compared to those observed for tPA or tPA:SerpinB2
(Table 3.2) suggests that no functional conformational change occurs within the
tc-tPA molecule upon complex formation. Therefore it is likely that the differences
in KD values for LRP and VLDLR observed between tc-tPA:SerpinE1 and tc-tPA
or tc-tPA:SerpinB2 are related to exposure of the high affinity cryptic binding site
within SerpinE1. Of note, comparison of the binding affinities of tc-tPA and tctPA:serpin for LRP and VLDLR reveals a preference of these ligands for LRP
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(Table 3.3). In contrast, uPA and uPA:serpin appear to bind with higher affinities
to VLDLR compared to LRP (Table 3.3). However, the significance of these
differences is unclear at this stage.

Table 3.3: Comparison of tc-tPA/tc-tPA:PAI to uPA/uPA:PAI affinities for LRP
and VLDLR
LRP
VLDLR
Analyte
KD (nM)
KD (nM)
tPA
67
124
tPA:SerpinB2
66
131
tPA:SerpinE1
21
139
0.95
23
uPA
200 *
31.2 ^
uPA:SerpinB2
32.6 *
4.68 ^
€
uPA:SerpinE1
0.226
1.6 €
84.8 ^
1.51 ^
Previously published data: * (Croucher et al. 2006), ^ (Croucher et al. 2007), € (Skeldal et al. 2006)

Interestingly, RAP inhibited the direct binding of Actylise-tPA to the PBM cell
surface by approximately 30%. This observation is similar to that reported by
Mulder et al. (1997), where pre-treatment with RAP resulted in a 25% reduction of
tPA binding to the cell surface of HUVECs. The identities of other receptors
responsible for the remaining proportion of tPA binding are potentially numerous,
of which p36 may partially contribute to total tPA binding on these cells, as
previously published (Brownstein et al. 2004). The absence of the mannose
receptor on our freshly isolated PBMs cells was not surprising as it is indicative of
a monocyte versus a differentiated macrophage phenotype (Noorman et al. 1995).
That fucoidin inhibited the clearance of tPA and tPA:serpin complexes from the
surface of PBMs by about 10 – 20%, suggests that other scavenger receptors
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present on PBMs play a minor role in the binding and subsequent endocytosis of
these ligands.

The traditional role of tPA in fibrinolysis and of SerpinE1 as a regulator of tPA is
well characterised. However in recent years it has become increasingly clear that
tPA is not restricted to maintaining homeostasis of coagulation and fibrinolysis
within the vasculature. tPA has been found to induce matrix metalloproteinase-9
gene expression in rat kidney interstitial fibroblast and promote activation of murine
myofibroblasts (Hu et al. 2007), control permeability of the blood brain barrier
(Yepes et al. 2003), facilitate migration of monocytes across the BBB into the
central nervous system (Reijerkerk et al. 2008) and coordinate macrophage
migration under inflammatory conditions (Cao et al. 2006). Interestingly, this
diversity in function appears to be dependent on tPA interaction with LRP, which
initiates activation of signalling cascades, whilst not always requiring the proteolytic
activity of tPA. Expression of both tPA and SerpinB2 by monocytes, macrophages
and myeloid progenitors within normal bone marrow (McWilliam et al. 1998),
suggests a physiological role for SerpinB2 as an inhibitor of tPA associated with
derivatives of the myeloid stem cells. The differential endocytosis mechanisms
identified in our work suggest that while SerpinE1 and SerpinB2 both function
similarly in the control of plasmin generation by tPA at the cell surface, they may
have opposing effects on the non-classical roles of tPA and activation of signalling
cascades via LRP or indeed VLDLR.
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The molecular mechanisms and biological significance of a role for VLDLR in the
endocytosis of tPA or tPA:PAI complexes are poorly understood. VLDLR is not
found within the liver, however it is expressed at varied levels throughout the body
(Strickland et al. 2002). Therefore, whilst the SPR analyses indicated that tPA and
tPA:PAI bound to VLDLR with approximately 2-fold lower binding affinities than to
LRP (Table 3.2), it is plausible that VLDLR may also play an important role in local
clearance of tPA and tPA:PAI complexes. This could be through removal of
proteolytic activity and/or potentiation of downstream signalling cascades through
cell surface interactions with these ligands.
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4. Biochemical analysis of SerpinB2 reveals chaperonelike activity.

94

4.1.

Abstract

SerpinB2 exists primarily as a non-glycosylated 47 kDa intracellular protein and is
significantly up-regulated during cellular stress responses, differentiation,
proliferation and innate immunity. However, a defined serine protease binding
partner for intracellular SerpinB2 has not yet been described, suggesting additional
functions for this protein, independent of its role as a serpin. The distribution of
SerpinB2 within the nucleus and cytosol, combined with high expression during
cellular stress is consistent with a role in cellular pathways associated with stress
responses. Molecular chaperones are classical stress response proteins, which
act to stabilise unfolded proteins and can promote refolding and/or degradation of
misfolded proteins (Hartl et al. 2011). Therefore, we have investigated a potential
role for SerpinB2 in functional activities classically associated with intracellular
protein stress responses by assessing its function as a molecular chaperone. As
molecular chaperones have been shown to bind specifically to misfolded or
aggregated proteins via hydrophobic interactions (Hartl et al. 2011), we conducted
ELISA based binding assays and found that SerpinB2 preferentially binds
misfolded proteins. SerpinB2 was also found to be an efficient inhibitor of
amorphous aggregation in some but not all models tested and an efficient inhibitor
of amyloid beta peptide aggregation measured in real-time. Our results indicate
that while SerpinB2 binds specifically to misfolded proteins the interaction does not
promiscuously shield inappropriate protein-protein interactions. This suggests that
whilst not a universal chaperone, SerpinB2 does exhibit chaperone-like activity,
which may contribute to its cytoprotective functions in vivo.
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4.2.

Introduction

SerpinB2 is a member of the Serine Protease Inhibitor super family and exists
within the extracellular or intracellular environment. Secreted as a 47 kDa or
glycosylated 60 kDa protein, extracellular SerpinB2 is thought to function as an
inhibitor of the urokinase plasminogen activator and to a lesser extent, tissue-type
plasminogen activator (Kruithof et al. 1995) (Lobov et al. 2008; Lee et al. 2010).
However, the majority of SerpinB2 is found within the intracellular environment, as
a 47 kDa protein. Whilst the 47kDa SerpinB2 maintains its inhibitory activity (AlEjeh et al. 2004), a target intracellular protease has not yet been defined, which
suggests a role independent of the classical inhibitory mechanisms, characteristic
of Serpins (Law et al. 2006). Importantly, SerpinB2 expression appears to be
associated with inflammation and cellular stress (recently reviewed in (Schroder et
al. 2010; Lee et al. 2011; Medcalf 2011)).

The main physiological producers of SerpinB2 are cells of the myeloid lineage, i.e
monocytes and macrophages (Kruithof et al. 1995). It is not surprising then, that
high SerpinB2 expression profiles have been described for activated microglial
aggregates, co-localised with senile plaques in brain sections from Alzheimer’s
disease patients (Akiyama et al. 1993; Walker et al. 2006). More recently however,
an association of SerpinB2 with Amyloid Lateral Sclerosis (ALS) was described,
whereby, primary cultures of cortical neurons isolated from the SOD1 (G93A
mutation) transgenic animal model, incubated under oxidative stress conditions,
showed an 8 fold increase in SerpinB2 mRNA expression, relative to non-
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transgenic control models, cultured under the same conditions (Boutahar et al.
2011).

Furthermore, SerpinB2 was recently identified as one of the 9 core

“Activity-regulated Inhibitor of Death (AID)” genes that mediate neuroprotection by
N-methyl-D-aspartate (NMDA) receptor-induced calcium signalling. Within 3 h
after injection of other glutamate analogues, such as kainic acid, into the brain
SerpinB2 expression is increased by greater than 1800-fold (Zhang et al. 2009).
Whilst adenoviral over-expression of SerpinB2 in the brain was protective against
this insult (Zhang et al. 2009), the functional mechanism was not defined. Taken
together these results suggest a potential role for SerpinB2 at sites of inflammation
within the CNS.

Importantly, disruption of normal protein homeostasis (proteotoxic stress) is
integral to the pathophysiology of both acute injury associated inflammation,
neuronal dysfunction and age related neurodegeneration. Therefore, cellular
quality control systems, such as the molecular chaperone network, are essential
for maintaining proteostasis (Morimoto 2008). Chaperones are traditionally defined
as molecules which interact with other proteins undergoing folding or unfolding
conformational changes, specifically stabilizing intermediate non-native forms and
either facilitating their conformational arrangement into a functional native state
(foldases) or preventing aggregate formation between misfolded intermediates
(holdases) (reviewed in (Tyedmers et al. 2010; Hartl et al. 2011)). Aberrant protein
conformations are problematic in that they may become cytotoxic either through
loss or gain of function and as such, form the basis of disease (Carrell and Lomas
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1997). Furthermore, overloading of the chaperone network in response to cellular
stress gives rise to protein aggregates which accumulate and may also become
cytotoxic (Bucciantini et al. 2002).

As alluded to above SerpinB2 is one of the most up-regulated proteins in neurons
and cells of the myeloid lineage in response to infections and inflammatory
mediators, representing up to 1% of total intracellular protein following cellular
stress (Schroder et al. 2010; Lee et al. 2011; Medcalf 2011). However, the
relationship between the up-regulated expression, protein interactions, and the
putative cytoprotective role of SerpinB2 is unclear. Of interest, chaperone activity
has been described for other members of the serpin super family, such as sHsp47
(SerpinH1/H2 (Gettins 2002)) (Sauk et al. 2005), which is a collagen binding/carrier
molecule and human alpha(1)-antitrypsin (AAT) (SerpinA1), which has been
shown to inhibit protein aggregation using a variety of common substrate models
(Zsila 2010).

More recently, chaperone functions have also come to include

macro-complex assembly, protein transport and direction of deleterious protein
conformations into proteolytic degradation pathways, in addition to their protein
folding functions (Hartl et al. 2011). In this context, some extracellular, noninhibitory serpins function as transport proteins, for example; SerpinA6 is a major
transporter of glucocorticoids and progestins within blood (Westphal 1986;
Hammond et al. 1987; Pemberton et al. 1988; Hammond 1990) and SerpinA7 is a
thyroxine transporter (Pemberton et al. 1988). Therefore, given the precedent
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within the literature we hypothesised that SerpinB2 may also function within
cellular pathways as a chaperone.

4.2.1.

Specific Aims

A defining characteristic of chaperones is their ability to bind to misfolded or
unfolded proteins (substrates), via hydrophobic residues which are normally buried
within the three-dimensional structure of the native protein (Feder and Hofmann
1999; Schroder and Kaufman 2005; Nardai et al. 2006; Korcsmaros et al. 2007).
Protein aggregation is also driven by hydrophobic forces and primarily results in
amorphous protein structures or highly ordered fibrillar aggregates (termed
amyloid), which are defined by β-strands that run perpendicular to the long fibril
axis (cross-β structure) (Westermark et al. 2007; Eichner et al. 2011). Importantly,
the latter is characteristic of neurodegenerative disorders such as Alzheimer’s
disease, Huntington disease, Parkinson’s disease and ALS (Muchowski and
Wacker 2005). Therefore, the specific aims of this chapter were to investigate the
possibility that SerpinB2 could act as a chaperone using in vitro biochemical
analysis of these key characteristics. Specifically, an ELISA based assay was
utilised to examine the binding of SerpinB2 to misfolded substrates. We then
assessed the ability of SerpinB2 to inhibit amorphous forming aggregation models
in real-time using a light scattering microplate based assay. Finally, we aimed to
investigate the ability of SerpinB2 to inhibit fibrillar aggregation, using the
aggregation prone amyloid-β 1-40 amino acid peptide, or the rapidly aggregating
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amyloid-β 1-42 amino acid peptide, associated with Alzheimer’s disease, within
real-time assays using Thioflavin-T as a reporter for fibril formation.

4.3.

Methods

4.3.1.

Materials

Recombinant human SerpinB2 (47 kDa form) was provided by SerpinB2 Pty Ltd
(Sydney, Australia). Bovine serum albumin (BSA), bovine Cu/Zn superoxide
dismutase (SOD1), Rabbit muscle creatine phosphokinase (CPK), dithiothreitol
(DTT),

iodoacetic

acid,

monoclonal

antibody

against

ovalbumin,

o-

phenylenediamine dihydrochloride (OPD), ovalbumin (SerpinB14), porcine citrate
synthase (CS), Thioflavin-T, casein, thimerosal, protease inhibitor cocktail and
urokinase plasminogen activator from human urine (uPA) were all from SigmaAldrich. were from Bio-Rad Laboratories, Inc. Human recombinant αB-crystallin
was a kind gift from Dr Heath Ecroyd (University of Wollongong) (Horwitz et al.
1998). Monoclonal antibody against human SerpinB2 (#3750) was from American
Diagnostica Inc. Microtitre 96 and 384 well plates were from Greiner. Tissue
culture supernatant containing antibody against human clusterin from the
hybridoma clone "G7" (5-10 ug.mL-1) (Humphreys et al. 1999) and purified human
clusterin from whole blood were a kind gift from Professor Mark Wilson (University
of Wollongong). Amyloid-beta peptide 1-40 (Aβ1-40) and NH4OH was from Anaspec.
Amyloid-beta 1-42 (Aβ1-42) was from Biopeptide, USA. Millex syringe filters (0.45
µm) were from Millipore. The concentration of protein in solution was estimated
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using the BioRad Dc Protein Assay kit, according to the manufacturer’s
instructions, using BSA as the standard.

4.3.2.

Expression and Purification of Recombinant SerpinB2

Wild-type human SerpinB2 (47 kDa) was purified from E. coli (M15) using the
pREP4/pQE-9 expression system, followed by a secondary purification using
anion exchange chromatography. Briefly, purified pQE9/SERPINB2 vectors
were transformed into electro-competent M15 [pREP4] cells using standard
methods. Cells were cultured overnight at 37 °C with shaking in TB containing
100 μg/mL ampicillin and 25 μg/mL kanamycin. A 20 mL aliquot of this starter
culture was added to 1 L TB and grown to an OD600 of ~0.6. Expression of
SerpinB2 was induced by the addition of 0.5 mM IPTG and the culture incubated
overnight at 18°C. Cells were collected by centrifugation at 10,000 g for 10 min.
Pelleted cells were resuspended in 15 mL of ice-cold loading buffer (50 mM
NaH2PO4, 300 mM NaCl, pH 7.0, containing protease inhibitor cocktail) and
lysed using a French press (Thermo, USA). The cell lysate (~20 mL) was then
incubated with 2.5 μg of DNase for 30 min on ice and cell debris pelleted by
centrifugation at 17,000 g for 30 min. The supernatant was loaded onto 3 mL
equilibrated TALON metal affinity resin at a rate of 1 mL/min. Unbound proteins
were removed using 20 column volumes of loading buffer. Bound protein was
eluted from the column using elution buffer (50 mM NaH 2PO4, 300 mM NaCl,
150 mM imidazole, pH 7.0). Samples were buffer exchanged into 20 mM Tris,
pH 8 using PD10 column and then loaded onto a mono-Q (5/50 GL) anion
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exchange column (GE Healthcare) at room temperature. The column was then
washed with 20 bed volumes of 20 mM Tris, pH 8 prior to elution of bound protein
by a NaCl gradient with salting buffer (20 mM Tris, 1 M NaCl, pH 8), increasing
NaCl concentration from 0 to 80% over 2 h, with flow rate at 1 mL.min -1. Purified
SerpinB2 was then buffer exchanged by dialysis, PD10 columns or Amicon Ultra4 centrifugal filter units (MWCO 10 KDa) into PBS (140 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 1.4 mM KH2PO4, 0.02% NaN3 pH 7.4). Purity and integrity of
the recombinant protein was assessed by SDS PAGE (Fig. 4.1). Purified protein
was stored at 4 C until required.
MW kDa

M

1

2

3

4

5

250 –
150 –
100 –
75 –

¥
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§

Figure 4.1: Representative gel showing visualisation of recombinant
SerpinB2 protein following anion exchange chromatography. Fractions
(Lanes 1-5) (20 µL) were prepared using non-reducing sample buffer and
resolved by 10% SDS PAGE (see section 4.3.8). Purified monomeric SerpinB2
(*) and polymerised SerpinB2 (¥) was recovered with minimal low molecular
weight impurities (§) and lanes 1-4 pooled for use in experiments. Precision dual
colour prestained markers (M) (Biorad) were used.
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Recombinant SerpinB2 made in house was used interchangeably with
recombinant SerpinB2 from SerpinB2 Pty Ltd/Biotech Australia (Sydney,
Australia), with comparable results.

4.3.3.

Heat denatured Casein (HDC)

PBS was heated to 70 ºC and 1 % w/v casein added followed by continuous stirring
for 2-3 h at 70 ºC. The solution was then cooled prior to the addition of 0.01% w/v
Thimerosal and pH adjusted to 7.4.

4.3.4.

End-point binding assays

Protein substrates in PBS were incubated overnight in 96 well microplates as
follows: BSA (1 mg.mL-1) was incubated at 37 C in the absence (control) or
presence of 20 mM DTT (reducing misfolded); creatine phosphokinase or citrate
synthase (250 µg.mL-1) were incubated at 4 C (control) or 43 C (heat denaturing);
(lysozyme 1 mg.mL-1) was incubated overnight at 37 C in the absence (control)
or presence of oxidative stress buffer (OSB) (100 µM CuSO4, 4 mM H2O2).
Unbound protein was removed by 2 x 5 min washes with wash buffer (1 x PBS,
0.1% triton-X100). Plates were then incubated for 1 h with blocking buffer (1 x PBS
containing 0.02% (w/v) NaN3 and 1% BSA). Unless otherwise stated wells were
then incubated with 5 mM iodoacetic acid (IAA) in PBS at 37 C for 1 h to acetylate
free sulphydryl groups of cysteine residues. Prepared plates were then incubated
with either a serial dilution (6.25 - 250 µg.mL-1, 1.3 nM – 5.3 µM) or fixed
concentration of SerpinB2 (100 µg.mL-1), SerpinB14 (ovalbumin) (250 µg.mL-1, 5.5
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µM; negative control) or clusterin (50 µg.mL-1, 800 nM; positive control) for 1.5 h
at 37 C. The plates were then washed 3 times with wash buffer and incubated
with blocking buffer for 1 h at 37 C prior to the addition of primary monoclonal
antibodies to either SerpinB2 (1:1000), SerpinB14 (1:30000), or clusterin (25
µL.well-1 hybridoma culture supernatant) and incubated at 37 C for 1.5 h. Wash
and blocking steps with heat misfolded casein (HDC 1% w/v in PBS, containing
0.04 % thimerosal) were repeated prior to the addition of HRP conjugated
secondary antibody (1:2000) in HDC/PBS. After 1 h at 37 C the plates were
washed 3 x 10 min with TBS-T buffer (50 mM Tris, 150 mM NaCl, 0.05% v/v
Tween-20) followed by 3 x 10 min washes with TBS (50 mM Tris, 150 mM NaCl).
Bound antigens were detected using 2.5 mg.ml-1 ortho-phenylenediamine (OPD)
substrate in citrate buffer (50 mM citric acid, 100 mM Na 2HPO4, pH 5) containing
0.03% H2O2 and absorbance at 490 nm was measured after 10 min using a
Spectramax 250 plate reader (Molecular Devices, USA) and Softmax Pro
software. Unless otherwise stated, the volume per well for all protein solutions and
buffers was 100 μL. All incubation and wash steps were conducted at 37 C with
gentle agitation. Assays were conducted in triplicate and data analysed in
GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego
California USA, www.graphpad.com), with background controls subtracted.
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4.3.5.

Light Scattering Assays

4.3.5.1.

Heat Denaturing Stress:

Working solutions of CS (706 nM) in the absence or presence of an equimolar ratio
of either SerpinB2, αB-crystallin (positive control) or SOD1 (negative control) were
prepared in filtered 40 mM HEPES-KOH Buffer, pH 7.5 then aliquoted into wells of
a 384 well microplate and incubated at 43 C for 4 h. Turbidity measurements
(absorbance at 360 nm, A360) were acquired at 5 min intervals using a FLUOstar
Optima plate reader (BMG Labtech, Germany).

4.3.5.2.

Reducing Stress:

BSA (15 µM) or BSA with either SerpinB2 (21 µM), αB-crystallin (50 µM) (positive
control) or SerpinB14 (22 µM) (negative control) were prepared giving 1:1
weight/weight ratios in filtered reducing buffer (PBS, 20 mM DTT, 0.02% NaN 3, pH
7.4) then aliquoted into wells of a 96 well microplate in triplicate and incubated at
37 C overnight. Turbidity measurements (absorbance at 360 nm, A360) were
acquired at 5 min intervals using a FLUOstar Optima plate reader (BMG Labtech,
Germany).

4.3.5.3.

Oxidative Stress:

Working solutions of lysozyme only or lysozyme and SerpinB2, α-crystallin or
SerpinB14 (negative control) at 20:1 molar ratios (French et al. 2008), were
prepared in filtered PBS then aliquoted into wells of a 384 well microplate and 10
x oxidative stress buffer (OSB: Filtered PBS, 1 mM CuSO4, 40 mM H2O2, 0.02%
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NaN3) added to all wells just prior to plate incubation at 37 C for 4 h. Absorbance
readings (360 nm) were acquired at 5 min intervals using a FLUOstar Optima plate
reader (BMG Labtech, Germany).

4.3.6.
4.3.6.1.

Fibril formation - Amyloid-β:
Amyloid-β 1-40 Peptide

Prior to use amyloid-β 1-40 peptide (Aβ1-40) was resuspended in 20 mM NH4OH to
a final concentration of 1 mM, then diluted to 500 µM with milli-Q H2O. The samples
were then aliquoted and frozen at -80 °C until required, as recommended by the
supplier. This preparation step was conducted by Dr Heath Ecroyd (University of
Wollongong) who generously supplied this reagent as a gift for use on this project.

On the day of the experiment an aliquot was diluted to 50 µM with ice cold
phosphate buffer (0.45 µm filtered 50 mM NaH2PO4, 100 mM NaCl, pH 7.4).
Working solutions of Aβ1-40 (25 µM) in the absence or presence of 2.5 µM
SerpinB2, αB-crystallin and SOD1 (negative control) were prepared on ice in
phosphate buffer. Aggregation of the Aβ1-40 peptide was monitored in real time by
following thioflavin-T fluorescence. 10 µM thioflavin-T (thio-T) was added and
solutions immediately transferred to wells of a 384 well microplate and incubated
for 12 h at 37 °C. Samples were excited at 440 nm and fluorescence intensity
(emission 485+/-10 nm) was acquired at 5 min intervals using a FLUOstar Optima
plate reader (BMG Labtech, Germany). Assays were conducted in duplicate,
repeated twice and data analysed in GraphPad Prism version 5.00 for Windows,
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GraphPad Software, San Diego California USA, www.graphpad.com, with
background controls (buffer containing 10 µM thio-T) subtracted.

4.3.6.2.

Amyloid-β 1-42 Peptide

Given the propensity of amyloid-β (Aβ) to aggregate, stock solutions were
prepared as previously described (Bolognesi et al. 2010). Prior to use amyloid-β
1-42 peptide (Aβ1-42) was dissolved at 1 mg.mL-1 in trifluoroacetic acid (TFA)
followed by sonification for 30 s. TFA was then removed over night by lyophilisation
and the Aβ1-42 was then redissolved in 1 mL hexafluoroisopropanol (HFIP),
aliquoted and HFIP removed by speed-vac. Samples were then frozen at -20 °C
until required. All preparation steps were carried out at 4 °C with pre-chilled
reagents. On the day of the experiment an aliquot was resuspended on ice in
filtered Milli-Q H2O, mixed using a sample oscillator (Millipore) for 60 s and
immediately placed back on ice. 10 x PBS was then added to give a 250 µM Aβ 142

working stock in PBS and the sample placed in an ice cold sonication bath for

30 s prior to use. These solutions of Aβ 1-42 were then used in thio-T assays at 25
µM, final concentration, as described for Aβ1-40 (section 4.4.5.1) with the following
exception in method; aggregation of Aβ1-42 was monitored in real time by adding
25 µM thio-T.

4.3.6.3.

Scanning electron microscopy (SEM)

Aβ1-42 peptide (25 µM) was incubated for 12 h at 37 °C in the absence or presence
of 2.5 µM SerpinB2, αB-crystallin or SOD1. Samples from each reaction were
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resuspended at a total protein concentration of 0.1 mg/mL in PBS and 2 µL of each
sample was blotted onto carbon coated nickel 400 mesh grids covered in formvar
resin (Gilder TEM grids, Proscitech, Townsville, Australia), incubated for 5 min at
RT, washed three times with filtered dH2O and negatively stained with 1% uranyl
acetate in milli-Q dH2O. The specimens were then visualised using a JSM7500FA
cold Field Emission Gun Scanning Electron Microscope (JEOL) with an
acceleration voltage of 20.0 kV and a working distance of 8 mm (spot size setting
of 8). The detector used was a transmission electron detector (TED) mounted
beneath the specimen platform. Secondary electron images were taken with a
semi in-lens detector at a working distance of 8.0 mm. SEM imaging was kindly
conducted by Patrick Constantinescu (University of Wollongong).

4.3.7.

Protease:Serpin complex formation

End-point samples were taken from thio-t assays, as described in section 4.3.5.2.
Briefly, SerpinB2 (2.5 µM) was incubated for 12 h at 37 °C in the absence (control)
or presence of 25 µM Aβ1-42 and 25 µM thio-T. Samples from each reaction were
then taken and incubated in the absence or presence of uPA (1.25 µM) for 30 min
at 37 °C. Formation of protease:SerpinB2 complexes were then assessed by
western blotting. Briefly, samples were resolved by 10 % SDS PAGE and
transferred onto ImmobilomTM-P PVDF (Millipore, USA) membrane, using a BioRad Mini Trans-Blot system. The membrane was prepared and protein blotting
apparatus was assembled according to the manufactures instructions with
electrophoresis conducted at 4oC for one h at 100 V. Once the transfer was
complete (ensured by complete transfer of pre-stained markers (BioRad,
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Australia)), blots were blocked with 10% skim milk powder in Tris-buffered saline
(TBS) with 0.05% (v/v) Tween-20 (TBST) overnight at 4oC. The blots were then
rinsed three times with TBST for 5 min per wash. Rabbit α-uPA polyclonal antibody
(1:500) or mouse α-SerpinB2 monoclonal antibody (1:1000) were applied in 2%
milk/TBST and blots were incubated for 2 h, at RT on a shaker. The membrane
was washed with TBST for 10 min, followed by three 5 min rinses with TBST. The
blot was then re-blocked with 6% milk/TBST for 30 min at RT followed by one rinse
with TBST for 5 min. Detection of bound primary antibody was conducted using
the appropriate horse radish peroxidise (HRP) labelled secondary antibody, which
was applied at a final concentration of 1:5000 in 2% milk/TBST for 1 h, at RT.
Three 5 min rinses with TBST were conducted to remove unbound secondary
antibody followed by three 5 min rinses with TBS.

Protein detection was visualised by an enhanced chemiluminescence (ECL)
reaction using SuperSignal® Substrate for Western Blotting as per manufacturer’s
instructions (Progen, Australia). The membranes were exposed to X-ray film in a
X-Omatic Cassette (Kodak) for 5 to 30 min depending on the strength of the signal.
The film was then placed in Developer solution (Kodak) for 2 min, rinsed in water
and placed in Fixer solution (Kodak) for 2 min. The film was rinsed in water and
analysed.
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4.3.8.

Protein Concentration Assay

Unless otherwise specified, the concentration of protein in solution was estimated
using the BioRad Dc Protein Assay kit, according to the manufacturer’s
instructions, using BSA as the standard. Absorbance was measured at 750 nm
using a Molecular Devices SpectraMax 250 plate reader, and SoftMax® Pro
software (Molecular Devices, USA).

4.3.9.

Sodium Dodecyl Sulphate – Polyacrylamide Gel
Electrophoresis (SDS-PAGE)

All SDS PAGE analysis was conducted using 10% polyacrylamide resolving gel
and 4% polyacrylamide stacking gel in a Bio-Rad Mini Protean Gel system (BioRad, Australia). Samples of 30 μL were prepared with 5 x non-reducing sample
buffer and boiled for 5 min prior to loading. Electrophoresis was run at 160 V for
2 h in 1 x SDS running buffer. Bio-Rad low molecular weight markers were used
to determine approximate protein size.

4.4.

Statistical analysis

Statistical significance was determined by Students t-tests using GraphPad Prism
version 5.00 for Windows, GraphPad Software, San Diego California USA
(www.graphpad.com). P values less than 0.05 were considered significant.
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4.5.

Results

4.5.1.

End-point binding assays

The ability of SerpinB2 to interact with native or misfolded client proteins, routinely
used in the biochemical analysis of chaperone activity, was first determined using
an ELISA approach. SerpinB2 was found to bind preferentially, in a saturable
manner, to reduction (DTT)-stressed BSA (Fig 4.2A), oxidised lysozyme (Fig
4.2B), and heat-stressed CPK (Fig 4.2C), as negligible binding to native proteins
was detected. Analysis of specific binding affinities, determined by non-linear fit
with one-site binding model (Y=Bmax*x/(Kd+x)), between SerpinB2 and reductionstressed BSA or heat-stressed CPK were similar with apparent KD of 0.705 µM (±
0.131 µM SEM) and 0.818 µM (± 0.114 µM SEM), respectively, whilst the apparent
KD between SerpinB2 and oxidative-stressed lysozyme was 1.927 µM (± 0.323 µM
SEM) (Tab 4.2). In contrast, SerpinB2 bound at low levels to both native and heatstressed CS (Fig. 4.2D).

Low levels of SerpinB14 (ovalbumin) (negative control) were also found to interact
preferentially with reduction-stressed BSA (Fig.4.2.E) and oxidised lysozyme
(Fig.4.2.F). However, comparison of fold increases in binding interaction observed
for each Serpin shows a 285 fold increase for SerpinB2 interaction with misfolded
BSA – relative to native BSA - compared to 17.5 fold increase observed for
SerpinB14 (Fig.4.2.E). Furthermore an 8-fold increase in SerpinB2 interaction with
oxidised-lysozyme was observed – relative to native lysozyme - compared to a 3
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fold increase in SerpinB14 (Fig.4.2F). In contrast, SerpinB2 binding interaction with
heat misfolded CPK increased 5-fold – relative to control CPK- whilst there was no
detectable interaction observed between SerpinB14 and either native or heatstressed CPK (Fig.4.2G); nor native or heat-stressed CS (Fig.4.2H), which
corresponded to a non-significant fold increase in binding.
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Figure 4.2: SerpinB2 binds preferentially to misfolded proteins. Left panel:
Dose dependent binding of SerpinB2 to native and misfolded proteins was
determined using an ELISA system with relevant specific antibodies and controls.
(A) BSA (1 mg.mL-1) was incubated overnight at 37 °C in the absence (native
control) or presence of 20 mM DTT (Reduced BSA) (B) Lysozyme (1 mg.mL-1) was
incubated overnight at 37 °C in the absence (control) or presence of OSB (100 µM
CuSO4 and 4 mM H2O2; Oxidised Lysozyme) (C) CPK and (D) CS (250 µg.mL-1)
were incubated overnight at 4 °C (control) or 43 °C (heat misfolded). Right panel:
Fold increase in SerpinB2 or SerpinB14 (control) interaction with misfolded
substrates, compared to controls. ELISA plates containing (E) BSA, (F)
Lysozyme, (G) CPK and (H) CS were prepared as per (A - D) and specific binding
of either SerpinB2 or SerpinB14 (250 µg.mL-1) was determined as above. Data has
been normalised to control (native) protein and represents mean fold increase in
detectable interactions ± SEM, n=3. Asterisks denote significant differences,
***p<0.001. ****p<0.0001, NS = not significant.

Table 4.1: Kinetic parameters for binding of SerpinB2 to misfolded protein
substrates.
Stressed
Substrate

BSA
Lysozyme
CPK
CS

appKD

± SEM (µM)

0.705 (0.131)
1.927 (0.323)
0.818 (0.115)
N.D

BMAX ± SEM

DF

R2

2.006 (0.109)
0.893 (0.066)
2.096 (0.090)

22
19
22

0.897
0.958
0.945

Specific binding was analysed by a non-linear fit regression using GraphPad. The data best fit a
one site specific binding model. Mean data ± SEM, n=3, from a representative experiment. N.D =
not determined.
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4.5.2.

Real-time protein aggregation

4.5.2.1.

Amorphous aggregation models

Given that SerpinB2 binds specifically to some unfolded proteins, we next tested
its ability to inhibit the stress-induced aggregation of the same client proteins.
When tested at the same w/w ratio to client protein, SerpinB2 (21 µM) inhibited the
DTT-induced aggregation of BSA (15 µM) to the same extent as αB-crystallin (50
µM) a well characterised chaperone (positive control) (Fig.4.3.A and B).
Interestingly, this level of aggregation inhibition was only observed when the realtime light scattering assay was conducted within a 96 well microplate (Fig.4.3.A).
When the assay was conducted within a 384 well plate, under the same conditions,
SerpinB2 was found to be less efficient (Fig.4.3.C). The variability in chaperone
activity observed between the two plate formats may be related to aggregation
dynamics, whereby loss of chaperone function is correlated with increasing rate of
substrate aggregation (Lindner et al. 2001). This is supported by the finding that a
1 mg.mL-1 solution of BSA/DTT aggregated faster and to a greater extent within
the 384 well plate (Fig.4.3.C), compared to that within a 96 well plate (Fig.4.3.A)
as is shown by the A360 trace over time. Regardless, in both assay formats
SerpinB2 was able to at least partially inhibit BSA aggregation suggesting potential
chaperone activity for this serpin under reducing conditions. In comparison,
SerpinB14 (22 µM) enhanced aggregation of BSA within the 96 well plate based
assay, when used at the same w/w ratio as SerpinB2 (Fig.4.3.A). Furthermore,
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when incubated alone under the same conditions, the serpins and αB-crystallin did
not aggregate (Fig.4.3B).

Mean Abs 360 nm

A 0.20

0.20

B

BSA
BSA:SerpinB2

0.15

0.15

BSA:SerpinB14

BSA: Bcrystalin

Bcrystalin

0.10

0.10

SerpinB2
SerpinB14

0.05

0.05

0.00

0.00
0

5

10

15

20

0

5

Time (hr)

10

15

20

Time (hr)

C

D
0.4

Mean Abs 360 nm

0.4
0.3
0.3
Bcrystallin

0.2

BSA

SerpinB2

0.2

BSA:SerpinB2

0.1

0.1
BSA: Bcrystallin

0.0

0.0
0

5

10

Time (hr)

15

20

5

10

15

20

Time (hr)

Figure 4.3. SerpinB2 inhibits aggregation of BSA under reducing stress.
BSA (1 mg.mL-1) was incubated for 15 h at 37 °C in the presence of 20 mM DTT
in the absence or presence of SerpinB2, αB-crystallin or SerpinB14 (1:1 w/w)
within either a (A) 96 or (C) 384 well plate. Controls are shown in panel (B and
D) for each experiment respectively. In all assays, aggregation was determined
in real time by assessing changes in turbidity (A360 nm). Data = mean ± SEM
with appropriate background controls subtracted, n=3.

We next investigated the chaperone activity of SerpinB2 under oxidative stress
using the substrate lysozyme, as previously described (French et al. 2008).
SerpinB2 is known to polymerise under these conditions (Wilczynska et al. 2003;
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Lobov et al. 2004), however the physiological function of this property is unknown.
SerpinB2 enhanced aggregation of lysozyme incubated at 37 °C in oxidative stress
buffer (OSB) at a molar ratio of 20:1 (Lysozyme:SerpinB2) (Fig. 4.4.A). SerpinB14
(negative control) used at the same molar ratio (20:1) also enhanced aggregation
of lysozyme, however the affect was greater than that seen for SerpinB2 (Fig.
4.4.B). It is important to note that incubation of SerpinB2 or SerpinB14 only in the
presence of OSB did not result in detectable protein aggregation (Fig. 4.4.B.).

A

B

Time (h)

Figure 4.4: SerpinB2 enhances amorphous aggregation of Lysozyme
under oxidative stress. Lysozyme (70 µM) was incubated at 37 °C for 4 h under
oxidative stress conditions in the absence or presence of (A) SerpinB2 or (B)
SerpinB14 (20:1 molar ratio). In all assays, aggregation was determined in real
time by assessing changes in turbidity (A360). Data represents mean ± SEM
with appropriate background controls subtracted, n=3.

We next investigated SerpinB2 chaperone activity in the presence of CS, under
heat denaturing conditions (Fig. 4.5). SerpinB2 had no effect on CS aggregation
at a 1:1 molar ratio and was indistinguishable to SOD1 (negative control), which
was not surprising given that there was no specific binding to the misfolded CS
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within the end-point binding assays (refer to Fig.4.1), whilst αB crystallin reduced
CS precipitation by approximately 50% (Fig.4.6).
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Figure 4.5: SerpinB2 does not inhibit amorphous aggregation of Citrate
Synthase (CS) under heat stress. CS was incubated in the absence or
presence of (A) SerpinB2, αB-crystallin or (B) SOD1 at 1:1 molar ratio for 4 h at
43 °C. Also shown in (B) are protein only controls. In all assays, aggregation was
determined in real time by assessing changes in turbidity (A360). Data
represents mean ± SEM with appropriate background controls subtracted, n=3.

4.5.2.2.

Amyloid-β peptide Fibril formation

Given the co-localisation of SerpinB2 with microglial aggregates, in association
with senile plaques of Alzheimer’s patients (Akiyama et al. 1993), up-regulation of
SerpinB2 by microglia following activation by incubation with amyloid-β 1-42
peptide for 24 h (Walker et al. 2006) and other published works showing
interactions between amyloid-β and other Serpin family members (Schubert 1997;
Janciauskiene et al. 1998; Kinghorn et al. 2006; Chiou et al. 2009) we also
investigated the potential for SerpinB2 to inhibit fibril formation of amyloid-β peptide
(Aβ) using a standard thio-T fluorescence assay. SerpinB2 was able to completely
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inhibit Aβ1-40 peptide from aggregating at a 10:1 molar ratio of Aβ1-40:SerpinB2
(Fig.4.6.A). The efficiency was comparable to that of αB-crystallin used at similar
molar ratios (Fig.4.6.A). SerpinB2 was not as efficient as αB-crystallin at inhibiting
the faster aggregating Aβ1-42 peptide (Fig.4.6.B). SerpinB2 was able to inhibit fibril
formation by Aβ1-42 peptide during the first 5 h of incubation as seen by the
extended lag phase, but this was not sustained as a substantial increase in thio-T
fluorescence was observed in the latter part of the real-time assay (Fig.4.6.B). In
comparison, αB-crystallin completely inhibited Aβ1-42 fibril formation for the
duration of the assay (Fig 4.6.B), whilst SOD1 (negative control) had minimal
effect.
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Figure 4.6: SerpinB2 inhibits the formation of amyloid fibrils in vitro.
Amyloid peptide (A) Aβ1-40 or (B) Aβ1-42 were incubated at 37oC in the absence
or presence of SerpinB2, αB-crystallin or SOD1 (negative control) at 10:1
Aβ:protein molar ratio for 11 h. (C) No fibril formation was observed in protein
samples alone. Fibril formation was determined using Thioflavin-T (25 µM) and
change in relative fluorescence (490 nm) over time. Data represents mean
fluorescence intensity with background controls subtracted, n=2.

As a complementary approach to analyse the ability of SerpinB2 to inhibit Aβ
peptide fibril formation, samples taken from Aβ1-42 solutions supplemented (or not)
with SerpinB2, αB-crystallin or SOD1, and incubated for 12 h at 37oC were
analysed by scanning electron microscopy (SEM). As expected under these
conditions we observed the formation of fibrillar structures within both the Aβ 1-42
(Fig.4.7.A) and Aβ1-42:SOD1 (negative control) (Fig.4.7.B) solutions, indicating that
SOD1 was unable to prevent fibril formation and this was consistent with results
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obtained within the thio-T assays (Fig.4.6). Importantly, Aβ1-42 fibrilar structures
were absent from the Aβ1-42:SerpinB2 (Fig.4.7.C) or Aβ1-42:αB-crystallin (Fig.4.7.D)
solutions, which is indicative of inhibited fibril formation.

A

B

C

D

Figure 4.7: Scanning Electron Micrographs of Aβ1-42 (25 µM) fibril
formation in the absence (A) or presence of either (2.5 µM) SOD1 (B)
(negative control), SerpinB2 (C) or αB-crystallin (D). Samples were incubated
at 37oC of 12 h prior to mounting onto carbon coated nickel 400 mesh grids
covered in formvar resin and visualised using a JSM7500FA cold Field
Emission Gun Scanning Electron Microscope (JEOL) with an acceleration
voltage of 20.0 kV and a working distance of 8 mm (spot size setting of 8).
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Previous work investigating the interactions between Aβ peptide and SerpinA1
(alpha1-antichymotrypsin) (Janciauskiene et al. 1998) or SerpinI1 (neuroserpin)
(Kinghorn et al. 2006) suggests that Aβ binding occurs within the β-sheet A of
serpins, which in turn, obstructs complete RCL insertion upon protease inhibition
and results in loss of inhibitory function (ref Fig. 1.1). To investigate this potential
interaction between SerpinB2 and Aβ peptide we used end-point samples taken
from the real-time assay shown in Fig. 4.6.B, and assessed SerpinB2 inhibitory
activity by formation of uPA-SerpinB2 complexes using a gel-shift assay and
western blotting. Samples were resolved and membranes probed for SerpinB2
(Fig. 4.8). As expected, SerpinB2 only (positive control) (Fig. 4.8, Lane i) consisted
of monomer and high molecular weight species indicative of polymerised SerpinB2
(Wilczynska et al. 2003; Lobov et al. 2004). In the absence of Aβ1-42, SerpinB2 was
able to form a high molecular weight complex with uPA (Fig. 4.8, Lane ii orange
arrows). A small amount of cleaved SerpinB2 was present in this sample (Fig. 4.8,
Lane ii; blue arrow), which is indicative of SerpinB2 acting as a uPA substrate
(Silverman et al. 2001). Importantly, the bands corresponding to uPA:SerpinB2
complex formation are diminished in the presence of Aβ1-42 peptide (Fig.4.8 lane
iii; orange arrows). Furthermore, the loss of signal intensity for complex formation
coincided with an increased signal intensity for cleaved SerpinB2 (Fig. 4.8, Lane
ii; blue arrow), indicating that the inhibitory activity of SerpinB2 is compromised in
the presence of Aβ1-42 peptide.
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Figure 4.8. Aβ1-42:SerpinB2 complex formation inhibits Serpin activity.
SerpinB2 was incubated for 11 h at 37 oC in the absence or presence of 10 molar
excess Aβ1-42 peptide. SerpinB2 (2.5µM) activity was then assessed by complex
formation with uPA (1.25 µM) at a 2:1 Serpin:protease molar ratio. Samples (15
µL) were fractionated under non-reducing conditions by SDS PAGE and
analysed by western blot. Detection of SerpinB2 was conducted with relevant
primary and HRP-conjugated secondary antibodies as stated in the methods.
Orange arrows indicate uPA:SerpinB2 complexes. Blue arrows indicate cleaved
SerpinB2.
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4.6.

Discussion

Disruption of normal protein homeostasis (proteotoxic stress) is integral to the
pathophysiology of both acute injury associated inflammation, neuronal
dysfunction and age related neurodegeneration (Hipp et al. 2014). As described in
section 4.2, recent research has shown that SerpinB2 expression is massively
upregulated in neurons and immune cells after stress. These observations, and
the role of other serpin molecules in modulating proteostasis through chaperonelike activities, such SerpinH1/H2 (Gettins 2002; Sauk et al. 2005), SerpinA1 (Zsila
2010), SerpinA6 (Westphal 1986; Hammond et al. 1987; Pemberton et al. 1988;
Hammond 1990) and SerpinA7 (Pemberton et al. 1988), led us to assess SerpinB2
for chaperone activity, as a potential mechanism for the putative cytoprotective role
described for SerpinB2.

A defining characteristic of chaperones is their ability to bind to misfolded or
unfolded proteins (substrates), via exposed hydrophobic residues which are
normally buried within the three-dimensional structure of the native protein (Tompa
and Csermely 2004; Schroder and Kaufman 2005). We show here that SerpinB2
also binds preferentially to misfolded-stressed BSA, CPK and lysozyme, compared
to their respective native-conformation controls and to either native or misfolded
conformations of CS. This shows that SerpinB2, like known chaperones such as
αB-crystallin (Carver and Lindner 1998) and clusterin (Humphreys et al. 1999), is
able to identify misfolded proteins. Whether the association of SerpinB2 with
misfolded substrates occurs via hydrophobic interaction remains to be
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investigated. Of note however, 44% of the amino acid residues within the highly
mobile C-D loop of SerpinB2 are hydrophobic. Furthermore, the finding by
(Wilczynska et al. 2003) that SerpinB2 undergoes redox sensitive conformational
rearrangements via disulphide bond formation between C79, located within the CD loop, and C161 at the bottom of helix F, is of interest. Disruption of this bond by
site directed mutagenesis (C79S), was shown to significantly increase the surface
hydrophobicity of SerpinB2, as determined by an observed increase in the 4,4′Dianilino-1,1′-binaphthyl-5,5′-disulfonic acid dipotassium salt (bis-ANS) binding, a
common dye used to identify or block pockets of hydrophobicity (Musci and
Berliner 1985). It is tempting therefore, to speculate that these hydrophobic
characteristics described for SerpinB2 contribute to the preferential binding of
SerpinB2 to misfolded proteins and as such warrant further investigation.
Interestingly, SerpinB14, used here as a negative control, also bound,
preferentially, to misfolded-stressed BSA and lysozyme, compared to their relative
controls, but not CPK or CS. Importantly, the fold increase in binding of SerpinB2
to misfolded substrate, relative to controls, was consistently higher in magnitude
than that seen for SerpinB14. Given the sequence identity of 36% (Benarafa and
Remold-O'Donnell 2005) and sequence similarity of 33% between SerpinB2 and
SerpinB14, it is possible that SerpinB14 contains exposed regions of
hydrophobicity, which contribute to these observed binding interactions.

Importantly, the ability of molecular chaperones to identify and interact with
misfolded substrates typically corresponds with protection of the substrate from
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aggregation (Hartl et al. 2011). In this respect, we show here that SerpinB2
significantly inhibited the formation of amorphously structured BSA aggregates
under reducing conditions and that this protective effect was indistinguishable from
that of a classical chaperone, αB-crystallin at the same BSA:chaperone (1:1 w/w)
ratio. It was therefore surprising to find that under oxidative conditions lysozyme
aggregation was enhanced by SerpinB2. However, this observation is supportive
of the increased hydrophobicity of SerpinB2 upon disruption of the C79-C161
disulfide bond, described by Wilczynska et al. (2003), which would also occur
under reducing conditions. In the presence of oxidative stress, formation of the
C79-C161 disulfide bond would be favourable, potentially not allowing the increase
in hydrophobicity and disrupting chaperone activity by decreasing hydrophobic
interactions. The loss or gain of chaperone activity in response to changes in redox
states, pH or temperature is well documented, for example, Hsp33 is a redox
sensitive chaperone found in bacteria and is activated under oxidative conditions
(Graumann et al. 2001) (Kumsta and Jakob 2009). Furthermore, the chaperone
activity of clusterin was found to been enhanced by reduction in pH (Poon et al.
2002), whilst that of αA-crystallin is enhanced by increased temperature (Bova et
al. 1997). Interestingly, the increased chaperone activity described for αA-crystallin
coincided with increased hydrophobicity, as determined by BIS-ANS binding
assays (Das and Surewicz 1995). Of note, SerpinB2 alone did not aggregate in
the presence of oxidative stress, therefore it seems most likely that SerpinB2
interaction with lysozyme, possibly through disulphide bond formation, enhances
the rate of aggregation. Therefore it is possible that the substrate model used for
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investigation of SerpinB2 chaperone activity, under oxidative stress conditions
may not be suitable and further experiments are required to characterise the
efficiency of SerpinB2 to inhibit aggregation undergoing oxidative stress.

SerpinB14 was found to enhance aggregation of BSA and lysozyme under the
same experimental conditions for SerpinB2. Interactions between lysozyme and
SerpinB14, undergoing heat-stress have been reported previously (Matsudomi
1986; Matsudomi 1987) and thought to occur via electrostatic attraction and
sulfhydryl-disulfide interchange. Recent investigation of the interaction between
heat-stressed lysozyme and ovalbumin shows incorporation of both molecules into
amyloid like fibril formations (Sugimoto et al. 2011). Whether fibril aggregation
occurred between lysozyme and SerpinB14, or indeed SerpinB2 in the presence
of oxidative stress is unknown however, the increase in relative turbidity suggests
that SerpinB14 is interacting with both BSA and lysozyme, and therefore is
contributing to amorphous aggregation through an unknown mechanism. In
contrast, αB-crystallin completely inhibited BSA and lysosome aggregation under
these assay conditions. Importantly, the preferential binding of SerpinB14 to either
BSA or lysozyme in the plate based assays did not correlate with chaperone
activity within the amorphous aggregation models investigated. Neither SerpinB2
or SerpinB14 were effective inhibitors of amorphous aggregation by citrate
synthase under heat denaturing conditions, whilst αB-crystallin reduced
aggregation by approximately 50%.
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Whilst rapid aggregation is largely driven by hydrophobic forces and primarily
results in amorphous aggregates, the formation of fibrillar aggregate structures is
slower and gives rise to neurodegenerative diseases (Chiti and Dobson 2006).
Interestingly, Serpins A1, A3 (Eriksson et al. 1995) (Aksenova et al. 1996) and I1
(neuroserpin) (Kinghorn et al. 2006) have previously been shown to inhibit fibril
formation by the Aβ peptides, associated with Alzheimer’s disease. Therefore, we
next investigated the potential chaperone activity of SerpinB2, using Aβ peptides
within fibril formation assays. Importantly, SerpinB2 was able to inhibit fibril
formation by Aβ1-40 peptide at a molar ratio of 10:1 Aβ:SerpinB2 and this was
indistinguishable from the inhibitory efficiency of αB-crystallin, at the same molar
ratio. The inhibition of Aβ1-40 fibril formation by αB-crystallin, under similar assay
conditions used herein, has been previously described (Dehle et al. 2010) and is
consistent with our findings.

In similar experiments, SerpinB2 was found to inhibit Aβ1-42 fibril formation over a
5 h period, however this effect was not sustainable and an increase in fibril
formation as assessed by Thio-T fluorescence was observed between the 5 and
10 h time periods. Conversely, no Aβ1-42 fibrillar forms were observed, by SEM,
within an alternate experiment, in the presence of SerpinB2 or αB-crystallin.
Fibrillar aggregation follows a classical sigmoidal trajectory whereby the initial
phase (lag phase) of the time course consists of dimer and trimer formations,
increasing in subunit association until nuclei form, at which point rapid
polymerisation/elongation (growth phase) occurs until the reaction reaches
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equilibrium and plateaus (Jarrett and Lansbury 1993). In this context it is possible
that SerpinB2 interacts directly with the monomeric form of Aβ1-42 peptide, either
blocking initial nucleation, as is suggested by the lack of fibril formation observed
within the SEM experiment, or by reducing the rate of elongation of pre-existing
nuclei (seeds) by sequestering soluble monomers.

Interestingly, early experiments conducted by Fraser et al. (1993) reported the
association of Aβ peptide with SerpinA3, via 10 amino acid residues within the Nterminal region of the peptide. It has since been shown that Aβ1-42 peptide interacts
directly with SerpinA3 via either the carboxyl-terminal segment (peptide) and βsheet C of the serpin or the amino-terminal segment (peptide) and β-sheet A
(Janciauskiene et al. 1998). Furthermore, Kinghorn et al., (2006) reported a direct
interaction between SerpinI1 (neuroserpin) and Aβ1-42 which was shown to
obstruct serpin function and inhibited SerpinI1 polymer formation. As both
conformational rearrangements of SerpinI1 require RCL insertion into β-sheet A,
this work corroborates Aβ1-42-Serpin (β-sheet A) interactions previously described
for SerpinA3 (Janciauskiene et al. 1998). Therefore, we have utilised a similar
gel-shift assay to that described by Kinghorn et al. (2006) and shown that Aβ
peptide interactions with SerpinB2 result in the same reduction of serpin function
as described for SerpinI1 (Kinghorn et al. 2006). Whilst a reduction in serpinprotease complex formation was observed, experiment confirmation of the
proposed β-amyloid binding site within β-sheet A of SerpinB2 is required.
Nonetheless, we have shown that SerpinB2 interacts with both forms of Aβ peptide
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and the binding interaction is consistent with those recently described for other
serpin members. Importantly, the loss of serpin function supports the observation
that SerpinB2 may bind to monomeric Aβ peptide, thereby limiting nucleation or
the rate of polymerisation by reducing the concentration of peptide in solution.

Taken together the work presented here provides preliminary evidence that
SerpinB2 may function within proteostasis networks, as a chaperone-like protein.
In this context we show that SerpinB2 identifies and binds preferentially to
misfolded proteins and displays holdase-like chaperone activity towards
amorphous aggregations within a reducing, but not oxidative or heat stressed
environment. Whether this variation in chaperone-activity is related to functional
conformational rearrangement and activation, is not clear, but warrants further
investigation. SerpinB2 also exhibits efficient chaperone-like activity towards Aβ
peptide, consistent with previous works for other serpins. Further investigation of
the proposed function of SerpinB2, within proteostasis networks is required at a
cellular

level.

Therefore,

experiments

investigating

the

cytoprotective

characteristics of SerpinB2 within a cell based, protein aggregation model are
described in chapter 5.
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5. SerpinB2 protects cells from proteotoxic stress
through modulation of protein degradation pathways.
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5.1.

Abstract

Up-regulation of SerpinB2 in response to cellular stress is well-established, the
intracellular pathways in which SerpinB2 may function, however, are poorly
defined. Key to cell survival are protein quality control systems which maintain
proteostasis through the chaperone and protein degradation pathways. SerpinB2
has been implicated within these networks via identification of potential intracellular
binding partners, such as proteasome subunit beta type 1 (PSMB1, a component
of the proteasome) (Fan et al. 2004) and the ubiquitin-like interferon stimulated
gene-15 (ISG15) (Giannakopoulos et al. 2005), which are functional components
of the ubiquitin-proteasome degradation pathway. In this context, the mutant Htt exn1

model of protein aggregation and proteotoxicity (Olshina et al. 2010) was utilised

to investigate the cellular processing of misfolded protein by SerpinB2 null mouse
embryonic fibroblasts and provides evidence of impaired inclusion body (IB)
formation and proteasome activity in the absence of SerpinB2. Furthermore, this
work suggests that SerpinB2 may exert its cytoprotective characteristics through
regulation of autophagy.

5.2.

Introduction

SerpinB2 is a member of the Serine Protease Inhibitor super family that has been
localised to both the extracellular and intracellular environment of numerous cell
types including keratinocytes, endothelial, epithelial, monocytic and neuronal cells
(Lee et al. 2011). Secreted as a 47 kDa or glycosylated 60 kDa protein,
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extracellular SerpinB2 is thought to function as an inhibitor of the urokinase
plasminogen activator and to a lesser extent, tissue-type plasminogen activator
(Kruithof et al. 1995). The majority of SerpinB2 is, however, retained within the
intracellular environment as a 47 kDa protein (Lee et al. 2011). The main producers
of SerpinB2 are cells of the myeloid lineage which up regulate SerpinB2
expression during cell developmental phases, such as proliferation and
differentiation, or in response to pathology, especially inflammation and cellular
stress (Schroder et al. 2010; Lee et al. 2011). As yet an intracellular protease target
for this serpin has not been defined which suggests a role independent of the
classical inhibitory mechanisms characteristic of serpins (Law et al. 2006).

Of interest are the intracellular networks upregulated in response to cellular stress
and the role SerpinB2 may pay within these pathways. We have previously shown
that SerpinB2 binds preferentially to unfolded proteins following reductive,
oxidative or heat stress (Chapter 4). Furthermore, SerpinB2 was found to inhibit
amorphous aggregation of reduction-stressed BSA, but not other models, and fibril
formation of both amyloid-β 1-40 or 1-42 peptides (Chapter 4). These chaperonelike characteristics of SerpinB2 suggest a role within quality control systems that
maintain proteostasis. The isolation or removal of deleterious proteins from the
intracellular compartment is key to cell survival and is facilitated through either the
ubiquitin/proteasome degradation pathways or autophagy and the lysosomal
degradation pathway (Tyedmers et al. 2010).
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The 26S proteasome is an ATP-dependent proteolytic macro-complex that is found
within the cytoplasm and nucleus (Peters et al. 1993; Brooks et al. 2000).
Comprising of a proteolytic core (20S complex), the proteasome forms a cylindrical
structure, which incorporates 28 protein subunits arranged into 4 rings (Gallastegui
and Groll 2010). The proteolytic component of the proteasome is made up of seven
β-subunits (β1 to β7) that are buried within the core of the complex. Proteasome
activity is tightly regulated with assembly and disassembly of the macro-complexes
facilitated by proteasome assembly chaperones; and access to the enzymatic core
- via the 19S regulatory subunits, which cap the 20S complex - is mediated by a
tightly regulated network of deubiquitinating enzymes (DUBs), shuttling factors and
unfoldase chaperones (reviewed in (Adams 2004; Nalepa et al. 2006; Herrmann
et al. 2007). Proteins are targeted to the proteasome for degradation through
modification with ubiquitin or ubiquitin-like adapter proteins, such as SUMO, Nedd8
and interferon stimulated gene-15 (ISG15) (Kerscher et al. 2006). In the context of
proteostasis, the proteasome system functions to recycle functional proteins that
are no longer required by the cell or to protect cells through the clearance of
soluble, misfolded proteins, thereby preventing protein aggregation (Tyedmers et
al. 2010). However, the proteasome does not function in the clearance of insoluble
protein aggregates (Bence et al. 2001; Verhoef et al. 2002). Therefore, alternative
quality control mechanisms, such as the autophagy-lysosomal degradation
pathway, are required to maintain cellular proteostasis, in complementation with
the proteasome.
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Macro-autophagy (herein referred to as autophagy) involves the complex cascade
of steps that give rise to the formation of double-membrane structures, which
incorporate substrates such as protein aggregates and damaged organelles, for
degradation via the lysosome (He and Klionsky 2009; Nakatogawa et al. 2009).
The class III phosphatidylinositol 3-kinase (PtdIns3K) complex mediates initiation
of the pathway through formation of the phagophore membrane. Recruitment of
autophagy specific (Atg) proteins into the phagophore, facilitates elongation of the
membrane and encapsulation of target substrates (Suzuki et al. 2007; Kawamata
et al. 2008), resulting in the formation of a complete vesicular compartment, known
as the autophagosome. This vesicle is transported along the microtubule network
via dynein and microtubule-associated proteins, such as the HDAC6 (Iwata et al.
2005), to the lysosome where autophagosome-lysosome fusion results in
formation of the autolysosome and cargo degradation by lysosomal proteases
occurs. Basal levels of autophagy activity within cells (under normal physiological
conditions) are low and regulation (positive or negative) of the pathway is tightly
controlled throughout each phase from phagophore initiation to neutralisation of
the autolysosome (He and Klionsky 2009). Interestingly, the initial seeding of the
phagophore is negatively regulated by B-cell lymphoma-2 (Bcl-2) inhibitory
interaction with Beclin-1 (Liang et al. 1998; Pattingre et al. 2005), a component of
the PtdIns3K complex.
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SerpinB2 expression was recently shown to stabilise Beclin-1 and promote
autophagy (Chuang et al. 2013). Furthermore, SerpinB2 was found to interact with
the β-subunit type-1 component of the proteasome 20S core chamber, following
GST-pulldown experiments (Fan et al. 2004), and SerpinB2 was identified as a
target for the ubiquitin-like adapter protein, ISG15, following mass spectrometric
analysis of anti-ISG15 immunoprecipitates (Giannakopoulos et al. 2005). Taken
together, these findings provide evidence for a possible role of SerpinB2 within
proteostasis pathways which warrants further investigation.

5.2.1.

Rationale and Aims

Given the in vitro chaperone-like activity of SerpinB2 (Chapter 4) and evidence in
the literature implicating SerpinB2 within autophagy and the ubiquitin/proteasome
pathways, we hypothesise that SerpinB2 may function in cellular stress response
pathways that involve binding to misfolded proteins. Therefore, using mouse
embryonic fibroblasts (MEF) from control (wild-type) mice or the SERPINB2 null
mouse model (Dougherty et al. 1999) we investigated the potential role of
intracellular SerpinB2 in proteostasis. To this end we employed an intracellular
aggregation model to investigate the processing of aberrant proteins and the affect
SerpinB2 may have on i) Cell viability ii) Inclusion body formation and iii) Protein
degradation pathways.
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5.3.

Materials and Methods

5.3.1.

Materials

Recombinant human SerpinB2 (47 kDa) was purified from E. coli (M15) using the
pREP4/PQE-9 expression system as described in section 4.3.2. ISOLATE RNA
Mini Kit and BioScript One-Step RT-PCR kit were from Bioline. 20 μm filter caps
were from Millipore and Polyfect was from Qiagen Pty Ltd, RPMI1640, tissue
culture flasks, Lipofectamine2000, fetal calf serum (FCS), trypsin EDTA. Sytox-red
was obtained from Invitrogen. Polybrene, gelatin, MG-132 and propidium iodine
were from Sigma Aldrich.

5.3.2.

Generation of Mouse Embryonic Fibroblast primary cell lines.

MEFs were isolated from wild-type and SerpinB2-/-mice as previously described
(Dougherty et al. 1999; Schroder et al. 2010). Briefly, a pregnant female
C57/Black-6 mouse was euthanised at day 13.5 post coitus by CO2 asphyxiation.
The uterine horns containing the embryos were dissected from the mouse and
placed in sterile PBS on ice. The uterine wall was cut and each embryo removed
and separated from its amniotic sac. A scalpel blade was used to remove the head
and liver and the remaining tissue was resuspended in 10 ml of trypsin-EDTA. The
embryos were finely minced with a scalpel blade for approximately 1 min and then
incubated at 37 ºC for 5 min. The tissue was homogenised by passing gently
through an 18 gauge needle several times and allowed to settle for 5 min at room
temperature. The supernatant (cell suspension) was transferred to a tube
containing 20 mL of pre-warmed RPMI + 10% FCS and centrifuged for 5 min at
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300 x g. The cell pellet was resuspended in RPMI1640 + 10% FCS and plated on
0.1% gelatin (passage 0). Primary cultures were then continually passaged until
spontaneous immortality was obtained. This work was conducted by Dr Wayne
Schroder, Queensland Institute of Medical Research (QIMR).

Mouse embryonic fibroblasts were maintained in RPMI-1640 containing 10% FCS
and cultured at 37 °C with 5% CO2.

5.3.3.

Generation of stable MEF cell lines expressing human
SerpinB2.

Human WT SerpinB2 cDNA was cloned into the Xho1 restriction sites of a murine
stem cell virus (MSCV)-based retroviral vector (pMIG) (Szymczak et al. 2004;
Brummer et al. 2006; Brummer et al. 2008), giving rise to pMIGSerpinB2 constructs
(Fig 5.1). Control plasmids (pMIGGFP) were also generated.
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Figure 5.1: Schematic representation of pMIG retroviral construct containing
SerpinB2 cDNA. This vector contains an internal ribosome entry site (IRES)
between the SerpinB2 open reading frame (1.2 kb) and a Green Fluorescent
Protein (GFP) reporter, driving expression of both from a single promoter. Correct
insertion of human SerpinB2 cDNA was confirmed by DNA sequencing of
constructs Dr S Lobov, University of Wollongong NSW.

For the production of stable cell lines, retrovirus packaging cell line, PlatE cells
(Jomar Biosciences Pty Ltd, Welland, South Australia), were transfected with the
pMIG constructs using Polyfect, according to the manufacturer’s instructions. Viral
supernatants were collected 48 h later, filtered through 20 μm filter caps, 8 μg/mL
of polybrene was added and supernatant was added to MEFs. Positive cells were
selected by cell sorting on a FACS Vantage (Becton Dickinson), based on the
bicistronic expression of GFP. Cell genotype was verified by rt-PCR and SerpinB2
expression within SerpinB2-/- (WT rescue) MEF cells was observed by western blot
detection system.
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5.3.4.

Reverse-transcription PCR

Extraction of total RNA from cell lines and subsequent rt-PCR was conducted
using the ISOLATE RNA Mini Kit and BioScript One-Step rt-PCR kit (both from
Bioline), as per the manufacturer’s instructions. The concentration and purity of
RNA obtained using this kit was then assessed by absorbance at 260 nm and
260/280 ratio using a NanoDrop 2000c Spectrophotometer (Thermo Fischer
Scientific, VIC, Australia) (Table 5.1).
Table 5.1: Characterisation of total RNA samples extracted from various
untransduced and pMIG transduced Mouse Embryonic Fibroblast lines.
Cell Line*

Conc. mRNA
sample (ng.µL-1)

260/280 nm Ratio

Volume used in
PCR (µL)

WT MEF

307.2

2.10

4.0

WT(vector) MEF

523.5

2.18

2.5

SerpinB2-/- MEF

371.2

2.12

3.4

SerpinB2-/(Vector) MEF

636.3

2.16

2.0

SerpinB2-/- (WT
rescue) MEF

791.2

2.16

1.6

U-937**

256.9

2.08

5.0

*Refer to Results section 5.4.1 for a description of the various MEF cell lines
**Human histocytic lymphoma cell line, used as a positive control for SerpinB2 expression
(Kruithof et al. 1986)

rt-PCR was performed using a Eppendorf, (Mastercycler Pro S) thermal cycler and
conducted in 25 µL reaction volumes containing 1.3 µg mRNA (Tab. 5.1), 12.5 µL
2 x One-step RT-PCR Buffer, 1 µL One-step enzyme mix, forward 5′CTGCTACCCGAAGGTTCTG-3′ and reverse 5′-GGAAGCAACAGGAGCATGC-3′
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murine SERPINB2 primers, 0.5 µL RNAse sample and 8 µL DEPC-treated water.
Cycling conditions were as previously described (Schroder et al. 2010) with one
cycle of 50 °C for 2 min and one cycle of 95 °C for 2 min, followed by 45 cycles of
94 °C for 5 s, 60 °C for 10 s, and 72 °C for 40 s. The resulting PCR products were
analysed by 2% agarose gel electrophoresis and ethidum bromide staining.

5.3.5.

Whole cell Lysis

MEF cells were harvested from confluent 25 cm 2 tissue culture flasks using
standard trypsinisation methods, washed twice with ice cold PSB then incubated
on ice with 500 µL RIPA mammalian cell lysis buffer (65 mM Tris-base, 150 mM
NaCl, 8.5 mM MgCl, 10% v/v Gycerol, 0.1% v/v Triton-X100, 12 mM Nadeoxycholate, 5 mM Ethylenediaminetetraacetic acid (EDTA), 1 mM αphenylmethylsulfonyl fluoride (PMSF)). Samples were then used for protein
detection via Western Blot.

5.3.6.

Western Blot Development

Proteins fractionated by SDS PAGE were blotted onto ImmobilomTM-P PVDF
(Millipore, USA) membrane using a Bio-Rad Mini Trans-Blot system as per
manufacturer’s instructions. After transfer, the PVDF membranes were blocked
with 10% skim milk powder in Tris-buffered saline (TBS) with 0.05% (v/v) Tween20 (TBST) overnight at 4oC. After washing in TBST the primary antibody (αSerpinB2 MAb (ADI#3750)) was applied at a final concentration of 1:500 in 2%
milk/TBST and blots were incubated for 2 hs at RT on a shaker. The membrane
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was extensively washed with TBST then re-blocked with 6% milk/TBST for 30 min
at RT followed by one wash with TBST for 5 min. Detection of bound primary
antibody was conducted using the appropriate horseradish peroxidise (HRP)
labelled secondary antibody, which was applied at a final concentration of 1:5000
in 2% milk/TBST for 1 h at RT. Three 5 min washes with TBST were conducted
to remove unbound secondary antibody followed by three 5 min washes with TBS.

Protein detection was visualised by an enhanced chemiluminescence (ECL)
reaction using SuperSignal® Substrate for Western Blotting (Progen, Australia) as
per manufacturer’s instructions. The membranes were exposed to X-ray film and
developed for analysis.

5.3.7.

Mammalian Transfection using the Huntingtin exon1
polyglutamine (polyQ) expansion cell model.

Huntington's disease is caused by autosomal dominant mutations in the HTT gene
resulting in expansion of a polyQ sequence near the amino-terminus of the
huntingtin (Htt) protein that promotes its aggregation (Hatters 2008). Wild type
alleles of the HTT gene encode polyQ sequences that range between 7 and 36
contiguous glutamine residues and mutant Htt is considered to contain >36 and up
to 250 contiguous glutamine residues (Hatters 2008). In the current work we used
a well-established Htt aggregation model comprising an exon 1 fragment fused to
either 25 polyQ or 46 polyQ sequences (Olshina et al. 2010; Ramdzan et al. 2010;
Polling et al. 2014). While longer expansions are more pathogenic, it has been
previously demonstrated that aggregation of the 46 polyQ Htt exon 1 fusion protein
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occurs in an experimentally tractable timeframe in a process that is well
characterised (Olshina et al. 2010).

Untransduced or pMIG construct transduced MEFs were seeded into 6-well plates
(in triplicate) containing 19 mm coverslips (2x105 cells per well) 24 h before
transfection with 200 ng of pcDNA3.1-mCherry (control) or pcDNA3.1-Huntingtin
exon1-polyglutamine variants fused C-terminally to mCherry (Httex125Q-mCherry
or Httex146Q-mCherry) expression vectors (Ramdzan et al. 2010; Polling et al.
2014), using Lipofectamine2000 (Invitrogen) as per manufacturer’s instructions. At
24, 36 and 48 h post-transfection, coverslips were removed prior to harvesting the
remaining cells for analysis of cell viability by flow cytometry (described below).
Cells grown on coverslips were then fixed by incubation in freshly prepared ice
cold PBS containing 4% paraformaldehyde (PFA) for 10 min prior to mounting on
microscopy slides using mounting solution (1 x PBS containing 50% glycerol). The
fixed cells were then visualised using a Nikon Eclipse TE2000-E (Nikon
Instruments) with FITC (ex 470-490, em 520-560) and Cy3 (ex 510 – 560 nm, em
565 - 625 nm) filter sets and 60x Plan Apo ∞/0.10-0.22 WD 0.13 oil emersion
lens. For analysis of cell viability, cells were harvested by brief trypsinisation,
washed in phosphate buffered saline (PBS), incubated on ice with 5 nM Sytox-red
in PBS and then analysed by flow cytometry (Becton Dickinson). All data obtained
was analysed using FLOJO software version 7.1 (Treestar, Inc).
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5.3.8.

Huntingtin aggregation assay

Monomeric Httex1-46Q-Cerulean-MBP fusion protein was aggregated as previously
described (Ramdzan et al. 2010). Briefly, recombinant Httex1-46Q-Cerulean-MBP
was thawed from frozen stocks, diluted to 9 μM, and rapidly mixed with a 1:20
stock of TEV protease. After 10 min Httex1-46Q-Cerulean was diluted, with or
without SerpinB2, to a final concentration of 2 μM and at a 1:1 final molar ratio of
SerpinB2: Httex1-46Q-Cerulean. Duplicate samples were taken at intervals and
total protein was determined by cerulean fluorescence (43,000 M-1.cm-1 at 434
nm). Samples were then centrifuged at 13,000 x g for 30 min and supernatant
collected as soluble fraction.

5.3.9.

Ligand binding assay

Aggregate ligand blots were performed as previously described (Yerbury et al.
2007). Httex1-46Q-Cerulean (1 μg) was spotted on nitrocellulose membrane and
then blocked with 1% (w/v) heat denatured casein in PBS buffer. SerpinB2 (10
μg/ml solution) or control proteins SerpinB14 (10 μg/ml solution) and clusterin (10
μg/ml solution) were then incubated with separate membranes for 2 h, at RT.
Bound interactors were detected using antibodies to either SerpinB2 (1:1000;
Abcam, UK; ab137588), SerpinB14 (1:30000; Sigma-Aldrich, C6534), or αclusterin (neat hybridoma culture supernatant) and subsequent HRP conjugated
secondary antibodies (1:2000) all diluted in 1% (w/v) heat denatured casein in PBS
buffer.
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5.3.10.

SerpinB2 Immunostaining

WT MEF cell lines were transiently transfected with Httex146Q:mCherry expression
vector as described above, fixed with 4% paraformaldehyde (PFA), permeabilized
with 0.1% triton X-100 and then blocked using 5% FCS, 1% BSA 0.1% tritonX100 in PBS. Cells were then incubated in the presence of either rabbit anti-mouse
SerpinB2 polyclonal antibody (2 µg.ml-1; diluted in 1% BSA, 0.1% TX-100 in PBS)
(Lee et al. 2015) or matched isotype control rabbit IgG antibody (2 µg.ml-1;
ABCAM; ab171870), followed by wash steps and binding detected using goat antirabbit IgG Alexa Fluor®488-conjugated secondary antibody (ABCAM; ab181448
1:500 dilution). Cells were then imaged using laser scanning confocal microscopy.
Imaging of SerpinB2 immunofluorescence was kindly conducted by Natalie
Farrawell, University of Wollongong.

5.3.11.

GFPu Ubiquitin-Proteasome System (UPS) reporter assay

To quantify UPS activity we used the fluorescent UPS reporter GFPu, which relies
on a 16 amino acid degron (ACKNWFSSLSHFVIHL) (CL1) fused to the carboxyl
terminus of GFP (Gilon et al. 1998; Bence et al. 2001; Bence et al. 2005).
Degradation of polypeptides containing the degron is specific to the proteasome,
therefore loss of GFP signal is indicative of ubiquitin dependent proteasome
activity. GFPu was transfected into MEF cell lines as previously described (section.
5.3.5) and the level of GFP fluorescence in the absence or presence of 250 nM
MG-132 was determined using flow cytometry (Becton Dickinson), 48 h post
transfection. Data represents viable cells only, as determined by propidium iodide
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exclusion and was normalised to MG-132 treated cells after removal of background
autofluorescence.

5.3.12.

Autophagy reporter assay

Autophagy dysfunction was assessed using the Lyso-ID autophagy reporter (Enzo
Life Sciences) as previously described (Francois et al. 2013). WT and SerpinB2-/MEF cell lines were seeded into a 96-well plate 24 h before addition of an
autophagy inhibitor, 3-methyladenine (3-MA, 0-5 mM; Adipogen) or an autophagy
inducer, verapamil (0-100 µM; Enzo Life Sciences). MEF cells were then cultured
overnight and autophagy quantified using Lyso-ID kit (ENZO), as per
manufacturer’s instructions. Briefly cells were washed and incubated with the
Lyso-ID red dye for 30 min at RT before measuring the level of red fluorescence
per cell on the IncucyteZoom automated imaging system (ESSEN Bioscience).
Data shown is corrected for background fluorescence. This experiment was
conducted by Natalie Farrawell, University of Wollongong.

5.3.13.

Statistical Analysis

Statistical analysis was conducted using GraphPad Prism 5. Comparison of growth
curves was conducted using nonlinear fit, exponential growth equation
(Y=Y0*exp(k*X)) to generate doubling times of respective cell lines.
Corresponding K values (rate constant) obtained from the analysis were compared
by One-way anova, applying the Tukey-Kramer multiple comparison test. Cell
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viability assays were analysed by 2-way anova with Bonferroni’s multiple
comparisons test for significant differences.

5.4.

Results

5.4.1.

Generation of stable MEF cell lines expressing human
SerpinB2 of Mouse Embryonic Fibroblast Cell Lines.

To investigate the role of SerpinB2 as a stress protein we used spontaneously
immortalised WT and SerpinB2-/- MEFs that had been retrovirally transduced with
either pMIGGFP or pMIGSerpinB2 vectors. Using this method three new cell lines were
made, consisting of two empty vector control lines, MEFWTpMIG [WT(vector)],
MEFSERPINB2-/-:pMIG

[SerpinB2-/-(vector)]

and

a

SerpinB2

knock-in

line,

MEFSERPINB2KI:pMIG [SerpinB2-/-(WT rescue)]. Efficiency of gene introduction was
assessed by flow cytometry, with the GFP positive population for each cell line
found to represent 93.8%, 92.4% and 80% of total viable cells, respectively
(Fig.5.2).
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i, WT

ii. SerpinB2-/-

iv. WT (vector)

v. SerpinB2-/- (vector)

iii. WT rescue

Figure 5.2: Generation of SERPINB2-/- WT rescue cell line. Spontaneously
immortalised MEF cell lines established from control (WT) and SerpinB2-/- mice
were transduced with mouse stem cell retroviral pMIG GFP. Transduction
efficiency of the parental lines was determined by GFP expression within the
transduction control cell lines (empty vector), WT (vector) and SerpinB2-/(vector) and the human SerpinB2 knock in (SerpinB2-/- WT rescue) cell line using
flow cytometry. Cells were gated as GFP negative or positive based on parental
lineage i) WT, ii) SerpinB2-/-, iii) SerpinB2-/- (WT rescue); iv) WT (vector) v)
SerpinB2-/- (vector). Data represents a minimum of 5000 viable cells as
determined by PI exclusion.

To confirm SerpinB2+/+, SerpinB2-/- status of the parental lines and transduced cell
lines we next conducted RT-PCR amplification of murine SERPINB2 transcripts
using fresh RNA extracts from all MEF cell lines (Fig.5.3A). As expected, the WT
and WT (vector) cell lines screened positive for the presence of murine SERPINB2
gene transcript as is evident by the 270 bp band within lanes 2 and 4 (Fig. 5.3A).

148

Importantly, no corresponding band was observed for the SerpinB2-/-, SerpinB2-/(vector) and SerpinB2-/-(WT rescue) cell lines, (lanes 6, 8 and 10 respectively,
Fig.5.3A) confirming their murine SerpinB2 null genotype. Comparable banding
intensity was observed for all cell lines corresponding to GAPDH amplification (250
bp) thus confirming the presence of equal template within rt-PCR starting sample
and equal loading of the sample onto the visualisation gel. Given the sequence
homology between human and murine SerpinB2 and the potential for non-specific
amplification of the human gene using the PCR primers designed to target the
murine gene, we also included mRNA extracted from the human U-937 monocytic
cell line as a negative control.

We next confirmed expression of SerpinB2 protein via western blot analysis of
whole cell lysates. We were unable to detect protein expression within the WT and
WT(vector) cell lines due to the lack of a sufficient antibody specific for murine
SerpinB2 detection via western blot analysis, at the time these experiments were
conducted.

Importantly, clear expression of human SerpinB2 was detectable

within the whole cell lysates of the SerpinB2-/-(WT rescue) cell line, confirming
transduction via the pMIG vector system (Fig.5.3B).
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Figure 5. 3: SERPINB2 gene and protein expression in mouse embryonic cell lines
(MEF). A) Reverse transcription-PCR screening for murine SERPINB2 gene. Fresh
mRNA extracts were prepared and equal quantities of template (1.3 µg) used for rt-PCR
amplification by BioScript One-Step RT-PCR kit. Predicted Murine SERPINB2 product
size is 270 bp (red arrow). Rt-PCR product was visualised by electrophoresis on a 2%
Agrose gel. Lanes: 2. WT 4. WT(vector) 6. SerpinB2-/- 8. SerpinB2-/-(vector) 10. SerpinB2/-(WT rescue) and 12. U937 cell line (negative control) show samples containing primers
specific for murine SERPINB2. Amplification of GAPDH (positive control) for each cell line
can be seen in adjacent odd numbered lanes. B) Western blot analysis of MEF whole
cell lysates for detection of human-SerpinB2 epression. Lanes: 1 SerpinB2-/-(WT rescue).
2. SerpinB2-/-(vector). 3. SerpinB2-/-. 4. WT(vector). 5. WT. Detection of human SerpinB2
was conducted using anti-human SerpinB2 MAb (ADI ##3750) and relevant HRP
conjugated secondary antibody
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We next assessed the effect, if any, the pMIG transduction had on the growth rates
of the respective MEF cell lines relative to parental (non-transduced) cells. Growth
curves were constructed from a 72 h time course with measurements taken every
12 h. Non-linear curves were fitted and analysed by application of the exponential
growth equation with least squares (ordinary) fit (Fig. 5.4.A). Using this method of
analysis it was possible to calculate the mean doubling times for each cell line,
being 57.57 h (WT), 61.4 h (WT(vector)), 53.58 h (SerpinB2-/-), 53.17 h (SerpinB2/-(vector))

and 71.11 h (SerpinB2-/-(WT rescue)) (Fig. 5.4.B). The overall growth

trend observed across cell lines was comparable as can be seen by the spread in
the calculated doubling times (Fig. 5.4.B) however, the mean doubling time of
71.11 h for the SerpinB2-/-(WT rescue) cell line was 10 to 20 h longer than the
time required for population doubling by all other cell lines. We therefore conducted
a one way anova analysis using the rate constants (K) obtained from the
exponential growth fit, and found that there was a significant difference in growth
rates between cell lines (p=0.0052, n=5). Further comparison using the TukeyKramer post test (CI = 95%) ascertained that this difference was only present
between SerpinB2-/-(WT rescue) and SerpinB2-/- or SerpinB2-/-(vector) cell lines
(Tab. 5.2). Importantly, the pMIG transduction did not significantly alter the growth
rates of the cells relative to their parental lineage, with respect to the control cell
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lines. There was no difference observed between the WT and SerpinB2-/- parental
lines, indicating that the cell models did not contain metabolic biases. Therefore
we concluded that adjustment was not required within future experiments.
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Figure 5.4: MEF growth rates. Parental and pMIG transduced MEF cell lines
were cultured for 72 h and growth rates determined every 12 h by relative change
in absorbance at 490 nm using MTS reagent. A) Non-linear curves were fitted to
data points and B) mean doubling times (symbols) calculated using the
exponential growth equation. Bars indicate the variance in mean doubling times.
Plots represent mean data, n=3, with relevant background controls subtracted.
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Table 5.2: Multiple comparisons of growth rate constants for MEF cell lines.
One way ANOVA Tukey-Kramer post-test (CI = 95%).
SerpinB2
-/-(vector)

SerpinB2
-/- (WT
rescue)

NS

NS

NS

NS

NS

NS

NS

NS

NS

-

NS

**

**

-

SerpinB2

WT

WT
(vector)

SerpinB2-/-(vector)

NS
NS
NS

NS
NS
NS

SerpinB2-/-(WT
rescue)

NS

NS

WT
WT(vector)
SerpinB2-/-

-/-

ns = not significant, ** = significantly different (p<0.05).

5.4.2.

SerpinB2 protects MEFs from proteotoxic stress of Huntingtin
protein expression/aggregation.

In order to test the hypothesis that SerpinB2 is involved in proteostasis pathways
within the intracellular environment we utilised wild type (Httex125Q-mCherry) and
mutant (Httex146Q-mCherry) huntingtin-mCherry mammalian expression vectors
as an intracellular protein aggregation model. Htt polyQ expansion is characterized
by the aggregation of Htt and decreased cell survival in a polyQ-expansion
dependent manner within neuronal models (Arrasate et al. 2004). Therefore we
conducted transient transfection experiments using the MEF cell lines to
investigate Httex1 aggregation and processing in the absence or presence of
SerpinB2, relative to controls. Initially, proteotoxic stress was determined by
quantification of cell viability using flow cytometry and SytoxRed staining at 24, 36
and 48 hs post transfection. Using flow cytometry, cells were firstly gated based
on forward and side scatter (Fig. 5.6.A.i) to remove debris from the analysis. This
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population was then gated based on mCherry (660_20, green laser 561 nm) and
GFP (515_20, blue laser 488 nm) expression (Fig. 5.6.A.ii). Analysis of cell viability
by SytoxRed (660_20, red laser 633 nm) exclusion (Fig. 5.6.A.iii) was then
conducted on mCherry and GFP positive cells only (Q2 of Fig. 5.6.A.ii) within the
pMIG transduced cell lines or mCherry positive cells (Q1 of Fig. 5.6.A.ii) within the
parental lines. The percentage of viable cells determined by this gating method
was then normalised against the relevant mCherry control populations to allow for
potential bias arising from the transfection process or possible differences in
transfection efficiency and vector expression between cell lines.

Using this model, a significant difference in cell viability between SerpinB2 null and
SerpinB2 expressing cell lines was observed and this was most obvious 48 h post
transfection (Fig 5.5.B). Cell viability was reduced to 60% and 45% at this time
point for Httex125Q-mCherry (Fig. 5.5.B.i) and Httex146Q-mCherry (Fig. 5.5.B.ii)
expressing SerpinB2-/-(vector) cells compared to 100% viability observed for the
WT (vector) cell line respectively. The latter observation [WT(vector)] is consistent
with previous work using wild-type MEFs that showed no difference in toxicity
responses between cells expressing Httex125Q and Httex197Q (King et al. 2008).
Importantly, cell viability was partially recovered with the reintroduction of SerpinB2
by pMIG transduction, SerpinB2-/-(WT rescue), showing normalised cell viability of
89% and 84% for Httex125Q-mCherry (Fig. 5.5.B.i) and Httex146Q-mCherry (Fig.
5.5.B.ii) expressing cells which was significantly different to the SerpinB-/- (vector)
cell line (p<0.001).
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Figure 5.5: SerpinB2 protects MEFs from Huntingtin protein toxicity.
Parental and pMIG transduced MEF cell lines were transiently transfected with
either Httex125Q-mCherry (WT), Httex146Q-mCherry (mutant) or mCherry
(control) expression vectors and cell viability assessed at 24, 36 and 48 h post
transfection using flow cytometry. A) Representative gating of data; (i) initial
removal of debris (ii) mCherry(660_20 green)/GFP(515_20 blue) positive cells were
selected for analysis of (iii) cell viability using SytoxRed(660_20 red) exclusion. B)
Comparison of cell viability in the absence (SerpinB2-/-(vector)) or presence
(WT(vector)) and (SerpinB2-/-(WT rescue)) of SerpinB2 following transfection
with either (i) Httex125Q-mCherry or (ii) Httex146Q-mCherry. Effects of pMIG
transduction on cell viability following transfection with Httex146Q-mCherry was
assessed by comparison to parental lines; iii) SerpinB2-/- and iv) WT. Data
represents mean percentage of viable cells normalised to mCherry only controls,
n=3, ± SEM. Significant difference to WT(vector) (i) and (ii) or parent line (iii)
denoted as *p<0.05. ***p<0.001.
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Comparison of the MEF parental cell lines and their respective pMIG transduction
control cell lines, 48 h post transfection with Httex146Q-mCherry was also
conducted to assess the effects if any of the mouse stem cell virus (MSCV - pMIG
transduction) on cell viability. Interestingly there was a significant difference
between the percentage of viable cells determined for SerpinB2 -/-(vector)
compared to the SerpinB2-/- parental cell line (p<0.05) (Fig. 5.5.B.iii), whilst no
difference was observed between the WT (vector) and WT cell lines (Fig. 5.5.B.iv).
Suggesting that pMIG transduction is impacting on the cell viability of SerpinB2 -/cell lines, however given that there was no significant difference in doubling times
for these cell lines (Fig. 5.4), it seems they are more sensitive to the accumulative
effect of GFP and Httex146Q-mCherry expression. This sensitivity may be
attributed to by the constitutive expression of GFP, which has previously been
shown to have a cytotoxic effect within some cell models (Liu et al. 1999). The cell
viability of Httex146Q-mCherry expressing SerpinB2-/- MEF cells (parental line, no
GFP) at 48 h post transfection was also found to be significantly reduced compared
to the WT (p<0.001) and WT (vector) (p<0.001) cell lines, confirming the cytotoxic
effect of Htt expression in the absence of SerpinB2. Importantly, WT rescue of the
SerpinB2-/- cell line (WT rescue) was shown to significantly increase cell viability
(p<0.05), indicating that reintroduction of SerpinB2 into the SerpinB2-/- cells not
only facilitated recovery of cell viability due to the pMIG transduction process but
also that resulting from the proteotoxicity of Httex146Q-mCherry expression.
Altogether, this supports a potential role for SerpinB2 in cellular protection against
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proteotoxicity. It was not possible, however, to identify within these experiments,
potential protein aggregation pathways associated with this observation.

Therefore, Httex146Q:mCherry aggregation and processing was visualised by
microscopy at 24 and 48 h post transfection. Expression of Httex146Q-mCherry or
mCherry only (data not shown) was clearly visible after 24 h in all cell lines with
mCherry fluorescence appearing evenly dispersed throughout the cytosol
(Fig.5.6). At this time point, inclusion bodies (IB) were observed within the WT
(Fig.5.6A) and SerpinB2-/- (WT rescue) (Fig.5.6C) cell lines, transfected with the
mutant huntingtin expression vector (Httex146Q-mCherry). However, negligible
inclusion formation was observed within the SerpinB2-/- cell lines (Fig.5.6B). This
subtle difference in IB profile became more distinct 48 h post transfection, whereby
a clear difference in phenotype between cell lines with respect to formation of IB
in the absence or presence of SerpinB2 was observed (Fig. 5.6). Importantly, the
WT rescue cell line showed clear recovery of wild-type phenotype verifying that
the difference observed between the WT (vector) and SerpinB2-/- (vector) cell lines
was due to absence or presence of SerpinB2. As expected, no observable IBs
formed within cells transfected with the mCherry control vector during the course
of the experiment (data not shown).
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24 h

48 h

A) SerpinB2 WT

B) SerpinB2 -/-

C) SerpinB2 -/- (WT Rescue)

Figure 5.6: Photomicrographs showing expression and cellular processing of
Httexn146Q:mCherry by Mouse Embryonic Fibroblasts (MEF). Inclusion body formation
(blue arrows) within (A) WT (vector), (B) SerpinB2-/- (vector) or (C) SerpinB2-/- WT rescue
MEFs, 24 or 48 h post transfection with Httex146Q-mCherry using Lipofectamine2000. Cells
were visualised using a Nikon Eclipse TE2000-E (Nikon Instruments) with FITC (ex 470-490,
em 520-560) and Cy3 (ex 510 – 560 nm, em 565 - 625 nm) filter sets and 60x Plan Apo ∞
/0.10-0.22 WD 0.13 oil emersion lens.
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We next compared the partitioning of Htt in wild-type and SerpinB2-/- MEFs.
Previous work has established that overexpression of Htt ex1 containing expanded
polyQ repeats (including 46Q used in this study) produces a dense round inclusion
in the cytoplasm or nucleus (Kaganovich et al. 2008; Polling et al. 2014), while
wild-type or 25Q expansion does not. Following expression of Htt ex125Q-mCherry
in wild-type MEFs we observed small, Htt-positive foci in ~15% of cells (Fig. 5.7A).
These foci were < 2 μm in diameter and were counted separately to inclusions
(Fig. 5.7B).

A

B

Figure 5.7: Differential partitioning of Httexn1 in WT vs SerpinB2-/- MEF
A. Inclusion formation in wild-type versus SerpinB2-/- MEFs 48 h post
transfection with either Httex125Q-mCherry or Httex146Q-mCherry. Two types of
Htt foci were observed, small (< 2um; white arrow heads) and large (> 2 um;
white arrows); B. Distribution of Htt in MEFs was quantified as diffuse, small foci,
or inclusion in each cell. Images were taken by Natalie Farrawell, University of
Wollongong.
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There was an increase in the proportion of cells containing these small foci (from
~ 15% to ~ 40%) in the absence of SerpinB2 (Fig. 5.7B), indicating a significant
shift in localisation of Httex125Q in SerpinB2-/- cells. Following expression of
Httex146Q in wild-type MEFs we observed a large proportion of cells containing
inclusions (~ 30%) that were not present in 25Q-expressing cells (Fig. 5.7A and
5.7B). However, ~ 15% of cells still contained small Htt foci in 46Q-expressing wildtype cells. In contrast, the proportion of cells containing inclusions was reduced
and the number of cells containing smaller fluorescent foci increased following
expression of Httex146Q-mCherry in SerpinB2-/-MEFs (Fig.5.7A and 5.7B).

Given that the expression of SerpinB2 modulated cellular inclusion formation and
cell viability we tested the ability of recombinant SerpinB2 to supress the in vitro
fibril formation of Httex146Q fused to the monomeric cyan fluorescent protein,
Cerulean. As previously reported (Olshina et al. 2010), activation of purified
recombinant Httex146Q-Cerulean through cleavage of the protective mannose
binding protein (MBP) with TEV protease, resulted in the formation of insoluble
Httex146Q-Cerulean fibrillar aggregates over 72 h (Fig. 5.8A). Whilst the presence
of SerpinB2 modestly attenuated the formation of insoluble Httex146Q-Cerulean
aggregates within this assay, there were no apparent changes in morphology of
the Httex146Q-Cerulean insoluble fibrils formed, in the absence or presence of
SerpinB2 (Fig. 5.8B). We next investigated the potential for SerpinB2 to interact
directly with Httex146Q-Cerulean using a solid phase ligand blotting assay and
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immunodetection, as previously described (Yerbury et al. 2007). Interestingly,
SerpinB2 was found to interact with non-aggregated Httex146Q-Cerulean, but not
to aggregated material (Fig. 5.8C-D).

Only negligible binding of SerpinB14

(negative control) to non-aggregated Httex146Q-Cerulean could be detected, whilst
no interaction between SerpinB14 and aggregated Httex146Q-Cerulean was
observed. Conversely, clusterin (positive chaperone control) bound both soluble
and insoluble Httex146Q-Cerulean (Fig. 5.8C-D), which is consistent with previous
work using clusterin within this assay format (Yerbury et al. 2007).
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Figure 5.8: SerpinB2 attenuates Htt42q fibril formation in vitro. A. Soluble
Htt remaining in Httex146Q-Cerulean aggregation reactions in the absence or
presence of SerpinB2 (equimolar ratio); B. TEM images of fibril formation at 72
h; C.Representative ligand blot (n = 3) showing differences in binding of
SerpinB2 to soluble and aggregated Httex146Q. Binding was determined by
immunoassay. SerpinB14 or clusterin binding to soluble and aggregated
Httex146Q are also shown. Data was kindly provided by Natalie Farrawell,
University of Wollongong.

As SerpinB2 was found to interact with soluble Httex146Q-Cerulean and inhibit
aggregation, albeit at modest amounts, we next examined a possible interaction
between SerpinB2 and aggregated Httexn146Q-mCherry within the WT cell line, by
immuno-staining. Using this method there was no evidence of SerpinB2 colocalisation with Httexn146Q-mCherry, indicating that SerpinB2 is not sequestered
into IBs containing Httexn146Q-mCherry aggregates (Fig.5.7). However, it is
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possible that SerpinB2 interacts, transiently, with the soluble oligomeric form of
Httexn146Q-mCherry, which would not be detectable within this system. Of note,
these experiments confirmed the presence of detectable amounts of endogenous
SerpinB2 protein within the WT cell line (Fig. 5.7.B).
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C

Fig. 5.9: Huntingtin does not co-localize with SerpinB2. Photomicrographs
showing (A) expression of Httex146Q:mCherry in WT MEFs following transient
transfection for 48 – 72 h and (B) SerpinB2, detected using rabbit anti-mouse
serpinB2 polyclonal antibody and goat anti-rabbit IgG Alexa Fluor®488conjugated secondary antibody immunostaining. (C) Image overlay showing
cellular distribution of Httex146Q:mCherry and SerpinB2. Control staining was
conducted on non-transfected WT MEFs for (D) SerpinB2 and (E) Rabbit IgG
antibody used as an isotype control. Cells were imaged using laser scanning
confocal microscopy. Imaging kindly performed by Natalie Farrawell, University
of Wollongong.

SerpinB2 has previously been shown to interact with the β-subunit of the
proteasome proteolytic core (Fan et al. 2004) and recent work has shown that
SerpinB2 co-localises with Beclin-1 and promotes the degradation of the NOD-like
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receptor-3 (NLR3) via the autophagy-lysosomal degradation pathway (Chuang et
al. 2013). Taken together these works suggest SerpinB2 may function within
protein degradation pathways, which led us to investigate if SerpinB2 influences
proteasomal or autophagy-lysosomal degradation pathways. To investigate this,
we conducted cellular based assays to compare proteasomal degradation activity
in the absence or presence of SerpinB2 utilising a proteasome reporter GFPµ
(Bence et al. 2001; Bence et al. 2005).

5.4.3.

SerpinB2 null MEFs have impaired proteasome activity
compared to wild-type MEFs.

SerpinB2 has previously been shown to interact with the β-subunit of the
proteasome proteolytic core (Fan et al. 2004) and recent work has shown that
SerpinB2 co-localises with Beclin-1 and promotes the degradation of the NOD-like
receptor-3 (NLR3) via the autophagy-lysosomal degradation pathway (Chuang et
al. 2013). Taken together these works suggest SerpinB2 may function within
protein degradation pathways, which led us to investigate if SerpinB2 influences
proteasomal or autophagy-lysosomal degradation pathways.

We thus first conducted cellular based assays to compare proteasomal
degradation activity in the absence or presence of SerpinB2 utilising a proteasome
reporter.

In these assays, WT and MEFSerpinB2-/- cell lines were transiently

transfected with the proteasome reporter expression vector containing GFPµ,
which relies on a 16 amino acid degron (ACKNWFSSLSHFVIHL) (CL1) fused to
the carboxyl terminus of GFP (Gilon et al. 1998; Bence et al. 2001; Bence et al.
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2005). Degradation of the degron is specific to the proteasome, therefore changes
in GFP signal is indicative of proteasome activity. Cells were analysed by flow
cytometry 48 h post transfection, following an overnight incubation in the absence
or presence of proteasome inhibitor, MG-132. Normalisation of the GFP signal
against MG-132 treated cells (100% inhibition) provides a basis to compare
relative levels of proteasome activity. Larger relative loss of GFP signal in the
absence of MG132 suggests a more efficient UPS. Interestingly, the loss of GFP
signal within the WT cell line was 70% compared to 40% loss, observed in the
SerpinB2-/- cell line (Fig.5.10.A), indicating that the proteasomal degradation
pathway is impaired in the absence of SerpinB2.

Whilst the GFP signal following MG132 treatment was normalised in order to
quantitate GFP degradation, it is important to note that the histograms showing
GFP signal intensity is comparable between cell lines (Fig.5.10.B). Therefore
indicating that the difference observed in GFP degradation was not due to
variability in transfection or expression efficiency between cell lines and that basal
levels of proteasome activity appears to be comparable between the two cell lines.
Furthermore, a dose response analysis of cell viability after 48 h treatment with
MG132 revealed half maximal inhibitory concentration values of ~10 μM for both
cell lines (data not shown), indicating that toxicity issues were not responsible for
this difference. These data suggest that the absence of SerpinB2 in cells places
stress on the UPS.
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Figure 5.10: SerpinB2-/- exhibit impaired proteasome activity. (A) Wild-type and
SerpinB2-/- Mouse Embryonic Fibroblast cell lines were transiently transfected with
proteasome reporter GFPµ then incubated overnight in the absence or presence of
[250 nM] MG-132, where indicated. Data has been normalised to geometric mean
GFP (515/20A) signal of MG132 viable cells only, as determined by propidium iodide
exclusion (695/40). (B) Overlay of MG132 treated MEF cell lines showing maximum
GFPµ signal following inhibition of p26 proteasome. Representative histograms for
(C) WT or (D) SerpinB2-/- showing GFP signal intensities in the absence (Blue
histogram) or presence (Red histogram) of MG132, grey histograms represent MEF
autofluorescence controls (non-transfected).
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5.4.4.

Autophagy-lysosomal degradation pathway dysregulation in
SerpinB2 null MEFs.

We next investigated a potential role for SerpinB2 within the autophagy-lysosomal
degradation pathway. WT and SerpinB2-/- MEF cell lines were cultured overnight
in the absence or presence of either an autophagy promoter (Verapamil) or
inhibitor (3-Methyladenine (3-MA)), then the number of acidic (autolysosome and
lysomsomal) vesicles quantified using the Lyso-ID kit as previously described
(Francois et al. 2013). Interestingly, basal level autophagy (indicated by cellular
fluorescence) was significantly increased in SerpinB2-/- MEFs compared to WT
cells (Fig. 5.11). Addition of verapamil, a known Ca2+ channel antagonist which
induces autophagy through the Ca2+-calpain–Gαs pathway (Williams et al. 2008),
resulted in a dose dependent increase in fluorescence in both cell lines, however
fluorescent signal was significantly increased within SerpinB2-/- MEFs compared to
WT MEFs (Fig. 5.11A), suggesting dysregulation of autophagy pathways.
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Figure 5.11: Autophagy is dysregulated in SerpinB2-/- MEF. Wild-type and
SerpinB2-/- Mouse Embryonic Fibroblast cell lines were incubated in the absence
or presence of either (A) verapamil (activator) or (B) 3-MA (inhibitor) overnight and
autophagy function quantified by addition of Lyso-ID red dye. Data shown
represents mean (± SEM) fluorescence intensity per cell as determined by
IncucyteZoom automated imaging system with background subtracted. Data kindly
provided by Natalie Farrawell, University of Wollongong.

In the presence of 3-MA, an inhibitor of class III phosphoinositide 3-kinases (PI3K)
(Seglen and Gordon 1982), a small increase in fluorescence was observed in WT
cells at the highest concentration (5 mM) (Fig. 5.9B). In contrast, while there was
a dose-dependent decrease in fluorescence in SerpinB2-/- MEFs with increasing
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3-MA concentration (likely due to the stress placed on the cells under these
inhibitory conditions), compared to WT cells the level of fluorescence was
significantly higher in the presence of 2.5 mM 3-MA.

5.5.

Discussion

Up-regulation of SerpinB2 in response to cellular stress is well-established, the
intracellular pathways in which SerpinB2 may function however, are poorly
defined. Key to cell survival are protein quality control systems which maintain
proteostasis through the chaperone and protein degradation pathways. SerpinB2
has been implicated within these networks via identification of potential intracellular
binding partners, such as proteasome subunit beta type 1 (PSMB1, a component
of the proteasome) (Fan et al. 2004), the ubiquitin-like adapter protein, interferon
stimulated gene-15 (ISG15) (Giannakopoulos et al. 2005) and autophagy
regulator, Beclin-1 (Chuang et al. 2013). In this context, this work utilises the
mutant Httexn-1 model (Olshina et al. 2010; Ramdzan et al. 2010) to investigate the
cellular processing of protein aggregates by WT and SerpinB2-/- cell lines, and
provides evidence of impaired inclusion formation, proteasome activity and
dysregulation of autophagy-lysosomal degradation pathways in the absence of
SerpinB2.

Huntington Disease (HD) is characterised by the accumulation of soluble and
insoluble fibrillar protein species, resulting from polyglutamine (polyQ) expansion,
in the N-terminus of the Huntingtin protein (MacDonald 1993) and represents one
of nine neurodegenerative disorders termed polyQ diseases. In normal, healthy
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humans the polyQ expansion may contain up to 35 repeats, whilst 36 upwards has
been shown to cause cell death through classic loss and gain of function
associated with protein aggregation, similar to those described for other
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s Disease (Bano
et al. 2011).

Here we have utilised the highly aggregation prone region of

Huntingtin protein, exon-1 fused to a poly-Q expansion, as a model for intracellular
protein aggregation and found that SerpinB2 protects against the cytotoxic effect
of Httexn-1-46Q-mCherry expression 48 h post transfection (Fig. 5.5), as determined
by cell viabilty.

Visualisation of MEFs, 24 and 48 h post transfection with either Htt exn1-25Q or
Httexn-1-46Q-mCherry, revealed morphological differences in Htt processing
between SerpinB2-/- (vector) and WT (vector) cells lines. Clear inclusion formation
was visible in WT (vector) cells within 24 h, becoming more pronounced by 48 h
post transfection (Fig. 5.6.A). This was in stark contrast to the SerpinB2 -/- (vector)
cells, which exhibited diffused cellular distribution of Httexn-1-46Q-mCherry at 24 hs
and minimal inclusion formation at 48 hs post-transfection (Fig. 5.6.B). It should be
noted however, that visualisation of Httexn-1-46Q-mCherry processing within the
SerpinB2-/- (vector) cell line was problematic, given the high cell loss due to the
sensitivity of these cells to the transfection process and Httexn-1-46Q-mCherry
expression. Importantly, recovery of WT phenotype was observed within the
SerpinB2-/- (WT rescue) cell line (Fig.5.6.C). This return of inclusion formation
coincided with recovery of cell viability, and supports recent research indicating
that inclusion formation - traditionally thought to be cytotoxic and concomitant with
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cell death - is a protective mechanism through which, cells are able to isolate the
cytotoxic, soluble oligomeric, forms of Httexn-1 and other pernicious protein species
(Waelter et al. 2001; Bucciantini et al. 2002; Arrasate et al. 2004; Takahashi et al.
2008).

Of interest is the finding that ubiquitinated, soluble substrates destined for
degradation are typically deposited within juxtanuclear compartments – termed
juxtanuclear quality control (JUNQ), whilst insoluble protein aggregates,
characteristic of amyloid-like fibril structures are preferentially directed to
perivascular compartments, or insoluble protein deposits (IPODs) (Kaganovich et
al. 2008). Furthermore, it is becoming apparent that misdirection of substrates
between these distinct quality control compartments, or delayed downstream
processing results in increased cytotoxicity (Weisberg et al. 2012; Amen and
Kaganovich 2015), as would be expected with the breakdown of a protein quality
control network. Importantly, JUNQ clearance is predominantly facilitated by
proteasomal degradation pathway (Weisberg et al. 2012; Ogrodnik et al. 2014)
whilst IPODs are processed through the autophagy-lysosomal degradation
pathways (Kaganovich et al. 2008). Whether SerpinB2 functions directly within
these compartmentalisation networks either in the formation of inclusions or to
sequester Httexn146Q-mCherry is unclear.

However, our observations of

decreased numbers of large IPOD inclusions (Fig.5.7) and increased cell death in
SerpinB2-null cells (Fig. 5.5) are consistent with a role for SerpinB2 in mediating
the formation of cellular inclusions. SerpinB2 binds soluble Httexn146Q (Fig. 5.8),
but has a modest effect on Httex146Q-Cerulean aggregation, nor does SerpinB2
171

co-localisation with Htt IPOD structures, but this does not preclude an indirect role
in inclusion formation. An RNAi genome wide screen in in C. elegans identified
RNA synthesis, protein synthesis, protein folding, protein transport and protein
degradation as vital classes of genes that control polyQ protein aggregation
(Nollen et al. 2004). This study implicated all aspects of the proteostasis network
as modulators of protein aggregation in vivo. Hence, our data showing reduced
numbers of large Htt46Q inclusions in the absence of SerpinB2 suggests SerpinB2
is part of the cellular proteostasis regulation network.

Given that the formation of quality control compartments are thought to appear as
a result of protein degradation pathway overload (Hipp et al. 2014), we compared
proteasome and autophagy function. Interestingly, the proteasomal degradation
pathway was impaired within SerpinB2-/- null cell lines, suggesting a role within this
protein degradation pathway. Surprisingly, the absence of SerpinB2 was found to
negatively impact on GFPµ degradation. Given the reported interaction between
SerpinB2 and PSMB1 by Fan et al. 2004 and the chymotrypsin-like specificity of
this enzymatic subunit (Baldovino et al. 2006), it is plausible to hypothesise that
SerpinB2 inhibits PSMB1 and therefore proteasome activity. This does not appear
to be the case given that depletion of SerpinB2 reduced proteasomal activity,
rather than enhanced it. Furthermore, it is unlikely that SerpinB2 is interacting with
PSMB1 within the intact proteasome as this would require direct access into the
proteasome which is tightly controlled by ubiquitin, unfoldases and an entrance as
narrow as 13 Aº, necessitating the linearization of proteins to allow spatial
placement within the proteolytic 20S core. It is tempting to speculate that SerpinB2
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may interact with PSMB1 during assembly and disassembly of the 26S
proteasome, functioning to help shuttle the subunit into place, either as a substrate
or as a non-inhibitory adapter protein.

Cellular mutant Htt is known to form insoluble aggregate deposits and degradation
has been reported to be predominantly autophagy-lysosomal degradation pathway
dependent (Martin et al. 2015). Here we show that the autophagy-lysosomal
degradation pathway becomes dysregulated in the absence of SerpinB2, which is
in keeping with recent work describing co-localisation of SerpinB2 with Beclin-1
and Hsp90, within the membrane of autophagosomes (Chuang et al. 2013). Whilst
it is not possible to elucidate the functional mechanism behind SerpinB2 regulation
of autophagy, given the dynamic nature of the pathway, dissociation of Bcl-2 from
Beclin-1 initiates seeding of the phagophore, which can wrap around aggregates
such as those found in iPODs and gives rise to autophagosomes. Our finding that
loss of SerpinB2 results in decreased numbers of large IPOD inclusions and
dysregulation of the autophagy-lysosomal degradation pathway suggests a
possible role for SerpinB2 within this initial seeding stage of the pathway.

Taken together this work indicates that SerpinB2 is a prominent component of the
cells proteostasis networks, which exerts its cytoprotective effects through
modulation of the protein degradation pathways. Intriguingly, loss of SerpinB2
results in attenuation of both the proteasome and autophagy-lysosomal
degradation pathways. Whether SerpinB2 functions within both systems or has an
indirect effect on one, through loss of the other, remains to be shown. It is clear
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however that SerpinB2 interacts with misfolded proteins, inhibits aggregation and
facilitates downstream processing of these deleterious protein species.
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6. Conclusions and Future Directions.

175

6.1.

Overview.

The specific aims of this thesis were to examine; 1) the role of SerpinB2 within the
extracellular environment as a plasminogen activator inhibitor in monocytes and 2)
the role of SerpinB2 within the intracellular environment as a potential stress
response protein. Accordingly, the conclusions drawn and future directions
suggested below have been divided into two sections centred on these distinct
cellular distribution and functions of SerpinB2.

6.2.

The role of Extracellular SerpinB2 as a plasminogen activator
inhibitor.

There have been many biochemical studies conducted which have defined and
supported the role of SerpinB2 as a classical inhibitory serpin. In vivo, SerpinB2
can be detected at very high concentrations under specific patho/physiological
conditions in the circulation, seminal fluid, tears, gingival crevicular fluid and saliva
(Croucher et al. 2010). SerpinB2 has also been shown to be efficiently externalised
on the surface of macrophage and cancer cell-derived microparticles (Schroder et
al. 2014). Thus SerpinB2 is present in the extracellular milieu, where it is available
to inhibit uPA or tPA. Moreover, SerpinB2 facilitates the rapid endocytosis of
uPA:uPAR complexes from the surface of prostate cancer (PC-3) (Croucher et al.
2006) and breast cancer (MCF-7) (Croucher et al. 2007; Cochran et al. 2011) cell
lines, via members of the Low Density Lipoprotein Receptor (LDLR) family.
Clarification

of

the inhibition and

possible

subsequent endocytosis of

uPA:SerpinB2 complexes by monocytic cells was of interest with respect to i)
understanding the role of SerpinB2 in modulating plasminogen activation on
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monocytic cells in a patho/physiological context, and ii) the possible future
development of SerpinB2 directed therapeutics for the treatment of hematopoietic
disorders such as acute myeloid leukaemias. We confirmed (Chapter 2) that
SerpinB2 inhibits monocytic cell surface uPA and the uPA:serpin complex is
subsequently cleared via LRP and VLDR, showing a consistent endocytosis
pathway to that previously described for prostate (Croucher et al. 2006) and breast
cancer (Croucher et al. 2007) cell lines.

Indeed, this work supports the development of ligand targeted therapy by Vine et
al. (2012), which shows the selective targeting of receptor bound uPA at the cell
surface of U937 and THP-1 cell lines, with prodrug, 5,7-dibromo-N-(phydroxymethylbenzyl)isatin (N-AI) conjugated via an esterase-labile linker (N-AIE)
to SerpinB2. The cytotoxicity of the activated (endocytosed) drug was found to
correlate with uPA levels, whereby the THP-1 cell line (high uPA expression profile
(Fig. 2.1)) was found to be more susceptible to the cytotoxic effects of SerpinB2N-AIE, compared to the U-937 cell line (low uPA expression profile (Fig. 2.1)).
Early work investigating the expression patterns for components of the uPA system
clearly indicate a correlation between differentiation towards macrophage
phenotype and uPAR expression (Lanza et al. 1998; Scherrer et al. 1999).
Importantly, uPA is the predominant plasminogen activator in leukaemic marrow,
a characteristic not found in healthy marrow (McWilliam et al. 1998; Scherrer et al.
1999), therefore SerpinB2 targeted therapeutics may prove successful in
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eradicating multiple drug resistant leukemic blasts and stem cells within the
marrow of patients and warrants further detailed preclinical investigation.

As such, a thorough understanding of the role SerpinB2 plays in the inhibition of
plasminogen activation at the cell surface of monocytes was required. SerpinB2 is
able to inhibit other cell type surface bound tc-tPA in vitro (Lobov et al. 2008).
Therefore, we next examined the inhibition and fate of cell surface tPA by SerpinB2
on freshly isolated peripheral blood monocytes (PBMs). We not only confirmed that
SerpinB2 inhibits monocyte-bound tPA but show for the first time that these
tPA:Serpin inhibitory complexes are subsequently endocytosed, predominantly via
an LDLR dependent pathway, thus clearing cell surface tPA activity. Definitive
proof for SerpinB2 as a physiological inhibitor of tPA in vivo requires
experimentation in appropriate animal models. However, co-expression of tPA and
SerpinB2 has been shown in normal bone marrow (McWilliam et al. 1998), skin
(Chen et al. 1993), saliva and salivary gland tissue (Virtanen et al. 2006), gingival
fluid (Brown et al. 1995; Kinnby 2002), as well during pregnancy (Astedt et al.
1998). Enhanced co-expression of both tPA and SerpinB2 by epithelial cells is
indicative of some disease states, e.g. periodontal disease (Kinnby 2002),
psoriasis and pre/eclampsia (Kruithof et al. 1995). Furthermore, in inflamed gingiva
the local concentration of SerpinB2 and tPA in gingival fliud can reach up to 5 μg/ml
(~100 nM) and 1.5 μg/ml (~20 nM), respectively (Brown et al. 1995; Kinnby 2002).
Therefore, SerpinB2 may dampen tPA mediated proteolysis, which is thought to
compromise epithelial integrity in these tissues. Taken together, these previous
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works suggest that extracellular SerpinB2 is localized in significant concentrations
where it may be a physiological inhibitor of cell surface tPA.

Definitive identification of uPA:serpin or tPA:serpin complexes within human tissue
or animal models has not been forthcoming, most likely due to the rapid clearance
of PAs complexed with SerpinB2 and their subsequent degradation via the
lysosomes. Furthermore, knock-out animal models may not offer conclusive
phenotypes to indicate where SerpinB2 and uPA or tPA may interact. For example,
the SerpinB2-/- murine model by (Dougherty et al. 1999) did not identify any clear
phenotype for SerpinB2-deficient mice. However, subtle phenotypes related to
viral infection (Schroder et al. 2010), adipose development (Lijnen et al. 2007) and
enhanced thrombus resolution attributable to enhanced uPA activity (Siefert et al.
2014) have since been reported in SerpinB2 null mice. This suggests that
development of knock-in models may offer further insight into the specific nature
of the PA systems and their inhibitors, SerpinB2 and SerpinE1. The development
of dual fluorescent expressing mice offers the opportunity to knock in fluorescently
labelled tPA/uPA and SerpinB2/SerpinE1, which will identify specific organs and
systems where co-localisation occurs. Recently the bimolecular fluorescence
complementation (BiFC) system, which enables direct visualisation (in live cells),
of protein interactions (Kerppola 2008), has been shown to work within a
Drosophila model (Hudry et al. 2011). This system utilises two complementary
fragments of the venus yellow fluorescent protein, which when brought into close
proximity by an interaction between proteins fused to these fragments, refold to
form a fluorescent protein (Kerppola 2008). Development of a murine models using

179

this system with uPA/tPA and SerpinB2/E1 will open up many new areas of interest
and contribute immensely to establishing physiological context to both SerpinB2
and SerpinE1, as mediators of proteolysis within the pericellular environment.

Importantly, expression of both tPA and SerpinB2 by monocytes, macrophages
and myeloid progenitors within normal bone marrow, has been reported
(McWilliam et al. 1998) and is consistent with the cell surface profile analysis
conducted here, showing very low levels of uPA compared to the U937 or THP-1
cell line and some detectable cell surface tPA, which was absent on the malignant
cell lines. The up-regulation of the uPA system within hematopoietic and solid
mass tumours is well characterised and is the basis for the development of ligand
targeted therapeutics, using SerpinB2 (Stutchbury et al. 2007; Ranson et al. 2012;
Vine et al. 2012). In this respect, whilst SerpinB2 clearly inhibits cell surface tPA
(Lobov et al. 2008) and is subsequently endocytosed via LRP or VLDLR (Lee et
al. 2010), the modest levels of endogenous tPA present on freshly isolated
monocytes suggests that minimal, non-specific drug delivery to these cell types
may occur. This is essential when considering the use of SerpinB2 targeted
therapeutics for the eradication of multiple drug resistant leukemic blasts and stem
cells within the marrow of patients, as it may tip the balance in prognostic outcome
through increased protection of healthy tissue whilst efficiently targeting aberrant
cell types. In conclusion, this body of work contributes towards the proof of concept
foundations for the development of SerpinB2 directed therapeutics for the
treatment of haematological disorders and lymphomas.
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6.3.

Intracellular SerpinB2 – The proteostasis moderator.

Up-regulation of intracellular SerpinB2 in response to acute and chronic
homeostatic imbalances is consistent with a potential function within cellular stress
response pathways. Molecular chaperones tightly regulate proteostasis within
cells under normal and stress conditions. The results within this thesis show for
the first time that SerpinB2 exhibits chaperone-like activity, whereby SerpinB2
binds preferentially to misfolded stressed proteins, inhibits amorphous aggregation
of DTT-reduced BSA and fibril formation of Aβ1-40 and Aβ1-42. Chaperones have
been shown to interact with target substrates via hydrophobic interactions, whether
the binding characteristics described here for SerpinB2 are also via hydrophobic
interactions requires further experimentation. Surface modelling reveals the
presence of a hydrophobic cluster, within a cavity on the surface of SerpinB2,
which is in close proximity to the CD-loop (Fig. 6.1 B). The CD-loop itself also
contains hydrophobic residues, contributing to 44% of the loop sequence (Fig.
6.1C). Early work by Wilczynska et al. (2003) showed significant changes in
surface hydrophobicity which were dependent on the formation of C79-C161
disulfide bond, involving the C-D loop of SerpinB2 (Fig. 6.1B). Intriguingly,
formation of this di-sulfide bond is thought to stabilize the opening of β-sheet-A
and promote polymersiation, however disruption of the bond, is thought to close
the β-sheet-A, whilst resulting in a 3 fold increase in the binding of a known
hydrophobic probe, bis-ANS (Musci and Berliner 1985). It is possible that release
of the CD-loop from the di-sulfide bond, allows interaction between the target
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protein and hydrophobic regions of the loop itself, whilst also opening up the region
of hydrophobicity along helix-D (Fig 6.1B).

In this context, future experiments investigating the effect of these hydrophobic
pockets, if any, on the ability of SerpinB2 to interact with native or misfolded client
proteins should be conducted using bis-ANS within the ELISA based end-point
binding assays (see section 4.3.4). Pretreatment of plate bound substrates with
bis-ANS, prior to the addition of SerpinB2, also in the presence of bis-ANS, should
block hydrophobicity (Poon et al. 2002) and reduce detectable bound SerpinB2.
Once established, site directed mutagenesis studies can be used to validate the
specific residues which function within these hydrophobic pockets. Furthermore,
the role of the CD-loop should be considered utilizing the ΔCD-loop mutant form
of SerpinB2 (Cochran et al. 2009). Given that SerpinB2 was shown to inhibit the
amorphous aggregation of BSA under reducing conditions, mild reduction of
SerpinB2 prior to use within either end-point binding or real-time aggregation
assays may improve the chaperone efficiency of the molecule. Of note however,
the redox sensitive conformational changes proposed by Wilczynska et al. (2003)
are thought to open the breach region of the serpin, when the C79-C161 di-sulfide
bond is formed. This may open a functional region of the molecule for interaction
with binding partners and is worth consideration in future experimentation
exploring SerpinB2 chaperone-like activity. This is of particular interest in the
context of fibril formation.
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Figure 6.1: SerpinB2 molecule contains a hydrophobic cluster located
along Helix D. A) Ribbon structure of SerpinB2 showing helices (light pink), βsheets (pale cyan) and hydrophobic residues (raspberry). C-D inter-helical loop
is located between residues 66-98 (grey dotted line). Helix D is labeled for visual
orientation. B) Hydrophobic surface residues (raspberry) reveals a cluster (blue
dotted arrow) within proximity of the C-D loop. Cysteine residues (C79-C161)
(red circles) essential for proposed redox sensitive conformational
rearrangement (Wilczynska et al. 2003) C) Amino acid sequence of the C-D loop
with hydrophobic residues (raspberry). Modelling was conducted with crystal
structure by (Harrop et al. 1999), 1BY7, using PyMOL Molecular Graphics
System, Version 1.7.4.4 Schrödinger, LLC.
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We show here that inhibition of Aβ1-42 peptide fibril formation by SerpinB2 impairs
its classic serpin inhibitory mechanism, suggesting that Aβ1-42 peptide binds within
the β-sheet-A region of SerpinB2. Whether the interaction occurs as a direct
insertion of the peptide, into the breach or shutter regions of the serpin is unknown.
However, further characterisation of this binding interaction may be obtained
experimentally using small synthetic peptides which mimic the RCL sequence
(Saunders et al. 2001). Such peptides will mimic insertion of the endogenous RCL
into β-sheet-A region of SerpinB2 and block Aβ peptide insertion, which would be
expected to abolish chaperone activity, thus confirming this particular mode of
action.

Interestingly, the association of Serpins with Aβ peptides (within the extracellular
environment) appears to be widespread in that Serpins A1 (α1-antitrypsin (AAT)),
A3 (α1-antichymotrypsin (ACT)) (Abraham et al. 1988; Rozemuller et al. 1991), B2
(Akiyama et al. 1993) and I1 (Neuroserpin) (Kinghorn et al. 2006) have all been
shown to co-localise with senile plaques associated with Alzheimer’s Disease
(AD). By means of in vitro studies SerpinA3 was reported to inhibit fibril formation
by Aβ1-40 (Eriksson et al. 1995; Aksenova et al. 1996) but not Aβ1-42 (Aksenov et
al. 1996) peptide, yet SerpinA3 reduced the cytotoxicity of Aβ1-42 but not Aβ1-40
peptide against rat hippocampal cell cultures (Aksenov et al. 1996; Aksenova et
al. 1996). Furthermore, Serpins A1, A3, C1 and F2 were all found to inhibit the
cytotoxicity of Aβ peptide added to rat pancreatic islet cell tumour line, subclone
(I5) (Schubert 1997). Whether SerpinB2 in the extracellular space also buffers
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against the cytotoxicity of Aβ-peptide requires investigation. Future cell based
experiments utilising inactive (RCL blocked) SerpinB2 as a control would be useful
in determining whether SerpinB2 interrupts endocytosis of toxic amyloid species.
The exact role serpins play in AD progression is unclear, therefore gaining an
understanding of how SerpinB2 inhibits Aβ-peptide fibril formation and determining
if SerpinB2 is able to protect against the cytotoxicity of Aβ-peptide, may clarify
whether serpins, in general, are actively involved within extracellular proteostasis
pathways or are themselves sequestered by Aβ-peptide.

Molecular chaperones are classically defined as proteins that participate in de
novo folding, facilitate the formation of functional tertiary conformations and refolding of stress-denatured proteins (Jakob and Buchner 1994; Netzer and Hartl
1998; Hartl and Hayer-Hartl 2009). These chaperones are active within the “onfolding” pathway (Fig. 6.2A) and belong to the family of heat shock proteins (HSP)
(Hartl et al. 2011). Alternatively, some molecular chaperones function to stabilise
stressed proteins but do not work within the folding pathway to re-conform
misfolded substrates into their functional native tertiary structures (Jakob and
Buchner 1994; Ehrnsperger et al. 1997). These chaperones are functional within
the “off-folding” pathway (Fig. 6.2B) and belong to the small heat shock protein
(sHSP) family (Hartl et al. 2011). Importantly, molecular chaperones within either
system bind preferentially to misfolded proteins, as does SerpinB2. Whether
SerpinB2 functions within the “on” folding pathway is not known. Of interest,
sHsp47 (SerpinH1) interacts transiently with pro-collagen during its folding,
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Figure 6.2. SerpinB2 identified as a potential player in cellular proteostasis
networks. Unfolded proteins are re/folded into their correct tertiary structure by
chaperones and co-chaperones within the folding pathway (A) or enter the
aggregate pathway (B) where they form small protein aggregates, which are either
degraded via the ubiquitin/proteasomal degradation pathway (C) or
sequestered into inclusion bodies such as the insoluble protein deposits (IPOD) for
degradation via the autophagy/lysosomal degradation pathway (D). SerpinB2
binds to misfolded protein and influences IPOD formation (Lee et al. 2015) (pathway
B). SerpinB2 influences proteasome activity (pathway C) (Lee et al. 2015) possibly
through interaction with proteasome subunit-β1 (red) (Fan et al. 2004). SerpinB2
deletion results in dysregulation of the autophagy/lysosomal degradation (pathway
D). Possibly through protective interaction with Beclin-1 (Chuang et al. 2013).
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assembly and transport from the endoplasmic reticulum (Tasab et al. 2000). Given
that SerpinB2 protein has been shown localized within the nucleus and cytosol it
is plausible to consider a potential role within the on-folding pathway.

The work presented within this thesis provides novel evidence that SerpinB2 may
function within proteostasis networks, as a chaperone-like protein. SerpinB2
identifies and binds preferentially to misfolded proteins suggesting it may interact
with soluble oligomers and small aggregates (Fig 6.2B) and facilitate their
trafficking into inclusion bodies or the proteasomal degradation pathway (Fig
6.2C). Indeed, our finding that loss of SerpinB2 results in decreased numbers of
large IPOD inclusions (Fig. 6.2B) is consistent with a role for SerpinB2 in mediating
the formation of cellular inclusions, which requires rearrangement of the
cytoskeleton. In this context, investigation of potential cytoskeleton interactions for
SerpinB2 are warranted. Intriguingly, loss of SerpinB2 also results in attenuation
of both the proteasome (Fig 6.2D) and autophagy-lysosomal degradation
pathways (Fig 6.2D). Whether SerpinB2 functions within both systems or has an
indirect effect on one, through loss of the other, remains to be shown. The reported
interaction of SerpinB2 with proteasome subunit beta type 1 (Fan et al. 2004) (Fig
6.2C) and autophagy regulator, Beclin-1 (Chuang et al. 2013) (Fig 6.2D) suggests
a role within both pathways. It is tempting to speculate that SerpinB2 may interact
with PSMB1 during assembly and disassembly of the 26S proteasome, functioning
to help shuttle the subunit into place, either as a substrate or an adapter protein.
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We also show dysregulation of the autophagy-lysosomal degradation pathway
suggesting a possible role for SerpinB2 within this initial seeding stage
(phagosome formation) of the pathway (Fig. 6.2D), possibly through cytoskeleton
rearrangement. Also of interest, dissociation of Bcl-2 from Beclin-1 initiates
seeding of the phagophore. Interestingly, Bcl-2 interacts with Beclin-1 through
hydrophobic interactions so it is plausible to consider that SerpinB2 may also bind
in a similar way, potentially obscuring the Bcl-2 binding site on Beclin-1, thus
promoting autophagy. Of interest, SerpinB2 expression was recently shown by
Chuang et al. (2013) to protect Beclin-1 degradation via the proteasome.
Furthermore, Chuang et al. (2013) found that SerpinB2 associated with and
enhanced the binding of Hsp90 and Beclin-90, suggesting a functional multiprotein complex arrangement for SerpinB2.

In this context, the role Hsp90 plays within the phagophore, in relation the
SerpinB2 is also of interest. Hsp90 is an essential mediator of proteostasis
networks and co-localises with co-chaperones to form macro-complexes (Hipp et
al. 2014). Investigation of the interaction between Beclin-1, SerpinB2 and Hsp90
is required to better understand how SerpinB2 influences autophagy. It is possible
that the chaperone-like biochemical properties described for SerpinB2 within this
thesis contribute to a co-chaperone like function for SerpinB2 within the Hsp90
complex systems. Previous work has shown that the co-chaperone and ubiquitin
ligase, CHIP, binds to Hsp70 and Hsp90, mediating ubiquitylation of target proteins
and transporting them to the proteasome (Kettern et al. 2010). The hypothesis that
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SerpinB2 may act as a co-chaperone or adapter protein is supported by the finding
that SerpinB2 interacts with ubiquitin in a non-covalent manner (Lee et al. 2015).
Furthermore, SerpinB2 has also been shown to interact with the ubiquitin-like
adapter protein, interferon stimulated gene-15 (ISG15) (Giannakopoulos et al.
2005) which has also been implicated in autophagy and proteosomal degradation
pathways (Nakashima et al. 2015).

Of interest then is the finding that SerpinB2 structure is unique whereby the highly
conserved Thr203 residue, found in all other serpins, is replaced by an asparagine
residue, resulting in the loss of a helical turn and the extension of a chain, at the
top of the molecule near the RCL (Fig. 6.3) (Harrop et al. 1999). Importantly, this
results in a more flexible region than that of the body of the protein. The lack of an
intracellular protease target for SerpinB2 has confounded progression of SerpinB2
research, particularly given numerous studies which report the characterization of
cleaved SerpinB2, post induction of cellular stress. Intriguingly recent work by
(Chuang et al. 2013), describing Hsp90 interaction with SerpinB2, showed that the
pro-autophagy and Beclin-1 protective mechanisms are dependent on an active
serpin. The authors report loss of function when using the R380A mutant of
SerpinB2, once again suggesting a protease target. If however, SerpinB2 forms a
functional multiprotein complex with Hsp90, or other proteins, in its proposed role
as a co-chaperone, it is hypothesized that cleavage of the RCL by protease/s
releases the serpin and/or its cargo.
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Figure 6.3: SerpinB2 contains a unique region of increased flexibility.
Ribbon structure of SerpinB2 showing helices (light pink) and β-sheets (pale
cyan). Region containing residues Glu213 to Tyr220 (blue) forms a unique
region of flexibility within SerpinB2. RCL superimposed (red line). Modelling was
conducted with crystal structure by (Harrop et al. 1999), 1BY7, using PyMOL
Molecular Graphics System, Version 1.7.4.4 Schrödinger, LLC
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In conclusion, this work opens up an exciting new focus of research for intracellular
SerpinB2 biology, in that SerpinB2 has chaperone-like characteristics and clearly
influences autophagy-lysosomal and proteasomal degradation pathways. The
cytoprotective role of intracellular SerpinB2 has remained elusive given it’s
everywhere whilst nowhere expression profile, within many cell types under many
varied conditions. Early work focused on an anti-apoptotic role for SerpinB2
(discussed section 1.14.1) with confounding results. Interestingly, BCL-2 has been
shown to inhibit both apoptosis and autophagy, furthermore over activation of the
autophagy pathway has a pro-apoptotic effect (Pattingre et al. 2005). This raises
the question then, if SerpinB2 is pro-autophagic and over-activation of the pathway
results in activation of apoptosis, then how may this have influenced the early
studies, using SerpinB2 overexpressing cell lines. Given the role of serpinB2 in
cytoprotection it is likely that further research will uncover therapeutic targets for
neurodegenerative disorders, as well as in cancer.
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8.1.

Buffers

10x PBS
NaCl
KCl
Na2HPO4
KH2PO4

80 g.L-1
2 g.L-1
14.4 g.L-1
2.4 g.L-1

Adjust pH as required. Dilute 1 in 10 before use.

10x TBS
Tris-Base
NaCl

500 mM
1500 mM

Adjust pH as required. Dilute 1 in 10 before use.

TBST
1x TBS (As above)
Tween 20

500 μL.L-1

Binding Buffer
Hanks modified buffered salt

9.7 g.L-1

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)

4.8 g.L-1

CaCl2

1 mM

MgCl2

1 mM
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BSA

1 g.L-1

Adjust pH to 7.4.

5x SDS PAGE Sample Buffer (non-reducing)
Tris-HCl

60 mM

Glycerol

10% W/V

SDS

2% W/V

Bromophenol Blue

0.01% W/V

RPMI 1640 Growth Media
RPMI
NaHCO3
Foetal Calf Serum

10.4 g.L-1
2 g.L-1
10% (v/v)

Coomassie Blue Stain
Methanol

400 mL.L-1

Glacial Acetic Acid

100 mL.L-1

Distilled Water

500 mL.L-1

Coomassie Blue R-250

2 g.L-1

Destain
Methanol

400 mL.L-1

Glacial Acetic Acid

100 mL.L-1
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Distilled Water

500 mL.L-1

SDS-PAGE

10% Acrylamide Gel
Tris-HCL pH 8.8

0.38 M

SDS

0.1% (w/v)

Acrylamide/Bis

10% (w/v)

Ammonium Persulfate APS

8% (w/v)

NNN’N’-tetramethylethylenediamine (TEMED)

8% (w/v)

4% Acrylamide Gel
Tris-HCL pH 8.8

0.125 M

SDS

0.1% (w/v)

Acrylamide/Bis

5.2% (w/v)

Ammonium Persulfate (APS)

8% (w/v)

NNN’N’-tetramethylethylenediamine TEMED

8% (w/v)

Running Buffer
Tris-base

15 g.L-1

Glycine

72 g.L-1

Sodium Dodecyl Sulphate (SDS)

5 g.L-1

Adjust pH to 8.3
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Western Blotting

Transfer Buffer
Tris-Base

3.03 g.L-1

Glycine

14.40 g.L-1

Methanol

200 mL.L-1

Distilled Water

800 ml.L-1
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